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1 Introduction and Motivation 
Communication is key. The development of language represents a milestone in human 
evolutionary history. Advancing simple sounds to distinct words and sentences 
enabled our ancestors not just to share information regarding the richest hunting 
grounds but to hand on acquired knowledge and skills. Furthermore, the capability to 
communicate individual emotions and needs facilitated the living in bigger social 
structures.[1] Long before verbal communication evolved, other, more essential forms 
of information transfer, had arisen. The necessity of interaction and transduction of 
information is omnipresent in living systems. Some plants for example are not just 
capable of producing defending or toxic substances to protect themselves from 
herbivores but also to emit hormones to warn neighbouring plants and to attract 
herbivore predators.[2,3] On extracellular (i.e. wound healing[4]) and intracellular (i.e. 
egg activation for fertilisation[5]) level, communications take place via messenger 
compounds, which are classified as extracellular, first messenger and intracellular, 
second messenger.[6] Some of the most prominent second messengers are cyclic AMP 
(cAMP), inositol-1,4,5-trisphosphate (IP3), diacylglycerin (DAG) and Ca2+ ions.[5,6] 
To investigate physiological processes, such as Ca2+-triggered neuronal exocytosis, a 
common procedure is the utilisation of fluorescence spectroscopy. One possibility is 
the usage of fluorophores, which can be incorporated into cells by stainings.[7,8] 
Another approach is the application of sensors. Fluorescent sensors alter their 
fluorescence behaviour upon environmental changes like shift in pH or alteration of 
specific metal ion concentration.[8] A major drawback of many dyeing techniques is the 
rapid exclusion of the fluorophore out of the cell.[9] To prevent exclusion or 
compartmentalisation, coupling to large tags, like dextran, or membrane anchors, like 
acyl chains, are used methods. 
The first chemically designed calcium sensor was described by R. TSIEN in 1980[10], 
followed by a variety of broadly applicable sensors.[11,12] In a previous work performed 
by J. GRAF, sensors based on fluorescein and rhodamine were modified and equipped 
with an azide carrying alkyl chain.[13] This modification enabled coupling with alkyne 
containing compounds via 1,3-dipolar cycloaddition (HUISGEN or click reaction). The 
first project in this work is concerned with the conjunction of membrane compartments 
with such functionalised calcium sensors. The selected membrane compartments, like 
lipids and peptides, were modified to carry an alkyne moiety and subsequently 
applied to HUISGEN reactions for calcium sensor labelling. Variation of the linker 
length connecting the lipid or peptide results in different distances between sensor and 





Ca2+ concentration can be measured in dependence of membrane distance. A first 
application of the labelled compounds was tested in SNARE-mediated membrane 
fusion experiments to follow fusion processes. Furthermore, such labelled molecules 
are readily available for in vitro and in vivo experiments for Ca2+-dependent 
fluorescence measurements. 
Other second messenger compounds cannot be taken up from external sources, as it is 
the case for Ca2+, but have to be generated. The source of the three second messengers 
phosphatidylinositol-3,4,5-trisphosphate (PIP3), IP3, and DAG is the lipid 
phosphatidylinositol-4,5-bisphosphate (PIP2), which is rarely available in plasma 
membranes.[14,15] What is more, PIP2 is thought to play a crucial role in SNARE-
mediated neuronal exocytosis by forming domains of increased PIP2 concentration. 
These so-called rafts enable the binding of the SNARE proteins, which allows 
subsequent Ca2+-triggered membrane fusion.[16,17] Usage of the well studied 7-azaindole 
enables observation of the environmental character, due to its ability to alter the 
fluorescence spectrum regarding to polar or non-polar surrounding.[18–21] Therefore, 
upon raft formation the locally increased concentration of lipid bound 7-azaindole can 
be monitored, since the fluorophore tends to form dimers in non-polar, aprotic 
surrounding, exhibiting a distinct red shift. For this reason, the goal of the second 
project was the synthesis of labelled lipids using 7-azaindole as fluorophore. 
In plants, signalling agents, such as jasmonic acid, are generated by digestion of 
polyunsaturated fatty acids by specialised enzymes.[22] The conversion of 
polyunsaturated acids exhibiting a 1Z,4Z-pentadiene moiety into hydroperoxides is 
performed by members of the lipoxygenase (LOX) family.[23] Even though LOXs have 
been investigated for some decades and are fairly well characterised[24], the precise 
mechanism of hydroperoxidation regarding the substrate orientation within the active 
site is still debated. To disclose this problem, the third project regards the synthesis of 
11,11-difluorolinoleic acid. The difluorinated fatty acid mimics the natural substrate 
linoleic acid and will therefore be bound by the enzyme. Due to the substitution of 
both hydrogen atoms at C-11 by fluorines no conversion can take place. Co-
crystallisation of the formed enzyme–substrate complex should allow to distinguish 
the exact substrate orientation in the active pocket. Hence, further insight into regio- 





2 Synthesis of Ca2+ Sensor-Labelled Membrane Components 
2.1 Introduction 
Nearly everything we do, how we think and store memories, how we move and even 
the beginning and end of life, is regulated by Ca2+.[25,26] On the other hand diseases like 
Alzheimer’s or cancer are thought to be connected to intracellular calcium as well. Due 
to calcium’s ubiquitous presence and influence on intracellular and more global 
processes, the system of Ca2+-signalling became a prime target for drug development, 
aimed at a variety of illnesses such as cancer, heart disease, arthritis or multiple 
sclerosis.[5] 
To further analyse the role of Ca2+ in these diseases and hence optimise treatment, real-
time visualisation of Ca2+ in living systems might provide crucial information.[27–29] 
Especially multicolour imaging, addressing other biomolecules besides Ca2+, under 
utilisation of fluorophores emitting visible light has drawn interest.[27,28,30,31] A well-
established method to observe changes in Ca2+ concentrations is the application of 
chemically engineered fluorescent Ca2+ sensors. These indicators bind free Ca2+ via a 
chelating moiety and thereby change their fluorescent properties, manifested in altered 
fluorescence intensity or shifted excitation or emission wavelength.[5,9] One example for 
usage of such a sensor is to measure changes in Ca2+ concentration to investigate the 
Ca2+ dependency of synaptic transmission in the brain.[32] The transduction of 
neurotransmitter is a Ca2+-triggered process, utilising the SNARE protein membrane 
fusion machinery, whose exact mechanism remains to be discovered.[33–36] 
For this reason a humble contribution to uncover the mechanism of Ca2+-dependent 
membrane fusion shall be presented in the following chapter. Labelling of membrane 
components with fluorescent Ca2+ sensors via 1,3-dipolar cycloaddition (HUISGEN or 
click reaction) enables full-fusion verification in vesicle fusion experiments and allows 









2.2 The Role of Calcium in Living Systems 
The human body contains an average of 1.4 kg of calcium, which is mainly bound in 
bones and teeth.[37] Not even 1 % of the calcium within a human is available outside the 
skeleton in its ionic form but this small amount occurs to be one the most important 
signalling agents in living systems.[37] Every aspect of life, from its beginning to its 
death, is regulated by Ca2+.[25,38–40] Already in 1883 S. RINGER discovered the significance 
of Ca2+ on the contractibility of heart muscles, when no contraction of hearts took place 
in distilled water but was observed in London tap water.[39,41] Following RINGERs 
finding, a tremendous variety of Ca2+-regulated processes was detected, including 
fertilisation[39,40,42], cell growth[43], gene expression[44], hypertrophy[45] and apoptosis[25,38]. 
Ca2+-dependent regulation of processes within cells demands a carefully adjusted 
equilibrium between uptake of Ca2+ into the cytosol and its removal out of the cell or 
storage in the respective organelles like the endoplasmic reticulum (ER) or 
mitochondria at all times (Figure 2.1).[40,46] The efficiency of calcium signalling is based 
on the enormous gradient between cytosolic (~10‒7 M) and extracellular (~10‒3 M) Ca2+ 
concentration. Activation of a cell via a primary stimulus opens Ca2+ channels, enabling 
rapid Ca2+ uptake of up to 10-6 M within milliseconds.[5,39,47] For precise concentration 
control of free Ca2+ a multitude of Ca2+-binding proteins has evolved, which trigger cell 
activation by a primary stimulus. These proteins are divisible in two categories: Ca2+-
buffering and transporting proteins and Ca2+ sensors.[46] 
Proteins responsible to transport or buffer Ca2+ are generally located in organelles, 
integrated into membranes or in the cytosol. The soluble cytosolic proteins can store 
high quantities of Ca2+ (i.e. parvalbumin, calsequestrin).[5,46,48] Proteins located 
intrinsically to membranes can form channels, pumps or exchangers to transport Ca2+ 
through membranes. These Ca2+-transporting proteins regulate the membrane 
potential and concentration gradients and by modulating the Ca2+ concentration in the 
cytosol lead to signal transduction. 
Ca2+ channels typically transport Ca2+ out of the extracellular space into the cell or 
enable removal of Ca2+ out of the ER or sarcoplasmic reticulum (SR). Channels 
positioned in the plasma membrane (PM) are triggered to open by extra- or 
intracellular binding of ligands or voltage change, while channels in the ER/SR 
regulate Ca2+-induced Ca2+ release, meaning that Ca2+ regulates itself. Still, this kind of 
control requires further ligands. Two of the best-known ligands are inositol-(1,4,5)-
triphosphate (IP3), that binds to the IP3 receptor (IP3R), and cyclic adenosine 
diphosphoribose (cADP ribose), which activates the Ca2+-sensitive ryanodine receptors 
(RyR).[38,46,47] 





Figure 2.1 Schematic illustration of control proteins in eukaryotic cells depicting Ca2+ transport via 
channels, pumps and exchangers. No differentiation between ligand and voltage gated channels is 
performed. Picture based on [46]. 
The second operation mode of membrane-intrinsic proteins is transportation of Ca2+ as 
ion pumps. A commonly discussed pump in eukaryotic cells is the Ca2+ ATPase. 
Within the ER membrane the sarco/endoplasmic reticular Ca2+ ATPases (SERCA 
pumps) convey Ca2+ uphill against the gradient into the ER, hydrolysing one ATP 
molecule to transport two calcium ions. Fulfilling the same task, the ATPase in the 
plasma membrane, the plasma membrane Ca2+ ATPase (PMCA) pump, reduces the 
cytosolic Ca2+ concentration by pumping Ca2+ out of the cell. In contrast to SERCA 
pumps the PMCA pumps consume one ATP molecule per Ca2+.[46,49,50] 
The last type of Ca2+-binding and transporting proteins are the exchangers. Two 
examples are the Na+/Ca2+ exchangers in the inner mitochondrial membrane (MNCX) 
and in the PM (NCX). MNCX removes one Ca2+ out of the mitochondrial matrix in 
exchange for two Na+, resulting in an electrically neutral process. In contrast, NCX 
substitutes one Ca2+ by three Na+, making it responsive towards voltage differences 
and Na+ and Ca2+ transmembrane gradients. 
The second category of Ca2+-regulating proteins comprises of the Ca2+ sensors. The 
best-characterised sensors are the proteins of the EF-hand protein family. For 
Ca2+-binding the helix-loop-helix motif is used, in which the on average 12 amino acid 
short loop binds Ca2+ via oxygen-rich side chains like aspartate or glutamate.[46,51] 





Processing of Ca2+ signals proceeds via two conformational changes of the EF-hand. 
Binding of Ca2+ induces the first change in conformation while activation of a 
structural protein or target enzyme, like kinases or phosphatases, by the EF-hand 
protein causes the second change.[46,51] 
The most frequently mentioned Ca2+ sensor exhibiting the EF-hand motif is calmodulin 
(CaM). The structure of this small (~148 amino acids) pervasive protein is highly 
conserved and has barely changed over the last 1.5 billion years.[38,52,53] CaM is formed 
like a dumbbell featuring a flexible joint in the middle, connecting two roughly 
balanced domains with two EF-hands each. Containing this motif, CaM exhibits 
distinct Ca2+ affinities (Kd = 5 · 10-7 M to 5 · 10-6 M) with four Ca2+-binding sites, located 
between the two α-helices of each EF-hand.[53] The Ca2+-free (apo) CaM is arranged in a 
closed conformation, shielding the hydrophobic residues from the polar surrounding 
(Figure 2.2, A). Complexation of Ca2+ alters the conformation to an open position, 
exhibiting hydrophobic areas of each domain (Figure 2.2, B).[53] The exposed 
methionine-rich hydrophobic surfaces are now enabled to bind target enzymes by 
wrapping around their amphipathic domains, i.e. myosin-light-chain kinase (MLCK, 
Figure 2.2, C).[38] 
Ca2+-bound CaM (Ca2+4-CaM) plays a crucial role in activation of a variety of enzymes. 
One example is the phosphorylase kinase, which is dependent on Ca2+4-CaM to trigger 
cleavage of glycogen under glucose release.[54] Furthermore, MLCK is activated by 
Ca2+4-CaM, leading to phosphorylation of the myosin light chain, hence enabling 
smooth muscle contraction.[55] As a conclusive example the Ca2+4-CaM-dependent 
protein kinase II (CaM kinase II) is to be mentioned. This kinase occurs in neurons in 
high concentrations and is responsible for activating further enzymes like calcineurin 
(CaN), tyrosine hydroxylase (TYH) and nitric oxide synthases (NOOSs).[56] 
 
Figure 2.2 CaM in its closed form, with shielded hydrophobic domains (A); Ca2+4‒CaM in the open form 
(B); Ca2+4‒CaM complexed a MLCK (red helix) with its hydrophobic binding domain (C). Pictures taken from [57]. 




2.3 SNARE-mediated Membrane Fusion 
As briefly presented in chapter 2.2  the alkaline earth metal calcium is in the ionic form 
(Ca2+) a highly versatile and important second messenger, triggering a diversity of 
enzyme driven processes. This finding seems to be true for membrane fusion events as 
well.[35] Already in 1967 B. KATZ and R. MILEDI discovered that Ca2+ triggers exocytosis 
of synaptic vesicles, leading to release of neurotransmitters and thereby instigating 
synaptic transmission.[36,58] Fusion processes of stable membranes require a driving 
force to overcome the electrostatic repulsion of the two membranes. Interaction of 
fusion proteins anchored in the respective membranes enables fusion to proceed.[59] 
They participate in steps like protein recognition, hemi-fusion of the respective 
membranes followed by fusion pore formation.[60] 
The general path of synaptic vesicles in the nerve terminal is depicted in Figure 2.3. 
During intervals between exocytosis, the synaptic vesicles carrying neurotransmitters 
are stored in the so-called active zone in the cytoplasm. The active zone, in which a 
multitude of inimitable multidomain proteins are located, supplies a template for 
vesicle docking. After stimulation of the cell, the docked and primed vesicles in the 
active zone fuse with the presynaptic plasma membrane and release their cargo into 
the synaptic cleft. Clathrin-assisted vesicle recycling via endocytosis provides 
precursor vesicles for future cycles.[26,34,61] 
 
Figure 2.3 Schematic view of synaptic vesicles in the nerve terminal. With neurotransmitter filled vesicles 
are stored in the cytoplasm. After relocation to the active zone the vesicles are docked to the plasma 
membrane and release the neurotransmitters into the synaptic cleft upon Ca2+-triggering. Vesicle recycling 
via endocytosis using clathrin allows cycle repetition. Picture taken from [61]. 
 





The key proteins for exocytosis are soluble N-ethylmaleimide-sensitive-factor 
attachment receptors (SNAREs), Rab proteins, Sec1/Munc18-like (SM) proteins and a 
protein group named complex associated with tethering containing helical rods 
(CATCHR).[61] These proteins form a fusion machinery, which is adapted to specified 
compartments. One example for these specialisations, which will be focused on in this 
chapter, is the neuronal exocytosis, utilising the above mentioned SNARE, Rab, SM 
and CATCHR proteins, and further regulatory proteins like complexins and 
synaptotagmins (Syt), which serve as Ca2+ sensors.[36,61] 
The synaptic SNARE proteins, that participate in the docking and fusion process in 
neurons, share an extended coiled-coil motif (SNARE motif) and can be divided into 
Q-SNAREs (Qa, Qb, Qc) and R-SNAREs.[62] Accordingly, a SNARE fusion complex is 
composed of three Q-SNAREs and one R-SNARE. Furthermore, most SNARE proteins 
feature a C-terminal transmembrane domain (TMD), connected to the SNARE motif 
via a short linker, providing a structure to anchor the SNARE proteins in the respective 
membrane. Synaptobrevin (Syb, R-SNARE) is positioned in the vesicle membrane 
while syntaxin 1 (Sx1, Qa) and the 25 kDa synaptosome-associated protein (SNAP-25, 
Qb and Qc) are located in the target membrane. SNAP-25 lacks a TMD but binds to the 
membrane utilising palmitoyl side chains.[63,64] The special feature of Sx1 is an 
additional N-terminal domain, consisting of a bundle of three antiparallel α-helices, 
termed Habc domain, whose participation in the fusion process is controversially 
discussed.[65] 
If the SNARE proteins of vesicle and presynaptic membrane come in contact with each 
other the proteins assemble in a parallel trans-complex of four parallel α-helices. The 
assembly is thought to start from the N-termini and to proceed towards the C-termini. 
This ‘zippering’ mechanism pulls the membranes closer together and has been 
postulated among others by R. JAHN et al. in 1997[66,67] and verified by D. FASSHAUER et 
al. in 2010 (Figure 2.4).[68,69] 
 
Figure 2.4 The trans-SNARE complex (4-helix bundle) brings the membranes into close proximity via 
‘zippering’. Picture taken from [70].  




The exact mechanism of the SNARE-mediated membrane fusion is still debated and 
further advancement in technologies will be necessary to fully understand the 
underlying processes. However, one model for fusion and protein recovery developed 
by R. SCHELLER and R. JAHN in 2006 has been broadly accepted.[71] In good agreement 
with this hypothesis T. SÜDHOF postulated a model including the influence of Ca2+ as a 
signalling agent (Figure 2.5).[72] Starting from the approach of the Syb-containing (also 
termed VAMP: vesicle-associated membrane protein) vesicle towards the presynaptic 
membrane, the SNARE complex forms, containing the SM protein Munc18. The 
loosely formed complex is then activated by complexin to generate a tightly bound 
SNARE/SM protein complex that brings the vesicle in close proximity to the target 
membrane. Binding of Ca2+ by Syt-1 then triggers the fusion of membranes to form a 
fusion pore, which expands to complete the fusion process. Under consumption of 
ATP, binding of N-ethylmaleimide-sensitive factor (NSF) and SNAP cofactors 
disassembles the complex to regenerate the proteins and to provide them for the next 
fusion cycle.[26,61,72] The described model is supported by plenty of evidence[68,69,73] but 
still many questions remain unanswered.[61] 
 
Figure 2.5 Schematic illustration of the SNARE-mediated fusion model under consideration of 
synaptotagmin and complexin as well as the influence of Ca2+. Picture taken from [72]. 
 





2.3.1 Recognition Units in SNARE Analogue Model Systems 
Investigations regarding SNARE-mediated fusion have proven to be quite demanding, 
since the SNARE complex formation is a highly complicated process with a broad 
variety of proteins involved.[16,26,61,74] To further unravel the process of membrane 
fusion with its engaged proteins, model systems of reduced complexity have been 
developed[75–78]. Different possibilities to generate and modify simplified model 
systems are thinkable. Using a bottom-up approach allows synthesising a diversity of 
SNARE analogues to gain information about influences of specific protein domains.[75] 
One possible modification site is the TMD, which is thought to have a great influence 
on fusion efficiency.[70,78] Another option is to alter the linker moiety between TMD and 
recognition unit. As artificial linkers PEG in differing lengths is broadly applied.[79–81] 
The focus of this chapter, however, will be on modified recognition units. Prominent 
examples are boronic acid/cis-diol recognition[82] and DNA-based recognition.[83–85] In 
the following, two other recognition motifs shall be briefly introduced: the coiled-coil 
peptide motif[80,81,86,87] and the PNA motif.[70,78,88,89] 
The coiled-coil recognition motif describes the interaction of several α-helices (at least 
two) to wrap around each other forming a bigger, α-helical structure.[90] To understand 
the mechanism and specificity of the helix-helix interaction the peptide sequence needs 
to be taken into account. The majority of coiled-coils exhibits a heptad repeat of seven 
residues (from ‘a’ to ‘g’) to two turns of the helix.[80] The positions ‘a’ and ‘d’ are 
usually populated by hydrophobic amino acids, facing another peptide for coiled-coil 
formation. The neighbouring amino acids ‘e’ and ‘g’ often feature charged side chains 
and therefore ensure specific binding of the α-helix (Figure 2.6).[80,91] 
 








Another recognition motif utilises peptide nucleic acid (PNA) in form of hybrids 
between peptidic TMD and PNA, which has been developed in this work group by A. 
LYGINA.[78,92] Recognition via WATSON–CRICK base pairing allows to control the 
orientation of the dimerising recognition motifs. The system of each two different 
PNA/peptide strands, shown in Figure 2.7, contains three complementary PNA 
domains, to interact in a parallel (PNA1 and PNA3) or antiparallel (PNA1 and PNA2) 
manner. Furthermore, the model systems comprise the native TMD and linker 
sequences of Sx, shown in orange, and Syb, shown in purple. The design of the applied 
PNA was evolved in 1991 by NIELSEN et al., substituting the negatively charged native 
deoxyribose phosphate backbone by neutral N-(2-aminoethyl)glycine (aeg) units.[93,94] 
The uncharged backbone of PNA does not entail electrostatic repulsion like its native 
template and is stable against nucleases or proteases.[94] 
In summary, both presented motifs of SNARE analoga represent well-suited 
recognition units. Specific interaction of complementary strands is ensured and 
recognition properties can easily be altered by modification of the amino acid sequence 
(coiled-coil) or substitution of specific nucleobases (PNA). 
 
Figure 2.7 Simplified system using PNA/peptide models for vesicle fusion. As TMDs and linker domains 
native sequences of Syb (purple) and Sx (orange) were applied. Depending on the nucleobase sequences 









2.4 Fluorescent Ca2+ Sensors 
After the importance of ionic calcium became apparent in 1883[41], it took another 60 
years for Ca2+ as signalling agent to provoke broad interest within the scientific 
community.[37] As the diversity of Ca2+-dependent processes, like SNARE-mediated 
membrane fusion to name just one example, was started to be unravelled, the necessity 
for Ca2+ probes like fluorescent Ca2+ indicators evolved. To satisfy the demands for 
fluorescent Ca2+ imaging TSIEN et al. developed the first chemical fluorescent Ca2+ 
sensor Quin-2 in 1980 (Figure 2.8).[10,95] Requisites of Ca2+ indicators are good selectivity 
towards Ca2+ and altered fluorescence properties after Ca2+-binding, like change in 
emission wavelength or increase in fluorescence intensity.[9] Quin-2 fulfils the demand 
of distinct fluorescence increase in presence of free Ca2+ and was used for intracellular 
measurements.[10,95,96] Drawbacks of Quin-2 are a low quantum yield, a small excitation 
coefficient and increased photobleaching after Ca2+-binding, which is why its usage is 
rather uncommon these days.[96] 
Since the design of Quin-2 numerous other indicators have been developed, which all 
have a similar structure.[9,11,12,28,97–99] Today’s most common Ca2+ sensors utilise Ca2+ 
chelators like 1,2-bis(o-amino-phenoxy)ethane-N,N,N’,N’-tetraacetic acid (BAPTA) or, 
more seldom, ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
(EGTA), which exhibit a one to one stoichiometry for Ca2+ and a high binding 
affinity.[100] Especially BAPTA is highly selective towards Ca2+ over Mg2+, less pH 
dependent in respect to metal chelation and conducts more rapid binding and 
releasing of Ca2+ than EGTA.[10,11] Introduction of electron-withdrawing groups, like 
halogen atoms or nitrile moieties, leads to an increase of the KD value while electron-
donating groups, like methyl or heteroatoms (O, N), favour a decrease of the KD value. 
These modifications thus allow to generate low and high affinity Ca2+ sensors.[11] 
Chemical sensors build up from two parts, the just discussed Ca2+-chelating moiety 
and a dye, and can be divided into ratiometric and non-ratiometric sensors. The non-
ratiometric Ca2+ indicators, which mainly utilise BAPTA and dyes like derivatives of 
Rhodamine or Fluorescein, exhibit a change in fluorescence intensity after Ca2+-binding 
without alteration of the excitation or emission wavelength. The mechanism that forms 
the basis of changes in the fluorescence intensity, is the photoinduced electron transfer 
(PET).[101] Sensors in absence of Ca2+ exhibit no or weak fluorescence, since the BAPTA 
moiety quenches the fluorescence by accepting the excited electron of the fluorophore 
unit. After Ca2+-binding, the PET mechanism becomes energetically unfavoured and 
the fluorescence increases.[102]  





Figure 2.8 Examples for chemical Ca2+ indicators with Quin-2 as the archetype and four high affinity Ca2+ 
sensors. Fluo-3, Fluo-4 and X-Rhod-1 belong to the family of non-ratiometric sensors while Fura-2 is a 
ratiometric indicator. 
These sensors, like Fluo-3, Fluo-4 or X-Rhod-1 (Figure 2.8), are excitable with a single 
wavelength of visible light and feature therefore a reduced phototoxicity.[27,103] 
Ratiometric Ca2+ sensors, like Fura-2 (Figure 2.8), experience a shift in their excitation 
or emission wavelength upon Ca2+-binding. This allows a very precise quantification of 
Ca2+ concentration, due to being independent of sensor concentration, equability of the 
loaded dye or photobleaching, for example. The constraint of ratiometric indicators is 
the necessity of an enhanced spectral bandwidth, leading to increased phototoxicity.[9] 
  





2.5 Calcium Sensor-Labelling of Membrane Components 
2.5.1 Synthesis of Alkyne-Carrying Lipids and Peptides 
Calcium detection in cells is generally performed using one of the many commercially 
available indicators. A multitude of those sensors is used as acetoxymethyl esters for 
facilitated cell loading. The ester will, once within the cell, be hydrolysed by an 
esterase to release the carboxylic acids for calcium binding. The drawback of this 
method is that the in vivo or in vitro generated active sensor will not distribute equally 
within the cell but will accumulate in specific regions and in many cases, will be 
discharged from the cell. To inhibit discharging of the sensor bulky, nontoxic 
molecules, like dextrane, are often bound to the sensor.[43,104,105] The modified sensor 
will stay within the cell but its distribution is still erratic. To overcome this obstacle, it 
was thought of to bind a Ca2+ sensor to membrane components, which will fixate the 
sensor in close proximity to the membrane. Since there is a concentration gradient of 
Ca2+ ions in living cells due to opening and closing of ion channels and pumps, 
placement of the sensor in different distances to the membrane should allow to 
observe this gradient. Therefore, a variety of potential membrane components were 
modified with an alkyne moiety for sensor-binding (Figure 2.9). 
To bind the sensor close to the membrane phospholipids were chosen. As the best-
suited phospholipid to incorporate an alkyne functionality into, a phosphatidyl-
ethanolamine (PE) lipid was selected.  
 
Figure 2.9 With alkyne functionality modified membrane components based on cholesterol (1), DOPE (2,3) 
and transmembrane WALP peptides (4). 




A considerably longer distance between sensor and membrane was supposed to be 
achieved by modification of cholesterol using a short PEG4 linker. The third employed 
system was alkyne incorporation into a transmembrane protein. For this work a 
distance of medium length was chosen, but elongation of the sequence with polar 
amino acids allows a broad variety in sensor–membrane distances. 
First, the modification of a phospholipid was performed. The amino group of 1,2-
dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE) is perfectly applicable for 
incorporation of an alkyne-carrying carboxylic acid as a linker via amide bond 
formation (Scheme 2.1, A). As linker 3-butynoic acid (BA) has been coupled by stirring 
a solution of BA and DCC in chloroform for 4 h, then DOPE and pyridine were added. 
After heating to 50 °C over 12 h, the formed side product could be filtered off and via 
RP-FC pure product 2 was obtained in 82 % yield.[106] 
Applying the same conditions as described above but using 4-pentynoic acid (PA), 
which differs from BA just in one additional methylene unit, the reaction proceeded 
smoothly to form 3 in 89 % yield (Scheme 2.1, B). 
The last lipid to be modified and labelled was cholesterol, which was purchased as 
cholesteryl hemisuccinate (ChHS). The hemisuccinate unit allowed the incorporation 
of 3,6,9,12-tetraoxapentadec-14-yn-1-amine (H2N‒PEG4‒Alkyne, APG4) via amide 
bond formation (Scheme 2.2) for subsequent click reaction. For coupling a solution of 
APG4 and ChHS in DCM was treated with 3-(ethyliminomethyleneamino)-N,N-
dimethyl-propan-1-amine (EDC · HCl) and stirred at r.t. for two days. After 
purification via FC pure product 1 was obtained in quantitative yield. 
 
Scheme 2.1 Coupling of BA (A) and PA (B) to DOPE for subsequent click reaction. 
 
 






Scheme 2.2 Coupling of PEG linker AGP4 to the cholesterol derivative ChHS. 
Besides these modified lipids, which will be located in one leaflet of the membrane, an 
alkyne carrying peptide was synthesised. For synthesis of a transmembrane peptide 
the well-studied WALP peptide class was chosen, since they form stable membrane 
spanning α-helices. WALP peptides consist of a hydrophobic core region, made of 
L-alanine (A) and L-leucine (L), as well as L-tryptophan (W) on both ends of the 
hydrophobic region to anchor the peptide in the membrane. In this work the WALP25 
structure 4 (Figure 2.9) was tailored, consisting of a hydrophobic (LA)9-region, framed 
by two W on each side. One A was included at the C-terminus. At the N-terminus one 
L-lysine (K) was incorporated for solubility reasons and terminal the non-natural 
amino acid propargylglycine was coupled. The designed WALP25 peptide had an 
approximate length of 37.5 Å as an α-helix with a hydrophobic (LA)9-domain of about 
27 Å.  
The synthesis of 4 was conducted via automated solid phase peptide synthesis (SPPS) 
using GP1.2 for coupling and GP1.3 for peptide cleavage. Test cleavage showed no 
product formation but several truncated sequences. Elongation of coupling times and 
application of double-coupling steps did not improve the synthetic outcome. To revise 
whether or not automated synthesis yields the desired peptide if the non-natural 
amino acid propargylglycine is omitted, a test cleavage was performed after coupling 
of the 24 natural amino acids (Figure 2.10). Mass spectrometry revealed fairly pure 
formation of the desired peptide 5 without truncated sequences. 
 
Figure 2.10 Test cleavage of 5 after coupling the 24 natural amino acids, omitting progargyl glycine. 




Peptide 5 was transferred into a BD-syringe equipped with a polyethylene filter. Via 
GP1.1 the N-terminal amino acid was manually coupled using N,N-dimethylform-
amide (DMF) as solvent. After test cleavage formation of small product amounts were 
observed but the high impurity made HPLC purification unfavourable. For a better 
yield with fewer side reactions the solvent was changed from DMF to N-methyl-2-
pyrrolidone (NMP). This led indeed to formidably increased yield while the quantity 
of impurities was minimised, so that for future WALP syntheses the combination of 
GP1.2 in DMF with GP1.1 in NMP was used. 
To verify that peptide 4 will form the desired α-helical structure, circular dichroism 
(CD-) measurements were conducted. As shown in Figure 2.11, two minima at 208 nm 
and at 222 nm were observed, displaying a typical curvature of α-helical peptides. 
Since the synthesis of WALP peptide 4 is quite resource-demanding, a variety of 
shorter peptides (Figure 2.12) was prepared as model systems for condition screening 
for the desired copper(I)-catalysed azide–alkyne cycloaddition (CuAAC). The three 
short peptides 6, 7 and 8, consisting of four to six amino acids, were manually coupled 
using GP1.1. Interestingly, for coupling of propargylglycine to these short peptides no 
difference was observed between usage of DMF and NMP. The fourth peptide 9 carries 
no alkyne but is intended for labelling via amide-bond formation. 
 
Figure 2.11 CD-spectrum of WALP peptide 4 measured in MeOH. 






Figure 2.12 Library of shorter peptides designed for condition screening. 
 
 
2.5.2 Labelling of Membrane Components via CuAAC (Click) Reaction 
For labelling of various membrane components like lipids and peptides the two 
different Ca2+ sensors X-Rhod-Azide and Fluo-Azide were chosen (Figure 2.13). Both 
sensor structures, consisting of a fluorophore moiety and a Ca2+-chelating BAPTA unit, 
are based on literature known compounds[12,27,28,99,107], which are commercially 
available. They were modified in a previous work[13] to enable covalent binding 
without disturbance of the sensor performance, under development of an improved 
synthetic route. For binding to alkynes a butyl group carrying an azide was 
incorporated, which allows subsequent copper(I)-catalysed 1,3-dipolar cycloaddition 
(click reaction), forming the five-membered heterocycle triazole. Performance of click 
reaction was carried out under light exclusion to inhibit decomposition of the sensor 
compounds. 
The developed conditions for click reactions are highly versatile.[108–110] At first, 
WALP25 peptide 4 was supposed to be labelled with sensor X-Rhod-Azide. Due to the 
small reaction scale of micro- to nanomolar, all compounds were previously prepared 
as stock solutions in DMF and the reactions were conducted in micro reaction vessels. 
Sensor and peptide 4 were treated with copper(I) iodide (CuI) and sodium ascorbate 
(NaAsc) in DMF under argon atmosphere (Scheme 2.3, Table 2.1, A).[111,112] The reaction 
mixture was shaken over night and extracted using DCM and water (1:1, v/v). After 
the organic solvent was removed, analysis of the residue via HPLC and mass 
spectrometry showed no conversion to the desired product 10. 









Scheme 2.3 Labelling attempt of WALP25 peptide 4 via HUISGEN cycloaddition. 
 
 





Since no labelled product was formed, sensor X-Rhod-Azide and lipid 2 were treated 
with the same conditions as described above (Scheme 2.4), to review whether utilising 
CuI in DMF is just unfitting for peptide 4 or for a lipid system as well. After workup 
procedure, again, no product formation was observed. As click reaction with 2 and 
X-Rhod-Azide did not perform, the system itself was changed by substitution of 
X-Rhod-Azide through Fluo-Azide. The conditions were altered to CuSO4 · 5H2O 
(20.0 eq.) and NaAsc (25.0 eq.) in MeOH and ultrapure water (4:1, v/v).[113] As reactant 
the lipids 2 and 3 were tested as well as peptide 4 (Scheme 2.5, Table 2.1, B). In all three 
cases no product was found using mass spectrometry and HPLC showed no 
conversion. 
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The catalytic active copper species in CuAAC reactions is Cu(I). Since now Cu(II) was 
added as CuSO4 · 5H2O to the reaction, reduction to Cu(I) using NaAsc was necessary. 
A possible explanation why the click reaction would not proceed was, that the active 
copper species might be too unstable in the given surrounding. Therefore, tris(3-
hydroxy-propyltriazolylmethyl)amine (THPTA) was added as ligand (Figure 2.14, 
left), which binds and thus stabilises Cu(I) to increase product formation.[108,114,115] While 
keeping the remaining conditions constant, addition of five equivalents THPTA to the 
click reaction of Fluo-Azide and peptide 4 was tested (Table 2.1, C). Via HPLC analysis 
a small, new signal was observed with absorption at 488 nm, whereas the main 
compounds remained Fluo-Azide and 4. After isolation of this compound CD-
measurement was conducted, revealing no peptidic character. Then, Ca2+-dependent 
fluorescence measurements were performed, which exhibited no Ca2+-dependent 
increase of fluorescence. Hence, the formed substance seemed to be decomposed 
sensor. 
Another reason for the lack of starting material conversion to product might be that 
the energy barrier of the reaction is too high for the existing system to overcome. If that 
is the case input of energy in form of elevated in temperature should solve this 
difficulty. Therefore, peptide 4 and Fluo-Azide were again treated with CuSO4 · 5H2O 
and NaAsc in methanol and water and shaken over night at 35 °C (Table 2.1, D). The 
HPL-chromatogram of this reaction showed the same outcome as when the ligand 
THPTA was added, yielding just starting material with small amounts of degraded 
sensor. 
 
Figure 2.14 Chemical structure of click ligands THPTA and BTTAA. 





Scheme 2.5 Click reaction of 2/3/4 with Ca2+ sensor Fluo-Azide using CuSO4 · 5H2O and NaAsc. 
A combination of heating and admixture of THPTA was tested as well together with a 
slight excess of peptide 4 (1.40 eq.). At first the reaction with 4 and Fluo-Azide was 
started at r.t. and without THPTA addition but with admixing of a few drops of 
trifluoroethanol (TFE) for enhanced solubility of 4 (Table 2.1, E). The reaction was 
shaken for 24 h and monitored via analytical HPLC. Since after one day no reaction 
took place, THPTA was added and the reaction mixture heated to 38 °C. After 32 h no 
conversion was observed and the reaction was stopped. 
Another possibility to overcome the energy barrier was the usage of microwave 
assisted coupling. Fmoc-protected peptide 6 and Fluo-Azide were dissolved in DMF, 
NaAsc and CuSO4 · 5H2O in water were added. The mixture was heated three times 
over 5 min to 80 °C by applying 25 W (Table 2.1, F). As this approach led to no product 
formation as well, it could be shown, that the energy barrier is not the limiting factor. 
Next, the equivalents were varied. The amount of copper sulphate was reduced by 
roughly 33 % and NaAsc by about 40 %. Using methanol and water as solvents and 
shaking at r.t. yielded no product formation. Therefore, the reaction was heated to 
35 °C and shaken for further 24 h (Table 2.1, G). HPLC monitoring revealed formation 
of a new compound with a slightly lower retention time than peptide 4, which and 
showed absorption at 488 nm (Figure 2.15).  






Figure 2.15 HPL-chromatogram of 4 with Fluo-Azide at 38 °C with addition of THPTA after 32 h. 
The isolated compound showed no Ca2+ dependency, therefore, it can be excluded that 
the desired product was formed. A possible reason is that some kind of binding 
between 4 and Fluo-Azide occurred while the ability to bind Ca2+ was lost. 
To analyse the influence of solvents a mixture of NMP, which proved to be beneficial 
for coupling of progargyl glycine, and water (1:1, v/v) was tested (Table 2.1, H). After 
24 h at r.t. no conversion was observed. Therefore, the temperature was increased to 
35 °C. The reaction was stopped after 72 h, when no further change was detected via 
HPLC. Utilising NMP instead of MeOH as organic solvent led to formation of the same 
new signal, as depicted in Figure 2.15. Another tested solvent was DMSO in 
combination with another, possibly more potential, ligand. 2-(4-((bis((1-tert-
butyltriazol-4-yl)methyl)amino)methyl)triazol-1-yl)acetic acid (BTTAA) was found to 
accelerate CuAAC reactions in comparison to THPTA, increase the CuII/CuI redox 
potential and reduce potential oxidative side reactions, e.g. on amino acid side 
chains.[109,115] Conditions stated in Table 2.1, I were applied. Even usage of BTTAA and 
shaking for 24 h could not lead to successful conversion. 
Another possibility for click reactions with peptides is to conduct the labelling on 
resin.[116,117] The coupled peptide is left on a resin instead of been cleaved and isolated. 
The peptide 4 (1.00 eq.) on resin was swollen in a BD-syringe and treated with 
Fluo-Azide (1.20 eq.), CuI (5.00 eq.) and NaAsc (5.00 eq.). The mixture was shaken at 
r.t. over night, followed by washing of the resin, drying under vacuum and subsequent 
cleavage of the peptide (GP1.3). This reaction was performed in DMF and in NMP, but 
in both cases unreacted peptide 4 was obtained. 





Scheme 2.6 Click reaction of WALP25 4 on resin. 
Another click attempt on resin was conducted using DMF but using 1.00 eq. of 
Fluo-Azide, 6.79 eq. of N-terminal Fmoc-protected 4 on resin, 7.54 eq. CuI and 9.03 eq. 
NaAsc. All compounds were placed in a micro reaction vessel, evacuated and flooded 
with argon. Anhydrous DMF was added and the reaction vessel was carefully shaken 
for two hours. The resin was thoroughly transferred into a BD-syringe and after 
washing and drying in vacuo the peptide was cleaved via GP1.3. HPLC and mass 
spectrometry revealed no formation of product. 
Since no conversion took place, the system was changed back to liquid phase reactions. 
So far, when the applied solvent system was changed, it was the organic fraction, 
which was altered. To verify that a specific pH range was maintained, the water 
fraction was exchanged by different buffer systems. The first buffer tested was a 
phosphate-buffered saline (PBS), consisting of NaCl (137 mM), KCl (2.7 mM) and 
phosphate (10 mM) at pH 7.4. The applied conditions are listed in Table 2.1, J ‒ L, and 
reaction time was 24 h for every reaction. The reaction conditions shown in row L were 
used as well to test applicability of an ultrasonic bath over 4 h for 1,3-dipolar 
cycloaddition. As alkynes the peptides 6 and 7 were used fully deprotected as well as 
N-terminal Fmoc-protected. With these short model peptides potential interfering 
effects of side chains like lysine or close proximity of tryptophan were supposed to be 
ruled out. Utilisation of Fmoc-protected peptides additionally masked the N-terminus. 
Copper ions might build complexes via coordination by free amino functionalities and 
thereby are no longer available anymore for click chemistry. Nevertheless, elimination 
or masking of the respective amino groups did not lead to product formation. 
To rule out the possibility that too many copper-ions are available and therefore inhibit 
the desired reaction[111,118], reduction of the applied CuSO4 · 5H2O to catalytic amount 
was tested. Peptide 6 was dissolved in MeCN and ultrapure water (1:1, v/v) and 
degassed with helium over 30 min. CuSO4 · 5H2O and NaAsc were dissolved in water, 
Fluo-Azide in MeCN was added and the reaction vessel shaken over night (Table 2.1, 
N). Monitoring via HPLC showed no conversion of the staring material, hence the 
copper concentration could successfully be excluded as potential reason for no 
conversion. 
The next step was to revise whether 1,3-dipolar cycloaddition will take place using a 
simplified system. The sensor was substituted with benzyl azide (BAz) and brought to 





reaction with Fmoc-protected 6 (Scheme 2.7, Table 2.1, M). After 24 h the reaction was 
stopped and analysed via HPLC and mass spectrometry. The obtained HPL-
chromatogram showed appearance of a new signal. ESI-MS of the isolated compound 
revealed that indeed click product (16) was generated, proving that CuAAC is possible 
with Fmoc-protected 6. As click reactions using Fluo-Azide in previous work[13] and the 
cycloaddition of BAz to 6 were successfully performed, an interaction between Fluo-
Azide and the respective peptide seems to inhibit the formation of product. 
Since the in Scheme 2.7 depicted conditions yielded no product formation when 
applied to Fluo-Azide, further screening was necessary. Therefore, another buffer was 
tested. A guanidine hydrochloride buffer (Gua · HCl) was selected consisting of 
guanidine hydrochloride (6 M), disodium phosphate (0.2 M) and tris(2-
carboxyethyl)phosphine hydrochloride (TCEP · HCl, 30 mM) and used at pH 7.3. 
Gua · HCl is known to denaturate proteins and inhibit nucleobases while very 
hydrophobic proteins remain naturated.[119] Applying the conditions shown in Table 
2.1, O, to click Fmoc-protected 6 and Fluo-Azide did not lead to triazol formation, 
which demonstrates that the used buffer does not represent the decisive factor. 
To evaluate whether application of click chemistry to Fluo-Azide in combination with 
peptides or amino acids is possible in general, cycloaddition with the Fmoc-protected 
amino acids propargyl glycine (Fmoc-Pra) and homopropargyl glycine (Fmoc-hPra) 
was sought of. Simultaneously, potential disturbance by the carboxylic acid groups of 
the sensor was avoided by utilising the methyl ester carrying sensor precursor 11 
Scheme 2.8). The respective amino acid and Fluo-Azide were treated with CuSO4 and 
NaAsc in MeOH and water. DIPEA was added and the reaction vessel shaken for 24 h 
(Table 2.1, P).[120] Since even cycloaddition with the amino acids did not precede using 
DIPEA as base, the MeOH/buffer system with ligand as additive was tested. The 
conditions shown in Table 2.1, Q were applied to both amino acids and the reactions 
shaken for 24 h. No full conversion took place but for both amino acids the desired 
products 17 and 18 were detected in mass spectrometry and purified via HPLC. 
 
Scheme 2.7 Successful click reaction using benzyl azide (BAz) and Fmoc-protected 6. 





Scheme 2.8 HUISGEN reaction of azide 11 and alkyne Fmoc-Pra or Fmoc-hPra. 
After successfully coupling Fmoc-Pra and Fmoc-hPra with sensor precursor 11 via click 
reaction, the same conditions were used to label Fmoc-protected peptide 6. Despite 
masking of amines and usage of 11, containing no free carboxylic acids, the 
cycloaddition would not proceed. 
With the labelled amino acids 17 and 18 in hand but unable to click precursor 11 
directly to a peptide, incorporation of 17 into a peptide on resin via standard coupling 
conditions (GP1.1) was sought of (Scheme 2.9). This synthetic route was highly 
unfavourable since the valuable labelled amino acid had to be utilised in excess of five 
equivalents. Furthermore, after coupling the methyl ester had to be cleaved, which 
might degrade the peptide, due to the harsh conditions, necessary. Nevertheless, using 
standard coupling conditions and NMP as solvent 17 was added to WALP24 5 on 
swollen resin in a BD-syringe. The reaction vessel was shaken for one hour, N-terminal 
Fmoc removed and the peptide cleaved from resin (GP1.3). Analysis of the resulting 
peptide revealed no product formation, but cleaved WALP24 5 was not detected 
either. 
Since coupling attempts if 17 were unsuccessful, the strategy was changed again. The 
new ligand BTTAA was tested for peptides 6 and 8 using the conditions shown in 
Table 2.1, R, and conditions S for peptides 4 and 6. Again, no conversion occurred, 
which is why the focus shifted from peptide labelling towards lipid labelling. 
Applying condition O (Table 2.1) to cholesteryl derivative 1 and DOPE derivative 3 
yielded no product but changing to conditions S in the case of 3 a new signal appeared 
in HPLC. Analysis via Ca2+-dependent fluorescence measurements and mass 
spectrometry revealed no product but degraded Fluo-Azide. Due to the fact that a test 
reaction of alkyne-modified PEG5000 with Fluo-Azide worked nicely, it was reviewed 
whether addition of unmodified PEG might be of assistance in this click reaction set up 
(Table 2.1, T). However, after addition of PEG5000 no reaction at all had taken place. 






Scheme 2.9 Coupling attempt to incorporate labelled amino acid 17 via standard peptide synthesis. 
Another approach to label membrane components instead of CuAAC was sought. The 
azide moiety of Ca2+ sensor Fluo-Azide is readily reducible to generate a primary 
amine, which can then be coupled via amide-bond formation. For azide reduction 
Fluo-Azide was treated with TCEP in THF and water and shaken over 24 h. Removal 
of solvents and isolation using HPLC yielded pure amine 19 (Scheme 2.10). As 
counterpart for the desired coupling reaction a short peptide (9) was synthesized and 
activated as NHS-ester (Scheme 2.11, top). For coupling 9 and 19 were dissolved in 
anhydrous DMF and treated with triethylamine for 24 h (Scheme 2.11, bottom). After 
solvent removal the labelled test-peptide 21 was not obtained. 
As this variety of labelling attempts all proved to be unsuccessful, one last effort was 
conducted. In 2014 SIMERSKA et al. published their work on construction of self-
adjusting lipopeptides using i.a. CuAAC reactions.[121] They reported complete 
conversion after one hour under utilisation of copper wire in DMF. At first these 
conditions were tested on 4 and 6. The peptides were dissolved in DMF along with 
Fluo-Azide in a micro reaction vessel. A piece of copper wire (approximately 0.7 g wire 
per 0.1 µmol sensor) was formed into a spiral, put inside the reaction vessel, and the 
reaction was shaken under light exclusion. To begin with, the reaction was conducted 
at 45 °C with occasional vortexing. Since no reaction was detectable after two hours, 
the temperature was increased to 50 °C. Even after three days no conversion took place 
in the case of WALP25 4. But using Fmoc-protected 6 a small new signal was observed 
by HPLC-monitoring after 17 h showing absorption at 488 nm. However, even after 
three days the newly formed signal would not increase. With these results, no further 
efforts to label peptides were performed. 
 
Scheme 2.10 Azide reduction using TCEP to obtain amine 19. 
 





Scheme 2.11 Activation of the test-peptide 9 as NHS-ester (top); Coupling attempt with 19 (bottom). 
On the other hand, when these conditions were applied to the modified DOPE 3 and 
cholesterol 1 full conversion of the sensor was achieved after 17 h at 50 °C (Figure 
2.16). Measurement of ESI-MS showed no product but using MALDI as ionisation 
technique with sinapinic acid as matrix formation of both labelled compounds 15 and 
22 was verified. 
To control whether the fluorescence and therefore the Ca2+-binding performance is still 
intact after binding the sensor to 1 or 3, Ca2+-dependent fluorescence measurements 
were conducted (Figure 2.17 and Figure 2.18). For both compounds (15 and 22) intact 
fluorescence comportment via Ca2+-binding was observed. These labelled membrane 
components can now easily be incorporated into model membrane to study membrane 
interaction, i.e. SNARE mediated membrane fusion.  
 
Figure 2.16 Progress of click reaction using 1 and Fluo-Azide; HPL-chromatograms of the reaction mixture 
after 0 h, 2 h and 17 h with normed intensity. 






Figure 2.17 Chemical structure of the Fluo-Azide-labelled cholesterol derivative 22 (A); Ca2+-dependent 
fluorescence measurements of 22 (B). 
 
Figure 2.18 Chemical structure of the Fluo-Azide-labelled DOPE derivative 15 (A); Ca2+-dependent 
fluorescence measurements of 15 (B). 




Due to the high sensitivity of Fluo-Azide towards Ca2+, the labelled compounds 15 and 
22 are well applicable for systems or cell compartments with low Ca2+ concentrations. 
But when the amount of available Ca2+ is too high, all Fluo-Azide molecules are 
saturated and a further increase in Ca2+ quantity cannot be detected. For such systems 
a sensor with lower Ca2+ affinity, like the X-Rhod-Azide, is preferable. Therefore, the 
X-Rhod-Azide sensor was used for click reaction as well. The respective alkyne (1 or 3) 
and X-Rhod-Azide were dissolved in DMF in a micro reaction vessel. A spiral of 
copper wire was added and the mixture shaken at 50 °C for 17 h. When letting the 
cholesterol derivative 1 react with the sensor longer reaction times of 24 h were 
necessary but still complete consumption was not achieved. In case of the lipid 
derivative 3 the reaction was complete after 17 h. The isolated labelled lipid 23 was 
used for Ca2+-dependent fluorescence measurements to verify its binding properties 
(Figure 2.19). 
After successful synthesis of the labelled compound 23 it can be used for a variety of 
Ca2+-dependent measurements, if rather high Ca2+ concentrations are present. 
 
Figure 2.19 Chemical structure of the X-Rhod-Azide-labelled DOPE derivative 23 (A); Ca2+-dependent 
fluorescence measurements (B). 
  





2.6 Application of Ca2+ Sensor-Labelled Lipids 
2.6.1 Analysis of SNARE-mediated Membrane Fusion using Labelled Lipids 
A problem of many fusion assays is the differentiation of hemi-fusion and full-fusion 
or even just aggregation. One major aspect of this difficulty is the potential of leakage, 
which can, depending on the applied fluorescence system, lead to false positive results. 
Furthermore, dye-loaded vesicles tend to disrupt in case of strongly differing 
osmolalities of the vesicles interior and the surrounding solution. Since Ca2+ is thought 
to be crucial for membrane fusion in living systems[26,29,122–124], developing a Ca2+-
dependent fluorescence system to detect full-fusion of membranes or vesicles might 
prove to be useful. 
To overcome the obstacles of established assays for detection of membrane fusion 
while respecting the importance of cellular Ca2+, a new assay was designed. This 
method uses the Ca2+ sensor-labelled cholesterol derivative 22, due to the high 
sensitivity of Fluo-Azide towards Ca2+ ions. Two species of model membranes in form 
of large unilamellar vesicles (LUVs) are supposed to be generated, with 22 
incorporated into the membrane of one species and Ca2+ ions filled in the lumen of the 
other species (Scheme 2.12). For fusion of the vesicles artificial SNARE analoga are to 
be applied. To follow the fusion process fluorescence measurements are to be 
conducted, since only in case of full-fusion, which means that the contents of the 
vesicles mix, Ca2+ ions and the sensor Fluo-Azide come in contact to increase 
fluorescence. The advantage of this type of content mixing experiment is that it 
remains unaffected by leakage. In contrast, self-quenching systems yield in 
fluorescence increase upon vesicle fusion as well as leakage and are therefore sensitive 
towards false-positive results. 
 









The lipid system used as the model membrane consisted of 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), DOPE and cholesterol (Chol) in the ratio DOPC/DOPE/Chol 
= 50:25:25, which is the standard lipid system utilised in our work group. Preparation 
of lipid films and LUVs was conducted following GP2.1 and GP2.2. Before starting 
with fusion experiments, it was tested whether the labelled compound 22 will show 
the same Ca2+-dependent fluorescence when incorporated into a model membrane than 
in solution. Vesicles containing 22 were prepared with a ratio of labelled to unlabelled 
lipids of 1:75, resulting in a rather high density of the Ca2+ sensor. Measuring 
Ca2+-dependent fluorescence using these labelled vesicles, however, showed no change 
in fluorescence dependency or emission wavelength (Figure 2.20). Hence, the 
possibility of self-quenching of the sensor was ruled out. 
Since incorporation of labelled cholesterol 22 into a model membrane did not alter the 
performance of the sensor, vesicle fusion experiments could be performed. The first 
applied SNARE system for vesicle fusion was developed and synthesised in our work 
group by B. HUBRICH. The SNARE peptides are modified with a PNA recognition 
domain. The backbone of the PNA consists of repeating N-(2-aminoethyl)-glycine (aeg) 
units. In this case PNA1s-synaptobrevin and PNA3s-syntaxin were chosen (Figure 
2.21). In previous work full-fusion using these SNARE analoga was achieved, while 
the peptide-containing vesicles seemed to remain stable over hours without 
aggregation or disintegration observable. Nevertheless, the best results were obtained 
when the fusion experiments were conducted immediately after extrusion 
(unpublished results by B. HUBRICH). 
 
Figure 2.20 Ca2+-dependent fluorescence measurements of labelled vesicles with 22 incorporated. 






Figure 2.21 Schematic representation of the SNARE-peptides with PNA recognition units. The chemical 
structure of the PNA-SNARE peptides is not shown due to the unpublished status. 
For the first content mixing experiment three different vesicle species were generated, 
which all had the previously mentioned lipid composition. Vesicle species A (VA) was 
labelled with 22 in the 22 to lipid ratio of 1:75 and with sulphorhodamine B-DOPE 
(0.75 mol-%). As SNARE the peptide PNA1s-synaptobrevin was incorporated in a 
peptide to lipid ratio of 1:200. Since for Ca2+-dependent fluorescence measurements 
MOPS-buffers with zero free Ca2+ (buffer A, 30 mM MOPS, 10 mM EGTA, 100 mM KCl, 
pH 7.2) and 39 µM free Ca2+ (buffer B, 30 mM MOPS, 10 mM CaEGTA, 100 mM KCl, pH 
7.2) were used (see chapter 2.5.2), these buffers were chosen for monitoring vesicle 
fusion via fluorescence as well. 
Prior to vesicle preparation the osmolality (bosm) of the utilised buffers was measured to 
ensure vesicle stability. The osmolalities detected were nearly identical for both buffers 
(bosm(A) = 0.272 osmol/kg; bosm(B) = 0.275 osmol/kg). Hence, a buffer exchange should 
not lead to disruption of the prepared vesicles. 
For extrusion of VA buffer A was utilised. To inhibit Ca2+-binding by the sensors on 
the outer membrane leaflet, the vesicles were treated with an aqueous solution of 
MnCl2. Mn2+ is bound by the BAPTA moiety with significantly higher affinity than 
Ca2+, which inhibits binding of Ca2+. Since complexation of Mn2+ by BAPTA does not 
block PET, the fluorescence intensity decreases drastically in comparison to the Ca2+-
bound complex. For verification a fluorescence measurement of the vesicles VA 
treated with Mn2+ was conducted (Figure 2.22). The vesicles were added to Ca2+-
containing buffer B and the fluorescence intensity was detected over 60 s. Then, Mn2+ 
was added to check the time needed for Mn2+ to quench the fluorescence as well as the 
amount of fluorescence decrease. After addition of Mn2+ an instant drop in 
fluorescence intensity was observed. 





Figure 2.22 Fluorescence measurement of vesicle species VA containing labelled cholesterol 22. Addition 
of Mn2+ after 60 s showed significant decrease in fluorescence intensity. 
To remove excessive Mn2+ ions from the VA-containing solution size-exclusion 
chromatography using Sephadex G-50 fine was conducted, which is why 
sulphorhodamine B-DOPE was included into the lipid mixture. By means of the pink 
colour of sulphorhodamine B the movement of the vesicles on the column could be 
observed. The pure vesicles VA were obtained in Ca2+ and Mn2+-free buffer A. The 
second vesicle species VB was labelled with the same amount of sulphorhodamine B-
DOPE as VA and as SNARE peptide PNA3s-syntaxin in the peptide to lipid ratio of 
1:200 was added. Swelling of the lipid film and extrusion were conducted using buffer 
B to fill the vesicles with Ca2+. To obtain Ca2+-free surroundings a buffer exchange of 
the vesicles VB to buffer A was performed by size-exclusion chromatography. The 
third vesicle species served as control vesicles (CV). It was labelled just with 
sulphorhodamine B-DOPE (0.75 mol-%) and extruded in Ca2+-free buffer A. For all 
three vesicle species the total lipid concentration was adjusted to 0.625 µM prior to 
extrusion. 
To analyse sensor–sulphorhodamine B interactions a solution of 60 nmol Fluo-Azide in 
1.3 mL buffer B was treated with an aqueous solution of sulphorhodamine B (0.5 mM). 
As shown in Figure 2.23, at low fluorophore concentrations no disturbance of sensor 
fluorescence occurred. After further addition of sulphorhodamine B the sensor 
intensity decreased and a new emission band appeared. When Fluo-Azide was treated 
with an excess of sulphorhodamine B the sensor band vanished while the 
sulphorhodamine B band with a maximum at 587 nm increased. From these 
measurements it was concluded that the influence of sulphorhodamine B on the sensor 
fluorescence was negligible when low fluorophore concentrations were applied. 






Figure 2.23 Interaction between Fluo-Azide and sulphorhodamine B shown on the basis of Ca2+-
dependent fluorescence of Fluo-Azide. 
After these preparations and pretests fusion experiments were conducted. Vesicles VA 
(72 µL) and buffer A (1.11 mL) were filled into a stirrable fluorescence cuvette and 
after one minute vesicle species VB (169 µL) was added, which equates a VA/VB-ratio 
of 1:4 relating to the vesicle concentrations. As can be seen in Figure 2.24, no increase 
in fluorescence intensity was detected, meaning that no fusion took place. Since no 
change occurred, VA solution (216 µL) was added after 4.5 min to yield a 1:1-ratio. The 
fluorescence intensity was observed for another 9 min but still no fusion occurred. 
Therefore, to destroy the vesicles the solution was treated with Triton X-100 (10 % (v/v) 
in ultrapure water). This led to a small but steady increase of fluorescence intensity, 
which did not alter after further addition of Triton X-100. The marginal increase can 
easily be explained by the fact that the only Ca2+ ions available to induce fluorescence 
were within the VB vesicles. After disrupting the vesicles the rather high concentrated 
(39 µM) Ca2+ was diluted in the much bigger Ca2+-free buffer volume, leading to a small 
fluorescence increase. To gain the maximum possible fluorescence intensity, 
concentrated aqueous CaCl2 solution was added to enhance the Ca2+ concentration, 
resulting in a distinct fluorescence increase. A second addition of CaCl2 yielded a slight 
decrease in fluorescence, probably due to dilution, and another addition of 
Triton X-100 led to another minor intensity increase. 





Figure 2.24 Fusion experiment using the SNARE-analoga PNA1s-synaptobrevin and PNA3s-syntaxin 
with a total lipid concentration of 0.625 µM. The arrows mark the point of which the indicated reagents 
were added. 
Since the fluorescence intensity was rather low during this first fusion experiment, the 
total lipid concentration during lipid film preparation was increased to 2.5 µM. 
Furthermore, a change in buffer system was performed. Since the previously used 
MOPS-buffers were utilised for Ca2+-dependent fluorescence measurements, it seemed 
consequential to test them for fusion experiments, too. The applied standard buffer for 
fusion assays in our work group was a HEPES-buffer, consisting of 20 mM HEPES, 
1 mM EDTA, 100 mM KCl, pH 7.4 (buffer C). For preparation of a Ca2+-containing 
buffer CaCl2 was added to the HEPES buffer to adjust the Ca2+ concentration to 0.1 mM 
(buffer D). Again, the osmolality was revised and nearly identical values were 
obtained (bosm(C) = 0.200 osmol/kg; bosm(D) = 0.203 osmol/kg). Applying these changes 
the procedure remained otherwise as mentioned before. After extruding the PNA3s-
syntaxin-containing vesicles (VB), immediately a white precipitate occurred, indicating 
aggregation of the vesicles and therefore making them unresponsive towards fusion. 
Nevertheless, a fusion attempt was performed but no successful fusion occurred. Even 
though the desired goal was not obtained, important information was reasoned: the 
influence of sulphorhodamine B on the sensor fluorescence, which was thought to be 
negligible, seemed to be great enough to disturb the fluorescence intensity. 
Sulphorhodamine B appeared to form Ca2+ complexes, thereby decreasing the amount 
of sensor–Ca2+ complexes and hence the fluorescence intensity as well. 
To avoid the obstacles of aggregating vesicles and disturbed data by 
sulphorhodamine B the system was altered. The total lipid concentration of the stock 
solution was reduced to 1.25 µM and no sulphorhodamine B-DOPE included. Without 
the fluorophore included no buffer exchange was performed. To avoid interference of 
fusion by Mn2+, which could not be removed by size exclusion chromatography as 





well, the sensor molecules on the outer leaflet remained untreated with MnCl2. 
Leaving the outer sensors active, while no rebuffering of Ca2+-containing vesicles into 
Ca2+-free buffer is performed, will result in a considerable increase in fluorescence 
when the sensor-containing vesicles are mixed with the vesicles in Ca2+-including 
buffer. Still fusion, if occurring, should be detectable since it is a slow process, while 
the fluorescence increase, caused by Ca2+ addition, occurs very fast. 
The prepared vesicles VA, containing 22 and PNA1s-synaptobrevin, and Ca2+-free 
HEPES buffer were given into a stirrable fluorescence cuvette and after 100 s treated 
with Ca2+-containing (1 mM) HEPES buffer to saturate the sensor molecules on the 
outer membrane leaflet. After stabilisation of the fluorescence intensity, the vesicles 
VB, including PNA3s-syntaxin, were added. A significant fluorescence increase was 
observed but no fusion detected. The experiment was repeated without previous 
addition of Ca2+ but again, no vesicle fusion was ascertained. 
Since no vesicle fusion had been achieved, the utilised SNARE-analoga were 
exchanged for a possibly more potent SNARE system, shown in Figure 2.25. The K3-
/E3-SNARE-peptides are a well studied system and form a coiled-coil bundle to 
mediate membrane fusion.[91] The proteins applied in this work were designed and 
graciously provided by J.-D. WEHLAND. Incorporation of the peptides was conducted 
likewise as before. Four vesicle species were prepared: VA containing 22 and E3-
synaptobrevin in Ca2+-free HEPES buffer, VB containing K3-syntaxin in 0.1 mM free 
Ca2+ HEPES buffer, VC containing 22 in Ca2+-free HEPES buffer and control vesicles 
CV in 0.1 mM free Ca2+ HEPES buffer. Since vesicles decorated with K3-syntaxin are 
prone to aggregation, the VB vesicles were extruded last and immediately utilised for 
fusion experiments. 
 









To start the experiment a stirrable fluorescence cuvette was equipped with vesicles VA 
and Ca2+-free buffer. After 145 s VB were added to obtain a VA/VB-ratio of 1:4. After 
the immediate and distinct increase of fluorescence intensity, due to addition of Ca2+-
containing buffer, a slower and slight fluorescence increase was observed (Figure 2.26, 
black curve). Addition of 1 mM free Ca2+ buffer after 500 s yielded no alteration in 
intensity, which indicates that all sensor molecules in the outer membrane leaflet are 
saturated with Ca2+. Further appending of VA to gain a 1:1-ratio of VA and VB after 
620 s resulted in a distinct and fast increase in fluorescence intensity due to the 
enhanced amount. Subsequently a light upward tendency of fluorescence intensity 
could be observed, which might be accounted by slow fusion processes. As expected, 
control experiments using VB with VC (red curve) or VA with CV (blue curve) 
showed no fluorescence increase, which could be referred to fusion processes.  
Magnifying the curve after addition of VB showed a curve progression of restricted 
growth (Figure 2.27). Due to the very low fluorescence increase of this measurement 
the experimental outcome has to be treated with caution. It might hint that vesicle 
fusion occurred but further measurements are needed to confirm these results. 
Precisely, it is necessary to enhance the overall intensity so that changes in the 
fluorescence intensity can unequivocally be detected and assigned to fusion processes. 
 
Figure 2.26 Fusion experiment using K3-syntaxin and E3-synaptobrevin (black curve) and control 
experiments with just one SNARE-species present (red and blue curves). The addition specifications 
shown refer to the black curve. 






Figure 2.27 Magnified view of probable fusion curve (black curve in Figure 2.26) with fit line (red). 
To establish this assay for membrane fusion measurements further enquiries have to 
be performed, which, unfortunately, could not be done in this work due to time 
limitations. These first experiments using the E3-synaptobrevin/K3-syntaxin system 
show promising results. With some refinements this assay will become a very useful 
and broadly applicable method to follow fusion processes, while taking the respective 





3 Labelling of Lipids via 7-Azaindole 
3.1  Introduction 
The phenomenon of membrane fusion is omnipresent in living systems and even 
though a lot is known about this fundamental process, there is still a tremendous 
amount to learn regarding the involved molecules and the underlying mechanism.[125] 
Via membrane fusion molecules are transported into and out of cells. This 
translocation is performed by encapsulation of the compounds as cargo and 
subsequent release by fusion into the target organelle or cell.[75] For instance, enveloped 
viruses use the process of membrane fusion to insert their genome into host 
cells.[75,125,126] One of the most prominent example for fusion processes is the fertilisation 
process by fusion of egg cell and sperm in order to create a new organism.[75,82,105] 
The fusion process in natural systems does not occur spontaneously. A highly complex 
and well-tuned fusion machinery was developed throughout time. In the 1980s, the 
evolutionary preserved SNARE proteins were discovered, which were identified as 
key components of this machinery.[71] Besides these proteins, the composition of the 
membrane at the fusion site is a crucial factor. A rather rare but significant membrane 
lipid is phosphatidylinositol-4,5-bisphosphate (PIP2). PIP2 is not just a source for 
essential second messenger compounds[14] but is required in the plasma membrane for 
fusion processes.[16,17] The amount of PIP2 is increased at the fusion site to form a 
domain also called raft of altered lipid constitution. To these rafts proteins (i.e. 
SNAREs) are bound and therefore the rate of vesicle priming is regulated, which 
includes the rearrangement and modifications of lipids and proteins under usage of 
ATP prior to fusion. Hence, the presence of PIP2 is indispensible for active molecule 
transport, such as Ca2+-triggered neuronal exocytosis.[16,17] 
To verify the enrichment of PIP2 and raft formation at the fusion site and to gain 
further insight into the fusion process, the ultimate goal of this project is to synthesise a 
fluorescent probe-labelled PIP2. In order to develop a synthetic route the sterically and 
electrically less demanding phosphatidycholine (PC) was chosen as first synthetic 
target. As fluorophore the well-studied and environment-sensitive 7-azaindole was 
selected and chemical modifications of 7-azaindole were performed to enable 
subsequent incorporation in model lipids for fluorescence measurements in 
membranes. 





3.2 Raft Formation in Lipid Membranes 
 A basic requirement in biological systems is the separability from the environment. 
This boundary protects the organism of undesired substances and influences while 
enabling controlled permeability.[6,127] Therefore, pH and electrical gradients in 
eukaryotic cells are maintained and due to membrane proteins the cell can react 
towards environmental changes or signals of other cells. The main components of 
membranes are lipids, which can reach a diversity of 500–2000 different lipid species.[6] 
Lipids are amphiphilic molecules, containing a polar/hydrophilic head group and 
usually two non-polar/lipophilic alkyl chains. Via non-covalent interaction lipids form 
a double layer of approximately 5 nm thickness. In aqueous systems the polar head 
groups are located facing the environment or cytosol, while the non-polar chains lay 
within the membrane, protected against the polar solvent.[6] 
The first broadly accepted membrane model was the so-called ‘fluid mosaic’ model, 
published in 1972 by S. SINGER and G. NICOLSON. They described a homogeneous lipid 
bilayer for cell-membranes with anchored membrane proteins, that are freely diffusible 
within the membrane.[128] Due to research progress, a few important modifications of 
the model were performed. Some of these findings are limited protein mobility owing 
to interactions with intra- or extracellular opponents, asymmetrical lipid composition 
of the bilayer and a drastic increase of protein density on the membrane surface.[129] 
Furthermore, dependent on conditions as pressure and temperature a membrane can 
adopt different states. The solid ordered (So or gel) state mainly contains lipids with 
saturated fatty acids or unsaturated fatty acids in all-trans conformation, which 
increases the VAN DER WAALS interactions and allows a very high degree of order 
(Figure 3.1, left).[127] The lateral movement is restricted and membrane rigidity 
enhanced.[130–132] Rise in temperature over the lipid’s respective melting temperature 
(Tm) leads to phase transition from So to the liquid disordered (Ld) state (Figure 3.1, 
middle). In this fluid state the degree of order regarding the acyl chains and head 
groups is decreased, resulting in an expansion of the membrane (increased area per 
lipid by 15–30 %[133]). Lipids and membrane proteins exhibit high lateral mobility in the 
bilayer. Addition of cholesterol to a bilayer in the Ld state changes the phase properties 
to generate the liquid ordered (Lo) state (Figure 3.1, right). The rigid and planar 
cholesterol molecules insert between the acyl chains and therefore impose 
conformational order comparable to the So state while barely restricting lateral 
mobility.[130] 





Figure 3.1 Lipid phases of membranes in aqueous medium, showing the solid-ordered (So, left), liquid 
disordered (Ld, middle) and liquid ordered (Lo, right) state. Picture adapted from [134]. 
In natural systems the lipid membranes, like the plasma membrane, consist of a 
diversity of lipids with phospholipids as the dominating species. Further components 
are sphingolipids, like ceramides, sphingomyelins or glycosphingolipids, and sterols, 
such as cholesterol or ergosterol.[132] The concentration ratio of the individual lipids 
influences the membrane properties as its thickness, curvature or the state of the 
membrane.[127,135] Every lipid has a distinct Tm, while lipids with long and saturated 
hydrocarbon chains reveal high Tm, lipids with shorter or (cis-) unsaturated alkyl 
chains have lower Tm. Lowering the temperature leads to phase transition and 
separation of lipids with higher Tm to form ordered domains. Present cholesterol is 
enriched in these ordered domains and inhibits formation of a So state under Lo phase 
generation. Therefore, co-existence of Lo and Ld phases is enabled.[130] 
Over time many proteins were discovered to be functionality-dependent towards 
membrane composition, and hence, the concept of small domains of micro- or 
nanoscale was developed.[129,132] The assembly of specific membrane proteins and lipids 
with increased acyl chain order was introduced as lipid or membrane rafts.[127,129] The 
raft idea was postulated as explanation for lipid sorting in vivo and selective self-
association of cholesterol and sphingolipids for lateral phase segregation in vitro.[136] 
Lipid rafts were thought to be stable domains of tightly packed cholesterol and 
sphingolipids with high concentration of membrane proteins (Figure 3.2).[129,137,138] 
Investigation of rafts proved to be difficult due to the lack of suitable methods to 
observe lipid rafts without disturbing or influencing the system. A popular approach 
was the use of detergents like Triton-X 100 to dissolve membranes and extract 
detergent resistant membrane (DRM) fractions at low temperatures, which might be 
the result of ordered rafts. The thus obtained membrane domains were not just rich in 
sphingomyelin and cholesterol but in glycosylphosphatidylinositol (GPI)-anchored 
proteins, as well.[131,136] Proteins with GPI anchors in the plasma membrane are 
exclusively positioned in the outer leaflet of the membrane (Figure 3.2). In case of other 
types of lipids as linker, the protein is to be found just in the inner leaflet.[139] 






Figure 3.2 Simplified lipid raft model. Sphingolipids and glycerophospholipids with saturated and longer 
acyl chain form a slightly thicker, cholesterol-enriched raft containing GPI-anchored (outer leaflet) or 
dually-acylated (inner leaflet) proteins. From: Lehninger Principles of Biochemistry 6e, by David L. 
Nelson, et al,  Copyright 2013  by W.H. Freeman and Company. Used by Permission of the publisher 
Macmillan Learning.[139]. 
Phosphoinositides (PI) are with only 1 % present in the plasma membrane but are not 
just important to fixate proteins to the membrane.[14,139] The twice phosphorylated 
phosphatidylinositol-4,5-bisphosphate (PIP2) is crucial for a variety of physiological 
processes, such as ion channel activation, enzyme activation, exocytosis and second 
messenger production.[14,16] PIP2 functions as source for three second messengers via 
hydrolysis or phosphorylation: inositol-1,4,5-trisphosphate (IP3), diacylglycerol (DAG) 
and phosphatidylinositol-1,4,5-trisphosphate (PIP3).[15,16] Hydrolysis of PIP2 to generate 
IP3 and DAG is performed by PI-specific phospholipase Cs (PLCs), following the 
IP3/DAG-pathway.[140] The water-soluble IP3 is emitted into the cytoplasm and induces 
Ca2+ release from internal stores.[15] DAG stays in the membrane, where it activates the 
protein kinase C (PKC), which will then phosphorylate various cellular proteins.[141] 
The importance of PIP2 and its metabolites becomes especially clear when considering 
egg fertilisation of mammals. During fertilisation, not just genetic material but also 
PLC-ζ is transported into the egg. The PLC activates the egg by generating a wave of 
IP3 and subsequently increased concentration of free Ca2+.[14] Furthermore, presence of 
PIP2 in the plasma membrane was found to be a requirement for neuronal exocytosis. 
During membrane fusion, synaptotagmin binds to PIP2 in a Ca2+-independent manner 
and is thought to direct and quicken the subsequent Ca2+-dependent fusion process.[17] 
Using stimulated emission depletion (STED) microscopy, a drastic increase of the PIP2 
concentration to 3–6 % in PC12 cells at fusion site could be verified.[16] 





Figure 3.3 Schematic visualisation of a GPI-anchored protein attached to the outer leaflet of a membrane 
bilayer. A short oligosaccharide consisting of mannose (Man) and N-acetylglucosamine (GlcNAc) serves 
as a linker between lipid and protein. From: Lehninger Principles of Biochemistry 6e, by David L. Nelson, 
et al,  Copyright 2013  by W.H. Freeman and Company. Used by Permission of the publisher Macmillan 
Learning. [139]. 
Although DRM isolation using detergents provided a variety of information regarding 
raft composition, the temptation to rely on detergent extraction might be deceptive. 
Other studies reported detergence-induced disruption of membrane raft composition 
and therefore isolation of non-authentic membrane domains.[142] Other, probably better 
suited methods to examine rafts are fluorescence techniques, utilizing fluorescent 
lipids or proteins, or spin-labelled lipids.[143] Another very promising approach is the 
application of super-resolution microscopy techniques like STED microscopy.[142,144,145]  
Due to the general difficulties in raft analysis it is still debated whether rafts in living 
cells even exist.[145,146] Nevertheless, an agreement regarding the definition of rafts was 
obtained: “Membrane rafts are small (10–200 nm), heterogeneous, highly dynamic, 
sterol- and sphingolipid-enriched domains that compartmentalize cellular processes. 
Small rafts can sometimes be stabilized to form larger platforms through protein-
protein and protein-lipid interactions.” (Keystone Symposium of Lipid Rafts and Cell 
Function 2006).[138,147] This rather vague definition of lipid or membrane rafts illustrates 
that, even though quite some information was assembled[148], further inquires to 
unravel existence, formation and functions of raft are inevitable. 






Identifying dynamics and structure of proteins is a non-trivial task. To address this 
problem tryptophan has been used as the most common optical probe.[21] However, 
two drawbacks exhibit this approach to be quite unfavourable. First, the fluorescence 
decay of tryptophan is non-exponential[149,150], which complicates the interpretation of 
measurements after the probe has been incorporated into a peptide.[21,151,152] Second, 
inartificial proteins usually comprise the natural amino acid tryptophan more than 
once and therefore, distinguishing of the respective emissions is required.[21] When 
searching for a better alternative the unnatural amino acid 7-azatryptophan (7AW, 
Figure 3.4), using 7-azaindole (7AI) as chromophore, came into focus. Compared to 
tryptophan, 7AW is a robust probe with specifiable absorption and fluorescence 
spectra with a red-shifted absorption maximum of 10 nm and fluorescence maximum 
of 70 nm.[21] The fluorescence decay in aqueous solutions is single exponential over a 
broad pH range. Comparison to tryptophan revealed a significantly different 
distribution of electrons and increased quantum yield.[153] Due to the non-invasive 
incorporability of 7AW into peptides via peptide synthesis and bacterial proteins, and 
the alterability of the fluorescence spectra, a broad field of potential applications is 
enabled.[21,154,155] 
The shift in fluorescence maxima of 7AW or 7AI is dependent on the environment of 
the chromophore. This characteristic can be explained by the increased lifetime of the 
exited state S1. Upon excitation the tautomeric form of 7AI is energetically favoured, 
hence, a hydrogen transfer will take place (Scheme 3.1).[20] Especially in alcohols such 
as methanol or ethanol the excited-state tautomerisation proceeds rapidly. 
Furthermore, the fluorescence intensity is affected by solvents, making 7AI a well 
applicable probe to analyse water restricted domains as lipid bilayers.[156] 
Upon publication of the DNA model by J. WATSON and F. CRICK the possibility has 
been suggested that proton transfer tautomerisation might be responsible for 
mutations.[157] Due to the structural similarity, the 7AI dimer is used as a model system 
to analyse mutagenesis of pair structures via photoinduced proton transfer.[157,158]  
 
Figure 3.4 Molecular structures of L-tryphophan and 7AW. 




In 1969, C. TAYLOR et al. proposed the excited-state double proton tautomerisation 
(ESDPT) of 7AI dimers caused by hydrogen bonds (Scheme 3.1, B)[159] and further 
studies revealed that a possibly cyclic state of solvation in alcohols enables such a 
proton transfer in monomers as well (Scheme 3.1, A).[18] Thus, the violet-fluorescing 
7AI dimer is converted into the green-fluorescing tautomer.[158] The monomer 
dissolved in methanol (comparable spectrum in ethanol shown in Figure 3.5) exhibits 
two maxima in fluorescence spectra as well with the normal species band of higher 
energy at 374 nm and the energetically lower tautomeric species at 505 nm.[18] 
Solvation of 7AI in non-polar, aprotic solvents like n-hexane or diethyl ether results in 
two slightly further blue-shifted emission maxima of approximately 490 and 340 nm, 
as shown in Figure 3.5. In water no emission due to ESDPT is detected, leading to just 
one signal with an intensity maximum about 390 nm.[19] The tautomerisation of near 
80 % of 7AI is inhibited in water by hydrogen bonds formed between one water 
molecule and one nitrogen atom, respectively (Figure 3.5).[18,19] The remaining 20 % 
capable of ESDPT produce an emission at ~500 nm, which would be visible if the 
population of tautomerising  7AI in water increases.[18] 
Furthermore, experiments with inversed micelles in n-hexane, performed by J. 
GUHARAY, showed a red-shift of 20 nm and drastic quenching of the fluorescence upon 
addition of distinct amounts of water.[156] These results are in good agreement with the 
findings of 7AI solvated in water. 
Another point of interest regarding 7AI as fluorescent probe is whether the double 
proton transfer proceeds in a concerted or stepwise mechanism. Various 
measurements, such as fluorescent upconversion and transient conversion 
techniques[160], isolated-molecule femtosecond dynamics[157] and time-resolved 
fluorescence[161], and calculations, like density functional theory (DFT)[162] and Franck-
Condon calculations[158] have been performed. So far, the concertedness or 
nonconcertedness is still debated with a variety of arguments and indications 
supporting both possibilities. Therefore, to find the decisive conclusion further 
investigations are necessary.  
 
Scheme 3.1 Chemical structure of the 7AI monomer in normal and tautomeric coordination of ethanol (A) 
and tautomerisation of the 7AI dimer in apolar solvents (B). 






Figure 3.5 Red-shifted fluorescence spectra of 7AI as effect of increased solvent polarity. Picture taken from [19]. 
 
  




3.4 Synthesis of 7-Azaindole-3-propionic Acid (25) 
7-Azatryptophan has been identified as an effective tryptophan inhibitor in the 
eukaryotic unicellular organism Tetrahymena pyriformis[163], and is built from 
7-azagramine. Subsequently, in 1956 ROBISON et al. published the synthesis of a variety 
of 3-substituted 7-azaindole derivatives to test their biological activities starting from 
7-azagramine (24).[163] 
In this work the synthesis of 24 was previously performed following the procedure 
stated by PIERCE et al. in 2011.[164] The retrosynthetic analysis for the complete synthesis 
of 25 is depicted in Scheme 3.2, B, starting with a MANNICH reaction to generate 
7-azagramine (24) from 7-azaindole (7AI), followed by alkylation of malonic ester with 
24. The last step of this route is the hydrolysis and decarboxylation of the diester 26 to 
form the desired compound 3-(1H-pyrollo[2,3-b]pyridine-3-yl)propanoic acid (25). 
For the first step of the synthesis, the conversion of 7AI into 7-azagramine 24, as shown 
in Scheme 3.3, dimethylamine (33 % (w/v) in ethanol) was dissolved in concentrated 
acetic acid and water at 0 °C. The mixture was treated dropwise with formaldehyde 
(37 % (w/v) aq.) and stirred for 30 min. 7-Azaindole in ethanol was added and stirred 
for 30 min at 0 °C followed by heating to 100 °C over 18 h.[164] Product 24 was obtained 
in 99 % yield and further reacted applying the procedure of ROBISON et al.[163] 
 
Scheme 3.2 Structures of 7-azaindole, 7-azatryptophan, 7-azagramine and the desired compound 25 (A); 
Retrosynthetic analysis to synthesise 25 starting from 7-azaindole (B). 
 






Scheme 3.3 Synthesis of 7-azagramine (24) starting from 7-AI. 
For the following substitution reaction of the dimethylaminyl moiety by a diethyl 
malonyl group a mixture of 24 and diethyl malonate was heated to 120 °C and treated 
with a catalytic amount of elementary sodium. After 6 h of stirring at 120 °C, the 
reaction was completed and product 26 was isolated with 58 % yield (Scheme 3.4, 
A).[163] To increase product formation a different procedure known from literature was 
tested employing milder reaction conditions and shorter reaction time (Scheme 3.4, B). 
A solution of 24 in diethyl ether was treated with diethyl malonate and ethyl 
propiolate was added at once.[165] The reaction mixture was stirred at r.t. for 1 h but 
after standard workup procedure no product could be detected. On this basis the 
previously stated reaction method was maintained. 
After the substitution reaction described above, hydrolysis and decarboxylation were 
necessary to form 25. Both reactions were performed in one step by heating 26 in 
concentrated hydrochlorid acid under reflux for 7 h[163], yielding the desired product 25 
with 99 % isolated yield (Scheme 3.5). 
 
Scheme 3.4 Tested procedures for synthesis of 26 using harsh (A) and mild (B) conditions. 
 





Scheme 3.5 Hydrolysis and decarboxylation of 26 in concentrated hydrochloric acid. 
In conclusion, the synthesis of 25 starting from 7AI worked well with an overall yield 
of 57 % using literature known protocols. 
 
 
3.5 Synthesis of Lipid Derivative 27 
The ultimate goal of this project is the synthesis of a 7AI-labelled phosphatidylinositol-
4,5-bisphosphate (PI(4,5)P2). To develop a synthetic route for fluorescent-labelled lipid 
synthesis the less sterically hindered and electron dense phosphatidylcholine (PC) 
presented a good starting point for the synthesis of synthetically labelled lipids. 
Incorporation of 7AI as fluorescence label was planned via amide bond formation 
using a six carbon atoms long linker carrying a terminal amino functionality. The 
retrosynthetic analysis of the planned synthetic route is depicted in Scheme 3.6. At first 
solketal is protected by a p-methoxybenzyl (PMB) group, followed by cleavage of the 
isopropylidene unit. As linker, Z-6-aminohexanoic acid is coupled to the primary 
alcohol, and consequently a fatty acid to the remaining secondary alcohol. 
Deprotection by removal of PMB allows subsequent incorporation of the PC-head 
group over two steps, followed by deprotection of the linker and coupling of the 
fluorophore 25. 






Scheme 3.6 Retrosynthetic analysis of 27. 
The first five steps for lipid backbone synthesis were described in 1996 by CHEN et al. 
beginning with the isopropylidene protected glycerine solketal.[166] First, the 
unprotected primary hydroxyl moiety of solketal is protected using p-methoxybenzyl 
chloride (PMBCl) to form a PMB ether by dissolving solketal in DMF and treating the 
solution with PMBCl and NaH at r.t. for 18 h (Scheme 3.7). Standard workup 
procedure yielded crude product 33, which was reacted further without previous 
purification. The subsequent reaction of 33 in THF with HCl (1 M) over 20 h cleaved off 
the isopropylidene protective group to reveal diol 32. 
CHEN et al. reported a short reaction time of 1 h each for both reactions. However, TLC 
monitoring showed that after 1 h barely product has formed. 
 
Scheme 3.7 Two step synthesis of 32 via PMB protection followed by isopropylidene deprotection. 




Another publication from NÄSER et al. stated a reaction time of 20 h under reflux 
conditions.[167] Therefore, the reaction period was increased but temperature 
maintained at r.t. while reaction progress was tracked via TLC. After 18 h the starting 
material had disappeared and the reaction was stopped. For deprotection of 33 to form 
diol 32 NÄSER et al. mention a longer reaction time than CHEN et al. of 6 h but TLC 
monitoring revealed that a significant amount of starting material still remained. 
Consequently, the reaction time was prolonged to 20 h, which resulted in complete 
conversion. Purification via flash column chromatography led to compound 32 in 
isolated yield of 67 %. 
To incorporate the linker unit via ester bond formation the procedure of CHEN et al. 
was applied. A solution of 32 and Z-6-aminohexanoic acid was treated dropwise at 
0 °C with a solution of dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine 
(DMAP) and stirred at 0 °C for 16 h (Scheme 3.8, A). The organic solvent was removed 
under reduced pressure and the residue redissolved in ethyl acetate. Since 
dicyclohexylurea (DCU), which is generated from DCC during the reaction, is 
insoluble in ethyl acetate it could easily be filtered off. The Steglich esterification 
worked smoothly and after purification 31 was obtained in up to 90 % yield. 
The next step was again a Steglich esterification to couple the respective carboxylic 
acid, in this case stearic acid, to 34. This was accomplished by treatment of 31 and 
stearic acid in DCM with a solution of DCC and DMAP at r.t. and stirring for 24 h. The 
generated product 34 was purified and obtained in 88 % yield as white crystals 
(Scheme 3.8, B). 
At this point of the synthesis two possibilities to proceed are conceivable. One way is 
to cleave off the carboxybenzyl (Z) protecting group to incorporate the fluorophore 25, 
followed by generation of the PC head group. The alternative is to first produce the PC 
head group and consecutively deprotect the linker and couple 25. 
 
Scheme 3.8 Steglich esterification of 32 with Z-6-aminohexanoic acid (A) and of 31 with stearic acid (B). 
 





In this case it was preferred to introduce the fluorophore as the very last step, hence 
the second route was followed. Thus, the next step was to cleave off the PMB group to 
generate a free primary alcohol. The protected compound 34 was dissolved in DCM 
and treated with dichlorodicyanobenzoquinone (DDQ) and small amounts of water 
over 24 h, which deprotected the alcohol following an oxidative mechanism under 
generation of p-methoxybenzaldehyde (Scheme 3.9, A). The isolated product 30 was 
obtained in 96 % yield. 
To introduce the PC head group the deprotected alcohol needed to be phosphorylated 
and subsequently coupled with ethanolamine. This was conducted in an one-pot 
reaction starting with deprotonation of 30 using triethylamine. The mixture was added 
slowly to a solution of phosphoryl chloride in THF at 0 °C, stirred at 0 °C for 10 min 
followed by stirring at r.t. for 45 min. The reaction mixture was again cooled to 0 °C 
and treated dropwise with ethanolamine and triethylamine in THF. After stirring for 
10 min at 0 °C the mixture was allowed to warm up to r.t. and stirred over night. 
Filtration and removal of the organic solvent yielded a residue, which was redissolved 
in concentrated acetic acid and water and heated to 70 °C for 1 h (Scheme 3.9, B).[168,169] 
After standard workup procedure compound 29 was obtained with a low yield of 8 %. 
For complete head group synthesis the next step was the methylation of the generated 
phosphoethanolamine derivative 29. Therfore, a solution of 29 in DCM and 2-propanol 
was treated with K2CO3 in water at 35–40 °C. Dimethyl sulphate in 2-propanol was 
added slowly and the reaction mixture stirred at 40 °C for 90 min.[168,169] Using mass 
spectrometry rather small amounts of formed product were detected, but could not be 
isolated. Interestingly, methylation of the phosphate group was observed as the 
dominating reaction (Scheme 3.10). Since the compounds 28 and 35 proved to be 
inseparable using column chromatography, no yield was determined.  
 
Scheme 3.9 Deprotection of 34 under mild oxidative conditions using DDQ (A). Introduction of the 
phosphate group and ethanolamine for PC head group formation (B). 





Scheme 3.10 Methylation of 29 yielded the desired compound 28 in traces and the fourfold methylated 35 
as main product. 
Due to the low yield of the reaction shown in Scheme 3.9, B and the undesirable side 
reaction forming 35, the strategy was changed, starting after coupling of the fatty acid 
(Scheme 3.8, B, product 34). Following the modified strategy, first the linker is 
deprotected to reveal the primary amino functionality (Scheme 3.11), second the 
fluorophore 25 is incorporated and last the head group is generated. Already the first 
reaction, cleavage of the Z protecting group (Scheme 3.11), proved to be not as trivial 
as expected. The tested reaction conditions are summarised in Table 3.1. 
To cleave the Z group 34 was given into a pressure vessel along with NaHCO3, 
palladium on charcoal (10 % Pd/C) and a t-butanol–water mixture (7:1, v/v). The 
reaction vessel was attached to a Parr apparatus. A hydrogen atmosphere was 
generated in the vessel and it was vigorously shaken over 24 h under 3.5 bar 
hydrogen.[166,170] The catalyst was then filtrated through Celite®, whereupon it was 
essential that the catalyst did not dry to avoid flying sparks and inflammation. 
Applying the above mentioned reaction conditions only led to product formation in 
traces, so the reaction conditions were modified by leaving out NaHCO3 but again no 
reaction took place. Therefore, reaction conditions described by WADHAVANE et al. 
were tested using dry THF as solvent and increased temperature. The reaction time 
was decreased to 4 h.[171] Mass spectrometry revealed no formation of the desired 
product 36 but cleavage of the linker to form 37 instead (Scheme 3.12). 
 
Scheme 3.11 Deprotection of primary amine of 34 by cleaving the Z protection group via hydrogenation. 






Scheme 3.12 Observed reaction after applying Z deprotection conditions to 34 as described by 
WADHAVANE et al.[171] 
Since the usage of hydrogen atmosphere seemed to be non-applicable for this system, 
another approach was searched for. A procedure published by BALDOLI et al.[172] was 
found utilizing ammonium formiate and methanol as solvent to generate hydrogen in 
situ. Compound 34 was dissolved in methanol under argon atmosphere and treated 
with palladium on charcoal and ammonium formiate. After reflux for 1 h, filtration 
and purification pure product 36 in 88 % yield was obtained. 
After successful cleavage of the protecting group forming 36, the next step was the 
incorporation of the fluorophore. Based on a procedure of JUMA et al.[173] the previously 
synthesised fluorophore 25 was activated as N-hydroxysuccinimide (NHS) ester using 
NHS and DCC mediation (Scheme 3.13). A solution of 25 in DCM was treated with 
NHS and DCC at 0 °C and stirred under ice cooling for one hour. After 12 h of stirring 
at r.t. and filtration of the reaction mixture 36 was added and stirred for additional 2 h. 
Analysis of the mixture after standard workup procedure revealed that no reaction 
product was formed but activation of 25 to NHS ester 38 was complete. The 
compounds 38 and 36 could be isolated.  
Table 3.1 Overview over applied reaction conditions for Z cleavage. 
Condition No. Solvent Temperature Time Admixture Product 
1 t-BuOH/H2O r.t. 24 h NaHCO3 + H2 traces 
2 t-BuOH/H2O r.t. 24 h H2 traces 
3 THF 50 °C 4 h H2 ‒ 
4 MeOH 75 °C 1 h NH4HCO2 
 
 
Scheme 3.13 Activation of 25 as NHS ester with subsequent coupling to 36. 




Due to its similar properties but higher alkalinity, DMF was tested as solvent for this 
reaction instead of DCM. At first no improvement was observed but after addition of 
triethylamine as supplementary base and washing with citric acid (10 % (w/w) aq.) 
during workup, traces of product 39 were detected. Isolation of 39 was not possible. 
Another attempt to label 36 by coupling with 25 was to vary the base. The lipid 
derivative 36 was dissolved in 400 µL anhydrous DMF per 1 mmol fluorophore, 
treated with N,N-diisopropylethylamine (DIPEA) and NHS activated 25 was added.[174] 
The reaction was allowed to stir over night but after workup again only traces of 
product formation was observed. 
The approaches to synthesise a 7AI-labelled lipid derivative described so far were 
unsuccessful or showed very low yields. Therefore, a general change in structure of the 
desired molecule was made, which is presented in the subsequent chapter. 
 
 
3.6 Synthesis of 7-Azaindole-3-decanoic Acid (40) 
In order to synthesise a 7AI-labelled lipid derivative the structure of the target 
compound was altered to exclude the unnatural amide bond, which is generated by 
fluorophore coupling. Therefore, the design of the fluorophore had to be altered. To 
avoid amide bond formation the previously used linker to couple the lipid backbone 
with 25 was omitted. In order to maintain the desired chain length the alkyl chain of 
the fluorophore needed to be elongated. The retrosynthetic analysis of the newly 
designed fluorophore 40 is shown in Scheme 3.14, starting with acylation of 7AI using 
sebacoyl chloride (SBC). After removal of the carbonyl unit by reduction, the ester is 
hydrolysed to obtain fluorophore 40. 
 
Scheme 3.14 Retrosynthetic analysis of 7-azaindole decanoic acid (40). 





The starting material of this synthetic route is, like in synthesis of 25, 7AI. In a Friedel-
Crafts-type reaction 7AI was acylated with SBC.[175,176] Four equivalents of aluminium 
chloride were suspended in DCM and 7AI was added. After stirring at r.t. for 1 h, the 
acid chloride was added dropwise to the suspension and stirred for 18 h. Treatment 
with MeOH at 0 °C stopped the reaction. To utilise an excess of AlCl3 of at least three 
equivalents is crucial in this system, since both nitrogen atoms of 7AI are likely to form 
complexes with the Lewis acid (Scheme 3.15, A).[175] The reaction conditions described 
by ZHANG et al. were first tested using decanoyl chloride (DCA), which led to pure 
product 45 of 88 % after purification (Scheme 3.15, B). Applying these conditions to the 
desired system containing sebacoyl chloride yielded in formation of 43 with 43 % of 
pure product (Scheme 3.15, C). Stopping the reaction with water instead of methanol 
to save the ester cleavage step of 41 and 42 (Scheme 3.14) has been tested as well but in 
this case only sebacic acid and 7AI could be identified as reaction products. Since 
cleavage of the methyl ester proved to be occasionally difficult and in need of harsh 
reaction conditions, EtOH was tested as well to stop the reaction (Scheme 3.15, D). The 
generated ethyl ester 44 demonstrated to be easier to cleave in the last step while stable 
under the conditions of the acyl reduction reaction (Scheme 3.16).  
 
Scheme 3.15 Likely explanation for necessary excess of AlCl3 are complexes formed during acylation 
reaction (A).[175] Acylation of 7AI utilizing decanoyl chloride (B), sebacoyl chloride with MeOH (C) and 
sebacoyl chloride with EtOH (D). 
 




After just a few repetitions of the reactions shown in Scheme 3.15, C and D, no 
conversion would take place anymore. Despite varying equivalents of reagents and 
reactants as well as amount of solvent and reaction temperature used, the product 
could not be obtained anymore. Only with exchanging the AlCl3 by a new batch the 
reaction would proceed again. But still this reaction remained unreliable. 
The succeeding step was the reduction of the generated ketone to form a methylen unit 
using triethylsilane (TES) and trifluoroacetic acid (TFA).[176] The ketone was dissolved 
in TFA, treated with TES and stirred at r.t. for 18 h. TFA was removed under reduced 
pressure and the residue diluted using aqueous potassium hydroxide (2 M). These 
conditions were applied to both ester compounds 43 and 44 as well as to test molecule 
45 and in all cases product was formed in mediocre to good yields (Scheme 3.16). In 
most cases this reaction was performed utilising the crude product of the previous 
reaction (Scheme 3.15, B–D), since purification of 43 and 44 via flash column 
chromatography with silica gel seemed to cause degradation of the product, which 
might explain the rather low yields. 
The last step to synthesise the modified fluorophore was the ester cleavage to obtain 
the carboxylic acid. A solution of the respective ester compound in MeOH and water 
was prepared along with about two equivalents of sodium hydroxide. After refluxing 
for 4 h, the corresponding carboxylic acid was supposed to be generated.[177] 
It turned out that employing two to five equivalents of sodium hydroxide and heating 
to reflux for 2–5 h was mostly sufficient for complete cleavage of the ethyl ester 42 
(Scheme 3.16, B). In contrast, cleavage of the methyl ester 41 required approximately 20 
equivalents sodium hydroxide for complete conversion to 40 (Scheme 3.16, A). 
Elongation of the reaction time led to no increase in yield. 
 
Scheme 3.16 Reduction of the keto-moiety of 43 and 44. 






Scheme 3.17 Ester cleavage of 41 and 42 using sodium hydroxide. 
In summary, product 40 was obtained in 5 % overall yield via the ethyl ester route and 
in 15 % yield over the methyl ester route. The former was more reliable so it became 
the preferred synthetic approach for 40 synthesis even though it resulted in lower 
yield. Due to the low yield and the toxicity of sebacoyl chloride, another synthetic 
approach was tested. In 1991 LAROCK et al. published a new palladium-catalysed 
strategy for the synthesis of indoles starting from o-iodoaniline and analogous 
derivatives.[178,179] The described procedure was adapted to the system in this work, 
shown in Scheme 3.18, A as retrosynthetic analysis, to prepare the fluorophor with a 
two carbon atoms shorter linker. 
The synthesis of 46 based on LAROCK and NADRES started with insertion of a 
triethylsilyl (TES) moiety to create a sterically demanding group. Incorporation of TES 
into 47 is crucial for the regioselectivity of the subsequent reaction since the bulkier 
group is selectively placed next to nitrogen in position two of the indole or 7AI. A 
solution of the protected alcohol 47 in THF was treated with n-BuLi at –78 °C and 
stirred for 40 min. Dropwise addition of TESCl at –78 °C and stirring for 1 h yielded 
the silylated product 48 with 91 % (Scheme 3.18, B).[179]  
 
Scheme 3.18 Retrosynthetic analysis of 46 based on LAROCK et al. and NADRES et al. (A). Silylation of 47 
using TESCl following the protocol of NADRES. (B) 




In the following step the 7-azaindole heterobicyclic structure is generated. 
Palladium(II) acetate, sodium carbonate, tetrabutylammonium chloride, 2-amino-3-
iodopyridine (AIP), 48 and triphenylphosphine were dissolved in DMF and heated to 
100 °C for 15 h. The product 49 was purified and obtained in 21 % isolated yield. The 
catalytically active species Pd(0) is generated out of the precatalyst Pd(OAc)2 by base, 
coordinates a chloride and is then readily available for oxidative addition by AIP. The 
alkyne 48 coordinates to the palladium atom, followed by regioselective syn-insertion 
into the previously generated aryl–palladium bond. In the resulting vinylic palladium 
intermediate the nitrogen replaces the iodide and subsequently palladium undergoes 
reductive elimination to produce the 7AI derivative while regenerating the Pd(0) 
species (Scheme 3.19).[180,181] 
 
Scheme 3.19 Heteroannulation of AIP to form 7-azaindole derivative 49 (A). Mechanism of LAROCK indole 
synthesis applied to the used system to generate 49 (B). 
 





With 49 in hand, the next step was the cleavage of the TES moiety as described by 
NADRES et al., to generate compound 50 (Scheme 3.20, A). Compound 49 was treated 
with concentrated hydrochloric acid and methanol (1:12.3, v/v) and stirred at r.t. for 
2 h. After applying these conditions, barely any conversion took place and the little 
amount of formed product 51 contained the alcohol without protecting group but still 
carried the TES group (Scheme 3.20, B). Therefore, the conditions were modified to 
stirring over night and addition of more hydrochloric acid (9.09 eq., HCl/MeOH, 1:2.7, 
v/v) but still starting material and formation of 51 were observed. In the next attempt 
the amounts of hydrochloric acid and methanol were increased to 45.5 equivalents HCl 
(HCl/MeOH, 1:1, v/v). These conditions led to complete conversion of starting material 
49 to form the deprotected alcohol 50 as well as small amounts of 52 with both silyl 
groups cleaved off. Since 52 seemed even more favourable then the beforehand desired 
compound 50, the complete cleavage of silyl moieties was now the aim. After 
dissolving 49 in hydrochloric acid (90.9 eq.) and methanol (HCl/MeOH 1:1, v/v) the 
solution was heated to reflux and stirred for 24 h. Utilisation of these conditions 
yielded in full conversion generating only the desired compound 52 (Scheme 3.20, C). 
To complete the synthesis of 40, oxidation of the alcohol 52 needed to be achieved in a 
final step (Scheme 3.21, A). To accomplish this, a solution of 52 in t-butanol was cooled 
to 0 °C and treated with a mixture of potassium permanganate and sodium hydroxide 
in water. The mixture was stirred for 1.5 h at 0 °C, warmed up to r.t. and stirred for 
24 h. It was again cooled to 0 °C, treated with another portion of KMnO4 and NaOH in 
water and stirred for further 24 h.[182] After quenching of excessive permanganate, the 
crude product was analysed to reveal no formation of the desired product 40. 
 
Scheme 3.20 Planned reaction based on NADRES et al. to cleave the TES group (A); Actually proceeding 
reaction deprotecting alcohol 50 (B); Modified reaction conditions to yield cleavage of both silyl groups 
(C). 




Instead addition of water located at the double bond of the five-membered ring took 
place (Scheme 3.21, B). Another approach to oxidise the alcohol was utilising 
2-iodoxybenzoic acid (IBX) along with Oxone® (Scheme 3.21, C).[183] All solid 
compounds were dissolved in ethyl acetate and water, and stirred for 4–7 h at 70 °C. 
After workup no starting material was left but product formation could not be 
detected.  
Since the described route to synthesise the fluorophore carrying an alkyl chain as 
linker were not as successful as hoped and the yields showed no significant increase 
compared to the approach via ethyl ester 44, the attempt to synthesise 46 was dropped. 
But usage of an oxidation agent like permanganate while applying anhydrous 
conditions might have enabled production of the desired carboxylic acid. 
 
Scheme 3.21 General oxidation reaction to convert alcohol 52 into carboxylic acid 46 (A); Oxidation 











3.7 Synthesis of Modified Lipid Derivative 55 
The new target molecule 55 carrying the fluorophore with the modified linker 40 
contains no unnatural functionalities besides the fluorophore itself. This increases the 
probability of smooth integration and arrangement of 55 in membranes. The synthesis 
started again with PMB protection of the free alcohol of solketal, followed by cleavage 
of the isopropylidene group to the primary and secondary hydroxyl functionalities. 
Since these reactions are already shown in Scheme 3.6, they are not depicted in Scheme 
3.22, in which the retrosynthetic analysis of compound 55 is illustrated. After 
deprotection, the primary alcohol is protected again by a t-butyldimethylsilyl (TBS) 
group and subsequently the fatty acid is coupled via ester bond formation. The TBS 
group is cleaved and fluorophore 40 incorporated. The last two steps of this synthetic 
route include deprotection by PMB-cleavage and generation of the PC-head group. 
The first few steps were performed based on a procedure published by JIANG et al. 
depicting the synthesis of lysobisphosphatic acid and its analogues.[184] For protection 
of the primary alcohol a solution of 32 and imidazole in DMF was treated with TBSCl 
in DMF at 0 °C over a period of 1 h. The reaction mixture was stirred at 4 °C over night 
and at r.t. for 8 h.[184] After standard workup procedure and purification 56 was 
obtained in up to 99 % yield (Scheme 3.23, A). Using NMR analysis it was ensured that 
only the desired product was formed and no protection of the secondary alcohol took 
place. 
 
Scheme 3.22 Retrosynthetic analysis of fluorophore 40 labelled lipid 55. 





Scheme 3.23 TBS-protection of the primary hydroxy functionality of 32 (A). Acylation of 56 by activation 
und subsequent coupling of stearic acid (B). 
To couple stearic acid to 56 the carboxylic acid was activated by treating a solution of 
56 and stearic acid in DCM with a solution of DCC and DMAP in DCM.[184] After 
stirring for 24 h at r.t. and purification, pure product 57 was obtained in 44 % yield 
(Scheme 3.23, B). 
Prior to incorporation of the fluorophore, the TBS group was cleaved off. This was 
performed by treating 57 in THF with tetrabutylammonium fluoride (TBAF, 1 M in 
THF) at r.t. over night[184] and gave product 37 in quantitative yield (Scheme 3.24, A). 
Following the deprotection reaction, fluorophore 40 was coupled (Scheme 3.24, B). 
Applying the same conditions as for stearic acid, coupling the fluorophore was 
activated by treatment with DCC and DMAP with the distinction that in this case 
addition of the reagent mixture was performed at 0 °C. Purification provided product 
58 in 57 % yield. 
Following the synthesis of the backbone of a labelled lipid, the generation of the PC-
head group was targeted. At first deprotection of the alcohol via PMB cleavage was 
required. Treating a solution of 58 in wet DCM with DDQ at r.t. for 24 h produced no 
product 59. Instead, oxidation of the alcohol to the corresponding carboxylic acid 
occurred (Scheme 3.25). 
 
Scheme 3.24 Cleavage of the TBS group of 57 (A) with subsequent fluorophore coupling to yield 58 (B). 






Scheme 3.25 Attempt to cleave off PMB for subsequent head group generation with the desired product 
59 (top right) and the actual reaction to form product 60 (bottom right). 
The PMB cleavage worked nicely in first synthetic route (Scheme 3.9) using the Z 
protecting group bound as carbamate. Since the presence of the fluorophore appeared 
to be problematic, protection of the secondary amine using the Z group was 
considered (Scheme 3.26). 
To protect the secondary amine a solution of 58 in THF was treated with triethylamine 
and Z-Cl at 0 °C and stirred at r.t. over night.[185] Mass spectrometry and TLC revealed 
that only traces of product 61 were formed, which could not be isolated. 
To avoid further protecting attempts as well as the challenge of PMB removal the 
sequence of deprotection was altered. So far for coupling of the fluorophore the TBS 
group was cleaved off instead of the PMB group. Exchanging the order and applying 
the previously stated conditions for PMB removal on compound 57 showed smooth 
conversion to 62 in good yield (Scheme 3.27, A). 
 
Scheme 3.26 Protection approach of NH using the Z protection group. 





Scheme 3.27 Removal of the PMB group of 57 previous to fluorophore incorporation (A); B: Coupling of 
fluorophore 40 (B). 
The change in deprotection sequence had one minor drawback. After removal of PMB 
no UV-active or stainable functionality was left within molecule 62, which made 
detection during flash column chromatography (FC) almost impossible. Fortunately, 
thorough extraction during workup removed nearly all impurities and usually no 
further purification was necessary. Anyhow, to ensure detectability the whole 
synthesis was repeated with coupling of oleic acid in place of stearic acid, which is not 
shown. 
Incorporation of fluorophore 40 was carried out analogous to the synthesis of 58, 
depicted in Scheme 3.24, B. After 16 h at 0 °C and subsequent FC, product 63 was 
obtained in 60 % yield (Scheme 3.27, B). Following the labelling step, cleavage of TBS 
was conducted. Compound 63 was dissolved in TFA, treated with TBAF (1 M in THF) 
and stirred over night (Scheme 3.28). The deprotected product 59 was obtained after 
FC in very good yield of 97 %. 
For head group generation the previously described conditions using phosphoryl 
chloride, triethylamine and ethanolamine were applied (Scheme 3.29). Analysis of the 
crude product revealed formation of product 64 in traces as well as formation of the 
intermediate 65 carrying a phosphate group without ethanolamine. Neither of the 
reaction products could be isolated. 
 
Scheme 3.28 Removal of the TBS group of 63 using TBAF. 






Scheme 3.29 First step of head group generation leading to formation of the desired product 64 and 
intermediate 65. 
After several attempts using these conditions as well as applying the coupling step of 
ethanolamine to intermediate 65 separately, no improvement was observed. Since this 
reaction is known to require dry conditions, the amounts of water traces were further 
reduced by drying DIPEA and ethanolamine previous to usage over molecular sieve. 
However, the reaction result stayed the same. Nonetheless, to connect ethanolamine to 
65 other conditions were tested. To avoid amide bond formation the amine group of 
ethanolamine was fluorenylmethoxycarbonyl (Fmoc)-protected using standard 
conditions (Scheme 3.30, A).[186] N-Fmoc-ethanolamine (66) was obtained in 
quantitative yield and then brought to reaction with 65 by addition of DCC and DMAP 
in DCM (Scheme 3.30, B) but no product was formed. 
Presumably the early assembly of the fluorophore hindered further reactions, as head 
group incorporation. On the other hand, previous generation of the charged PC-head 
group inhibits fluorophore coupling. Therefore, starting from compound 62 a 
phosphatidylethanolamine (PE) head group was to be generated (Scheme 3.31), 
followed by fluorophore incorporation with subsequent methylation of the amine for 
PC-generation. 
 
Scheme 3.30 Fmoc-protection of ethanolamine in aqueous Na2CO3 solution (A); Coupling attempt to 
connect N-Fmoc-ethanolamine (66) to 65 (B) 





Scheme 3.31 PE-head group generation previous to fluorophore coupling for subsequent methylation of 
68 (A). Coupling attempt of 69 with N-Fmoc-ethanolamine (66) (B). 
Following this approach, phosphorylation could be observed but no coupling of 
ethanolamine took place. To subsequently bind ethanolamine to the phosphate group 
the conditions depicted in Scheme 3.30, B were applied (Scheme 3.31). High resolution 
mass spectrometry verified that the formed reaction product was not the desired 
compound 70 and attempts to identify the substance were unsuccessful.  
Since the synthesis of target compound 55 following the described routes was not 
possible, other approaches for head group generation came into focus. Instead of 
incorporating a phosphor(V) unit, a phosphor(III) compound was used. Treatment of 
59 with methyl dichlorophosphite and DIPEA with subsequent addition of 
ethanolamine was proposed to generate the head group precursor 71 (Scheme 3.32).[187] 
 
Scheme 3.32 Attempted phosphitylation of 59 using methyl dichlorophosphite. 





By application of a phosphite instead of phosphoryl chloride no conversion was 
observed at first. After increasing the amount of phosphite from 1.20 equivalents to 
2.40 equivalents small amounts of intermediate product 72 were formed but no 
product 71. Increasing reaction times and varying the volume of solvent used did not 
improve the reaction outcome. To investigate every angle a coupling attempt of 72 
with N-Fmoc-ethanolamine (66) using DCC and DMAP was undertaken (Scheme 3.33). 
Mass spectrometry revealed that the desired product 73 did not form but starting 
material (74) as well as coupling product (75) lacking a methyl group were detected in 
traces. 
A well-known and broadly used procedure to incorporate phosphite units is the 
application of phosphoramidites. Especially in DNA synthesis phosphoramidites are 
used for nucleoside building block preparation. Therefore, chloro-(2-cyanoethyl)-N,N-
diisopropylaminophosphoramidite (P-amidite 1) was used. A solution of 59 in 
acetonitrile (MeCN) was treated with DIPEA and P-amidite 1 and stirred at r.t. for 4 h 
(Scheme 3.34).[188] To increase solubility 20 % (v/v) of DCM was added in respect to 
total solvent volume, but applying these conditions led to very low product 76 
formation. The reaction time was elongated to achieve better yields and after 24 h no 
further change in reaction was observed on TLC. Interestingly, with increased reaction 
time no product formation was observed but small amounts of starting material along 
with partially deprotected compound 77 (Scheme 3.34, A).  
For optimisation MeCN was completely substituted by DCM while keeping the 
remaining reaction conditions stable. After 4 h barely any starting material was left but 
no formation of the desired product 76 had occurred. Instead, partially deprotected 77 
was formed (Scheme 3.34, B). 
 
Scheme 3.33 Coupling reaction of 72 and 66 resulting in two demethylated species 74 and 75. 





Scheme 3.34 Phosphitylation of 59 using P-amidite 1 (A). Change of solvents led to cleavage of the 
diisopropylamino moiety forming 77 (B). 
Since changing completely to DCM as solvent proved to be unfeasible, the solvent was 
changed again in favour of THF. Furthermore, DIPEA dried over molecular sieve was 
used to assure water-free conditions. Changing the solvent to THF produced the same 
result as utilization of DCM and yielded in formation of 77. 
Using P-amidite 1 for phosphitylation was additionally tested on the unlabelled 
compound 62 (Scheme 3.35). After 4 h using MeCN as solvent, conversion of the 
starting material was complete but just a small amount of product 78 was formed. 
Attempts to isolate the product were unsuccessful and besides 62 and product 78 just 
degraded P-amidite 1 could be identified. 
 
Scheme 3.35 Phosphitylation of 62 using P-amidite 1. 
To avoid the unwanted cleavage of the diisopropylamino group bis(2-cyanoethyl)-
N,N-diisopropylphosphoramidite (P-amidite 2) was used for phosphitylation. After 
the coupling step, the phosphite was directly converted into a phosphate using sodium 
peroxidate (Scheme 3.36).  






Scheme 3.36 Phosphitylation of 59 using P-amidite 2 followed by oxidation for phosphate generation. 
A solution of 59 and P-amidite 2 in THF was cooled to 0 °C, treated with 1H-tetrazole 
and stirred at r.t. for 1 h. The reaction mixture was cooled again to 0 °C, treated with 
pyridine and a solution of sodium peroxidate in water and stirred at r.t. for 1 h.[189] 
Mass spectrometry of the crude product revealed complete conversion of the starting 
material 59 under formation of product 80 along with unidentified side products. 
Without further purification except extraction during workup the phosphate unit of 
compound 80 was deprotected using sodium methoxide (1 % (w/w) in methanol) over 
the period of three days.[189] Analysis of this reaction showed that conversion of 80 was 
complete but no product 81 formed. 
As already mentioned, all synthetic approaches including stearic acid at the sn-2 
position have been repeated with oleic acid at this position to ensure detectability of 
each reaction product and thereby enable purification via FC. Reaction conditions were 
not altered when using oleic acid instead of stearic acid and the obtained reactions 
yields were comparable. 
 
Scheme 3.37 Cleavage of the 2-cyanoethyl protection groups of 80. 
 
 




3.8 Enzymatic Synthesis of Modified Lipid Derivative 55 
After the purely synthetic route proved to be highly time and energy demanding 
without promising results, an entirely different strategy was approached. Instead of 
synthesising modified lipids starting from solketal, an isolated, natural lipid can be 
modified using an enzyme. The commercially available 1-myristoyl-2-stearoyl-sn-
glycero-3-phosphocholine (MSPC) was chosen as lipid. For modification the likewise 
commercially available enzyme phospholipase A1 (PLA1) from Thermomyces 
lanuginosus was seleceted. PLA1 is known to selectively hydrolyse ester bonds of PC-
lipids at sn-1 position.[190] This semi-enzymatic route consists of two steps: In the first 
step myristic acid is cleaved off to generate a free hydroxy functionality (1-lysoPC, 82), 
shown in Scheme 3.38. The second step contains coupling of the fluorophore 40 
(Scheme 3.39) to obtain the desired target compound 55. 
For 1-lysoPC 82 generation MSPC was dissolved in Tris buffer with additional 5 % 
MeOH for solvation purposes. The enzyme was added and the reaction mixture 
shaken at 37 °C for 30 min. After extraction with diethyl ether, the organic solvent was 
removed to obtain 82.[191,192] To verify the success of this reaction preparative thin layer 
chromatography (PLC) was used. The crude reaction product, starting material and 
two standard compounds for reference were applied to the plate and a mixture of 
chloroform, methanol, acetic acid and water (25:15:4:2) was used as eluent system. 
Once the PLC was finished and dried, it was treated with aqueous CuSO4 solution, 
heated to 120 °C for approximately 30 min. The now charcoaled substances appear as 
brown stains on the plate. Evaluation of the plate revealed complete conversion of the 
starting material, a new 1-lysoPC band had appeared as well as two other, unknown 
bands. Attempts to isolate 82 were unsuccessful but after changing the solvent for 
extraction from diethyl ether to a chloroform/MeOH mixture (1:1) further purification 
was no longer necessary. After just a few repetitions of this reaction no product would 
form anymore without any obvious cause. Various lipid and enzyme concentrations 
were tested as well as the amount of methanol used for increased solvation. Reaction 
temperature and time were diversified and different shaking rates reviewed. 
 
Scheme 3.38 Myristic acid hydrolysis at sn-1 position to generate lysolipid 82; buffer system used: Tris 
(200 mM), pH 7.5. 
 





The activity of the enzyme was tested and showed still high conversion rates with 
p-nitrophenyl palmitate as substrate. Besides Tris buffer (200 mM), Tris-HCl buffer 
(200 mM) and Bis-Tris propane buffer (20 mM) were tested. All buffer solutions were 
freshly prepared every four weeks, the pH was measured and readjusted to 7.5, if 
necessary. The lipid used for hydrolysis was screened for degradation using NMR 
spectroscopy and mass spectrometry, which both showed no evidence of 
decomposition. Since the reaction was carried out in reaction tubes made of 
polypropylene, tubes of different companies were tested to check for cytotoxicity or 
lability towards specific solvents. None of these variations led to product formation in 
good or at least moderate yields again. 
Following another procedure[193], MSPC was dissolved in diethylether in a snap-cap 
vial and a solution of enzyme in Bis-Tris propane buffer was added, whereby the ether 
volume was four-times greater than the buffer volume. The mixture was vigorously 
shaken for 20 min and extracted using chloroform. With these conditions product 
formation was obtained but in low yields and purity. Therefore, the organic solvent to 
buffer ratio was varied to 3:2 and the reaction time decreased to 15 min, which led to a 
great increase in yield and improved purity. For further optimisation the organic 
solvent was exchanged from diethyl ether to chloroform. Indeed, applying these 
changes, complete conversion was achieved with rather pure product 82 in very high 
up to quantitative yields. The purity was further improved as the volume of solvents 
was decreased by one-third in total.  
After successful hydrolysis of MSPC to generate 1-lysoPC 82, the next step was to 
couple fluorophore 40. For ester bond formation the same coupling conditions as 
previously described, using DCC and DMAP, were applied (Scheme 3.39). After 24 h 
the starting material was completely processed but no product was formed. The 
resulting compounds detected in mass spectrometry could not be identified. 
To increase the electrophilic character of the fluorophore, transformation of 40 into an 
acyl chloride (83) was conceived. For conversion a solution of 40 in DCM was cooled to 
0 °C and treated with DMF and oxalyl chloride (Scheme 3.40). After stirring for 1.5 h at 
0 °C the organic solvent was removed.[194] Without intermission it was redissolved in 
DCM and added to a solution of 1-lysoPC 82 and DMAP in DCM at 0 °C and stirred at 
r.t. for 4 h.[166] 
 
Scheme 3.39 Labelling attempt of 1-lysoPC 82 with fluorophore 40. 





Scheme 3.40 Conversion of fluorophore 40 into an acyl chloride with subsequent coupling attempt to 
generate 55. 
The coupling reaction yielded no product. One reason might be that the acyl chloride 
did not form, another possible explanation is that the activiated acyl chloride 
undergoes an immediate ring closing reaction (Scheme 3.41) with the amino 
functionality of 7-azaindole to build a lactam 84. 
To inhibit the lactam formation the amino functionality had to be protected. The 
required protecting group needed to fulfil several demands. A suitable protecting 
group has to bind selectively to the secondary amine without interfering with the 
carboxylic acid and be acid stabile to endure reaction conditions for acyl chloride 
generation. Furthermore, the labelling reaction of 82 with fluorophore 40 must not be 
disturbed by the protecting group, while the group itself has to be stabile under 
coupling conditions. Finally, cleavage of the protecting group should take place in a 
rapid fashion under mild conditions to ensure that no decomposition of the labelled 
lipid occurs. The chosen protecting group was Fmoc (Scheme 3.42), which is stabile 
under acidic conditions as well as under a broad variety of coupling conditions. It 
binds amines selectively and cleavage of Fmoc using piperidine is mild enough to not 
impair the lipid. 
 
Scheme 3.41 Possible ring closing reaction of 83 to form lactam 84. 
 






Scheme 3.42 Protection of amine 40 using Fmoc-Cl. 
For Fmoc-protection 40 was dissolved in aqueous NaHCO3 solution (10 % w/w) and 
treated dropwise with Fmoc-Cl in dioxane with at 0 °C. The reaction mixture was 
stirred at 0 °C for 1 h and then at r.t. for 4 h, while the reaction was monitored via TLC. 
Using this procedure, just traces of product were formed, which is why the reaction 
time was prolonged and dioxane was substituted by DMF to enhance alkalinity. 
Applying these conditions no increased product formation was obtained, so the 
reaction conditions were varied again. The solvent was changed back to dioxane but 
another base was added. At first DIPEA was used as additional base. When after 24 h 
no reaction occurred, triethylamine was added as a stronger base. After treatment with 
triethylamine, a new spot on TLC appeared but mass spectrometry revealed no 
product formation. Since the first tested conditions provided at least product traces, 
those were applied again with elongated reaction time to four days. After 4 d 
approximately 50 % of the starting material was converted into product 85 and with 
extraction at different pH values as well as varying solvents the unprotected 
fluorophore and the protected 85 could readily be separated from each other. Attempts 
to isolate 85 from side products were unsuccessful. To further increase product 
formation the reaction time was increased to 7 d, after which just small amounts of 
starting material were left. Since complete purification remained unsuccessful the 
unpurified product was used for acyl chloride generation. The previously described 
conditions using oxalyl chloride (Scheme 3.40) were applied with subsequent coupling 
reaction with lysoPC 82 (Scheme 3.43). Even using the Fmoc-protected fluorophore 85 
did not lead to formation of the desired labelled lipid 86. The most probable reason 
seemed to be that no acyl chloride was generated. Therefore, instead of oxalyl chloride 
thionyl chloride was tested (Scheme 3.44). 
 
Scheme 3.43 Labelling attempt via conversion of 85 into an acyl chloride followed by coupling with 82. 
 
 




To generate acyl chloride 87 a solution of 85 in DCM was heated to 80 °C and treated 
with thionyl chloride for 30 min. After the mixture had cooled down to r.t., excess of 
thionyl chloride was removed in vacuo[195] and then brought to reaction with ethanol 
using the previously described conditions (Scheme 3.44, A). Analysis via mass 
spectrometry revealed that just deprotected fluorophore 40 was obtained. 
This semi-enzymatic route yielded the hydrolysed lysoPC 82 after short reaction time 
and in good purity in quantitative manner but target compound 55 could not be 
synthesised. Since the enzyme PLA1 is known to not just cleave the respective fatty 
acid at sn-1 position but to be able to incorporate specific fatty acids as well[196–198], a 
full-enzymatic approach was made. To test whether or not fluorophore 40 would be 
accepted as substrate by PLA1, lysoPC 82 and fluorophore 40 were brought to reaction 
with the enzyme (Scheme 3.44, B). 40 and 82 were dissolved in MeOH and added to a 
solution of PLA1 in Tris buffer at pH 7.5. After incubation under shaking at 37 °C for 
30 min, the mixture was extracted using chloroform and the solvent removed under 
reduced pressure. Analysis of the residue revealed that neither lysoPC nor fluorophore 
was left, neither could the desired product be detected. 
After these tests no further efforts were made to synthesise target compound 55. 
Adviceable for further attempts is screening of better suitable protecting groups. One 
protecting group worth testing is allyloxycarbonyl (Alloc), which is acid stabile and 
can be cleaved via transition metal catalysed cleavage. The purely synthetic route 
using P-amidite 2 could still lead to formation of the target compound 55, if the 
protecting groups were not cleaved after phosphitylation and oxidation to phosphate. 
Instead direct incorporation of ethanolamine via a substitution reaction should enable 
formation of compound 55. 
 
Scheme 3.44 Test reaction to check for acyl chloride generation using 85 and ethanol (A). Full-enzymatic 
attempt for 55 synthesis using enzyme PLA1 (B). 





3.9 Fluorescence Measurements of 7-Azaindole-Labelled Lipids 
As the synthesis of the 7AI-labelled lipid precursor 59 was successful, incorporation of 
59 into membranes was intended. Thereby, the behaviour of 59 in artificial membranes 
was to be characterised using fluorescence spectroscopy to pave the way for its 
utilisation in fusion experiments in artificial and possibly natural systems. At first, to 
determine whether the modification of 7AI to generate 59 altered the fluorescence 
properties, fluorescence spectroscopy of 59 was performed by applying an excitation 
wavelength of 288 nm. The first measurements were performed with 2.5 µM 59 in the 
polar protic solvent methanol, which is known to influence the fluorescence of 7AI. At 
a wavelength of 390 nm an emission maximum (max) was detected along with a broad 
and shallow shoulder at ~480 nm (Figure 3.6). These findings show a red shift of max of 
about 16 nm in comparison to data regarding 7AI in literature.[18,19] A possible 
explanation for this shift might be the presence of the neighbouring long alkyl chain, 
which might locally decrease the polarity of the surrounding of the fluorophore. 
Since membrane fusion experiments are usually not performed in methanol, 
fluorescence measurements were repeated with 59 suspended in an aqueous solution. 
As solvent a HEPES buffer (20 mM HEPES, 1 mM EDTA, 100 mM KCl, pH 7.4) was 
used. The labelled compound was suspended in buffer and via ultrasonication a 
homogeneous solution of 2.5 µM 59 was prepared. The fluorescence spectrum, shown 
in Figure 3.7, revealed a drastically lowered fluorescence intensity, probably due to 
water molecules blocking the tautomerisation, and a max of 400 nm, which is in good 
accordance to literature-known data for 7AI.[155] 
 
Figure 3.6 Fluorescence spectrum of 59 in MeOH with an excitation wavelength of 288 nm and an 
emission maximum at 390 nm. 





Figure 3.7 Fluorescence spectrum of 59 suspended in HEPES buffer. The emission maximum emerged at 
400 nm. 
After having obtained the spectra of 59 in aqueous and alcoholic environment, the 
labelled lipid precursor was incorporated into artificial membranes. Thereto vesicles 
consisting solely of DOPC and 59 were prepared following GP2.1 and GP2.2 using the 
previously mentioned HEPES buffer. In total, the amount of substance was 2.5 µmol in 
a ratio of labelled to unlabelled lipids of 1:1000. The generated vesicles were measured 
immediately after extrusion and again, an excitation wavelength of 288 nm was 
applied. Figure 3.8 pictures the obtained fluorescence spectrum with max = 430 nm. 
Considering former studies regarding 7AI in hydrophobic environment, a different 
emission maximum was expected. Analysis of 7AI-labelled transmembrane proteins 
revealed a maximum of max = 372 nm after incorporation into membranes consisting of 
1,2-dimyristoyl-sn-glycero-1-phosphocholine (DMPC).[199] A possible explanation of the 
obtained spectrum is that the 7AI-modified fatty acid of 59 does not insert into the 
membrane. Instead, the alkyl chain tilts suchlike that the fluorophore is located in the 
polar head group region of the membrane. This theory is supported by the fact that 
tryptophan, which bears the structurally very similar indole moiety in the side chain, is 
often used as a peptide anchor. It embeds in the head group area and therefore 
stabilises transmembrane proteins in the membrane.[200,201] 






Figure 3.8 Fluorescence spectrum of 59 incorporated into DOPC vesicles in a ratio of 1:1000 showed an 
emission maximum at 430 nm. 
To analyse the influence of 59 concentration in membranes, vesicles with a 59 to DOPC 
ratio of 1:250 were prepared. Instant fluorescence measurements of this vesicle species 
yielded the same emission wavelength with slightly decreased intensity (spectrum not 
shown). The decrease in fluorescence intensity by increased fluorophore concentration 
was not expected but might be explained by self-quenching or augmented blocking of 
tautomerisation by water molecules. 
Nevertheless, vesicles with a drastically increased 59 to DOPC ratio of 1:20 were 
established, since lipid rafts at membrane fusion sites are supposed to be greatly 
enriched in PIP2. The obtained spectrum still exhibits a local emission maximum (s) at 
the wavelength of 429 nm but the dominating signal is a maximum (max) at 389 nm 
with an overall explicitly decreased fluorescence intensity (Figure 3.9). The signal at 
max = 389 nm cannot be assigned to 7AI in a hydrophobic environment like a 
membrane core but might be generated by dimer formation of the fluorophore in the 
polar head group region. This possibility is supported by the nearly identical 
maximum of 59 obtained in methanol (Figure 3.6) elicited by hydrogen bond formation 
in a polar environment. 





Figure 3.9 Fluorescence spectrum of high 59 concentration in DOPC vesicles in a 1:20 ratio exhibiting a 
drastically decreased fluorescence with a maximum comparable to 59 in MeOH and a second, smaller 
maximum at 429 nm. 
In conclusion, the synthesis of a 7AI-labelled lipid precursor with no head group was 
successful. Subsequent incorporation of fluorophore and head group proved to be a 
difficult task but investigations towards finding a suiting protecting group should 
enable to complete the synthesis of the labelled DOPC compound 55. Before 
performing further attempts to finalise the synthesis of 55, compound 59 was tested for 
membrane labelling. Fluorescence spectroscopy revealed that insertion of the 
fluorophore into the hydrophobic domain of the membrane did not take place. Instead, 
the 7AI moiety seems to rest on the membrane surface in the polar head group region. 
For this reason, distinct structural modifications of the target compound 55 are 
necessary to generate a driving force for fluorophore incorporation into the 











4 gem-Difluorinated Fatty Acids 
4.1 Introduction 
One of the most versatile and important second messenger is Ca2+, as discussed in 
detail in chapter 2, but it is by no means the only one. A tremendous variety of 
compounds can act as signalling agent. The phytohormone jasmonic acid for example 
is an essential signal compound in gene expression induced by wounding. Evolution 
of plants created several chemical defence mechanisms upon wounding, such as the 
production of toxic compounds or the formation of attractants towards herbivorous 
insect predators.[2] In these and other plant responses jasmonic acid plays a key role. It 
is generated by hydroperoxidation of polyunsaturated fatty acids followed by further 
processing and hence belongs to the class of oxylipins.[22] 
The insertion of dioxygen into polyunsaturated fatty acids containing a 1Z,4Z-penta-
diene unit to generate the respective hydroperoxidised derivatives is catalysed by the 
large lipoxygenase family in a regio- and stereoselective manner.[23,202] Non-enzymatic 
autoxidation is highly unspecific, yielding a variety of twelve diverging mono-
hydroperoxidised derivatives in the case of arachidonic acid. In contrast, 
dioxygenation catalysed by lipoxygenases generally leads to one specific 
hydroperoxide enantiomer.[203] 
Lipoxygenases have already been investigated for several decades[204] and a 
tremendous amount of knowledge about their incidence, structure and functionality 
has accumulated.[24] Still debated is the exact mechanism of substrate conversion, 
especially the orientation of polyunsaturated fatty acids in the active site. Therefore, 
this project aims for synthesising the geminal difluorinated substrate analogue 
11,11-difluoro-linoleic acid, which shall be bound by the enzyme. By substituting both 
hydrogen atoms at C-11 by fluorine atoms no digestion of the substrate can take place 
and co-crystallisation experiments become feasible in order to resolve the substrate 









Fatty acids represent a major part of mammal nutrition and especially polyunsaturated 
fatty acids (PUFAs) like linoleic acid are essential. The necessity of PUFAs was already 
discovered in 1929 by G. BURR and M. BURR in fat exclusion experiments on rats.[205] 
Since more than half of naturally occurring fatty acids are unsaturated[206,207], their 
oxidation constitutes a great portion of lipid metabolism.[202] One possible reaction 
pathway is the formation of oxylipins such as hydroperoxy fatty acids.[3] These are 
then further metabolised to signalling agents, e.g. jasmonates or leaf aldehydes[22] in 
plants and leukotrienes or lipoxins in mammals.[208] 
The digestion of PUFAs is performed by enzymes like lipoxygenases (LOXs, 
linoleate:oxygen oxidoreductases). LOXs belong to a non-heme iron containing 
enzyme family that performs hydroperoxidase reaction, leukotriene synthase reaction, 
and most importantly, generates hydroperoxy fatty acids by dioxygenation of PUFAs, 
containing a (1Z,4Z)-pentadiene unit.[2,3] LOXs consist of a single polypeptide chain of 
approximately 75–80 kDa in animals[209] and 95–100 kDa in plants[3], featuring two 
domains (Figure 4.1, left). The bigger C-terminal domain of 55–65 kDa in plant LOXs 
consists of α-helices and contains the catalytically active centre, while the β-barrel-











Figure 4.1 Crystal structure of a soybean 13S-LOX with the β-barrel shown in dark blue and the α-helical 
domain containing the active site with the catalytically active iron ion in grey (left)[246]; Coordination 
sphere of the iron ion within the active centre (right).[3] 





The active site contains one iron atom that is, in case of plant LOXs, coordinated by 
three histidines, one asparagine and the C-terminal isoleucine in an octahedral fashion 
(Figure 4.1, right). 
Historically, two ways to classify plant LOXs have been established and are still 
commonly used. An earlier categorisation differentiated between type 1-LOXs, that 
exhibit their activity optimum at alkaline pH, and type 2-LOXs with a neutral pH 
optimum.[212] More recently, plant LOXs are classified by their subcellular localisation, 
meaning plastidial (type 2-LOXs) and extraplastidial (type 1-LOXs) LOXs, or the 
positional specificity of linoleic acid oxygenation.[3] Categorisation by positional 
specificity yields 9-LOXs and 13-LOXs, respective to the carbon atom carrying the 
hydroperoxide after conversion.[24] Including stereochemistry a total of four linoleic 
acid LOX (9S, 9R, 13S, 13R) classes arise. 
The exact mechanism of the hydroperoxidation reaction is still under investigation but 
can be divided into three steps (Scheme 4.1). The first reaction step is the 
stereoselective hydrogen abstraction under generation of a free radical. The hydrogen 
is cleaved off the methylen carbon of the (1Z,4Z)-pentadiene unit by Fe3+–OH under 
Fe2+–OH2 formation, allowing delocalisation of the radical over both double bonds.[213] 
The rearranged radical then regioselectively binds an oxygen molecule in an 
antarafacial manner. The antarafacial oxygenation has been verified by experiments 
using deuterium or tritium labelled fatty acids.[214,215] Incorporation of O2 at positions 1 
or 5 of the pentadiene unit (respectively position 9 or 13 for linoleic acid) yields a 
conjugated diene and is therefore thermodynamically favoured over position 3. 
Reduction of the peroxyl radical completes the catalytic cycle under generation of four 
possible products.[213] 
As the distinct cause for regio- and stereospecificity of individual LOXs is still to be 
discovered, differing theories have been proposed.[3,24,213] The space-related model 
proposes a general tail-first (methyl group first) orientation, in which the depth of the 
active site dictates the position of lipoxygenation.[216] The substrate orientation 
hypothesis suggests the orientation of the entering substrate as a key factor. Entering 
the active site tail-first would lead to dioxygen insertion at C-13, while head-first, 
penetrating primarily with the carboxylic acid, results in lipoxygenation at C-9.[217] 
 





Scheme 4.1 LOX reaction pathway showing oxygenation of linoleic acid with respect to the regio- and 
stereospecificity yielding four possible products. Scheme adapted from [3]. 
Modelling and mutagenesis studies revealed an arginine (R) in the binding pocket of 
plant 13-LOXs, which might act as a counterpart for the carboxy group in case of head-
first substrate orientation and therefore favours dioxygen insertion at C-9. The arginine 
is usually shielded by sterically demanding amino acid residues like phenylalanine (F) 
or histidine (H), preferring the tail-first orientation over head-first (Figure 4.2, left). In 
plant 9-LOX the less bulky amino acid valine (V) substitutes F/H, minimising the 
shielding effect (Figure 4.2, right). 
Besides the regiospecificity the stereospecificity of the enzyme determines the reaction 
product. Using mutation studies COFFA et al. discovered that a single conserved 
residue is responsible for R or S stereocontrol. The sterically more demanding alanine 
(A) was identified in S-LOXs and the smaller glycine (G) in R-LOXs.[203] This so-called 
‘Coffa site’ is located in the active site opposite to the complexed iron ion. As it turned 
out, A/G-exchange of the residue does not just alter the chirality but switches the 
position of dioxygen insertion as well. Hence, a 9S-LOX will be converted after 
mutation into a 13R-LOX. 
 
Figure 4.2 Orientation-dependent model depicting linoleic acid in an active side of a 13-LOX in tail-first 
orientation (left) and of a 9-LOX in head-first orientation (right). Figure adapted from [3]. 





Assuming that in all LOXs oxygen is furnished from the same side, these findings can 
be explained by the substrate orientation model.[3] In case of 13S- and 9R-LOXs 
substrate entering of the binding pocket occurs in tail-first manner, leading to a 
shielded C-9 position in the 13S-LOX by the alanine side chain. Since in the 9R-LOX 
enzyme this residue is absent, preferred dioxygen insertion at C-9 can take place, 
yielding the R product (Figure 4.3, top). For 9S- and 13R-LOXs the substrate penetrates 
the binding site head-first. In this case the alanine residue blocks C-13 and the 
respective 9S-product is formed. The 13R-LOX enzyme is lacking the methyl group, 
which is why dioxygenation at C-13 in R-configuration is favoured (Figure 4.3, 
bottom). 
However, it must be mentioned that exceptions of this model are known. 
Crystallographic analysis of an inhibitor-bound 13-LOX revealed a U-shaped channel 
for substrate binding but the exact orientation of substrates within the active side 
remains elusive.[218] Therefore, further investigations are required to fully uncover the 
mechanism of LOX-catalysed fatty acid hydroperoxidation. 
 
Figure 4.3 Explanation of LOX stereospecificity using the substrate orientation model under assumption 
that O2 is inserted from the same side. Figure adapted from [3]. 
 
  




4.3 Synthesis of 11,11-Difluorolinoleic acid 
In 2011 PRÉVOST et al. published an approach for the total synthesis of the bioactive 
ceramide symbioramide[219]. On the basis of this strategy and under consideration of 
the work done so far on this project by former PhD-students, the decision was made to 
synthesise 11,11-difluorolinoleic acid (89) with the strategy shown in Scheme 4.2. At 
the beginning, an ester containing an alkynyl moiety on second position will be 
converted into a Weinreb amide[220], which will then undergo a reaction with a terminal 
alkyne to form a ketone. After this step, the final chain length of 18 carbon atoms will 
already be achieved. Substitution of the keto-moiety by two fluorine atoms should 
yield the gem-difluorodiyne. Hydration of both alkynes using Lindlar catalyst should 
result in cis-alkenes, followed by oxidation of the terminal alcohol to form a carboxylic 
acid function. During the synthesis, the terminal alcohol has to be protected using a 
protecting group orthogonal to all employed reaction conditions. 
Starting the synthesis of 11,11-difluorolinoleic acid (89) based on the work of PRÉVOST 
et al., methyl 2-octynoate (90) was converted into the Weinreb amide 91 using the 
commercially available N,O-dimethylhydroxylamine hydrochloride in combination 
with the Grignard reagent isopropylmagnesium chloride (i-PrMgCl) (Scheme 4.3, A 
left). After 30 min at r.t. the product 91 was obtained in 58 % purified yield. 
9-Decyn-1-ol (92) was protected using triisopropylsilyl chloride (TIPSCl) to form a silyl 
ether (93) (Scheme 4.3, A right)[221], which was received in quantitative yield after flash 
columnchromatography (FC).  
 
Scheme 4.2 Retrosynthetic analysis of 11,11-difluorolinoleic acid. 
 
 





To undergo the Weinreb-Nahm ketone synthesis, 93 was deprotonated with butyl 
lithium (n-BuLi, 2.5 M in n-hexane) at ‒30 °C for 2 h and coupled with the Weinreb 
amide 91 at ‒78 °C (Scheme 4.3, A bottom). This approach led to no product formation 
but recovery of 93 was possible. Since usage of an organolithium reagent did not show 
the desired reaction, Grignard reagents were applied. The deprotonation step with 
1.3 M or 2.0 M i-PrMgCl in THF was conducted at ‒10 °C but gave no different results 
(Scheme 4.3, A, bottom). Interestingly, when utilizing methyl dec-9-ynoate or 
unprotected 9-decyn-1-ol traces of product (98, 99) were detected in mass spectrometry 
but no isolation attempt was successful (Scheme 4.3, B and C). 
Since the strategy based on the research of PRÉVOST et al. gave no promising results, 
the approach was changed with the introduction of a new starting material. Instead of 
utilising the Weinreb amide 91 the commercially available 2-octynal was deployed. 
Applying the same conditions as before, alkyne 93 could be deprotonated with either 
an organolithium reagent or a Grignard reagent to undergo the subsequent coupling 
reaction with the aldehyde.[222] 
 
Scheme 4.3 Synthesis of Weinreb amide 91 (A, left) and protection of the terminal alcohol of 9-decyn-1-ol 
(A, right) followed by coupling attempts of 91 and 93; a: deprotonation of 93 with n-BuLi at ‒30 °C, 
stirring for 2 h r.t., addition of 91 in THF at ‒78 °C, stirring at r.t. for 15 h; b: deprotonation of 93 with 
i-PrMgCl, THF, ‒10 °C, 1 h, addition of 91 in THF at ‒10 °C, stirring o.n. (A, bottom). Coupling of 90 with 
91 (B). Coupling of 92 with 91 (C). 




In Scheme 4.4 the reactions to form 100 are displayed utilising the Grignard reagent 
(A) or the organolithium reagent (B). In A protected alcohol 93 was treated dropwise 
with i-PrMgCl in THF at ‒10 °C and stirred for 1 h while keeping the temperature. A 
solution of 2-octynal in THF was slowly added at ‒10 °C and the reaction mixture was 
stirred at r.t. over night. After standard workup procedure and FC, the pure product 
was obtained with maximal 32 % in rather low yields. Very similar conditions were 
applied in B. A solution of 93 in THF was slowly treated with n-BuLi (2.5 M) at ‒30 °C 
and then stirred at r.t. for 2 h. The mixture was cooled to ‒78 °C and carefully treated 
with a solution of the aldehyde in THF. After stirring at r.t. for 15 h and filtration 
through silica, the solvent was removed and the product 100 isolated via FC. This 
approach led with up to 31 % yield to comparable amounts of product 100 as the 
reaction depicted in A. 
Since the hitherto stated synthetic routes showed no or insufficient product formation 
and, especially in the case of organolithium reagent application, high amounts of side 
products occurred, further strategy investments were required. In 1984 IMAMOTO et al. 
published their studies on carbon-carbon bond formation using elementary cerium or 
organocerium(III) compounds.[223] They state that organocerium(III) reagents are less 
basic than Grignard or organolithium reagents and react fast with carbonyl 
compounds with few or no side reactions at low temperature (‒78 to ‒65 °C). Even 
though the reaction set up on systems with alkyne functionalities in one or both of the 
coupling partners is not shown there, it was applied on the present system (Scheme 
4.5). For that purpose the terminal alkyne 93 was deprotonated at ‒30 °C using n-BuLi. 
After 2 h at r.t. the mixture was added to a ‒65 °C cooled suspension of cerium(III) 
iodide in THF and stirred for 30 min. 2-Octynal was slowly added and the mixture 
stirred at ‒65 °C for additional 3 h. The reaction was stopped via treatment with 
saturated ammonium chloride solution and after workup and FC the pure product 100 
was obtained in 76 % yield. 
 
Scheme 4.4 Synthesis of 100 with i-PrMgCl (A) or n-BuLi (B) as deprotonation agent. 






Scheme 4.5 Synthesis of compound 100 via organocerium(III). 
 This approach using cerium(III) iodide proved to be very beneficial with a smooth 
reaction showing barely side product formation. 
The next synthetic step was the oxidation of the generated secondary alcohol to a keto 
moiety.[179,224,225] As oxidising agent Jones reagent was chosen[222], which was prepared 
from chromium(VI) trioxide in concentrated sulphuric acid and water. A solution of 
the secondary alcohol 100 in acetone was treated at 0 °C with the Jones reagent and 
stirred at r.t. for 1 h (Scheme 4.6, A). After standard workup procedure and FC, only 
5 % yield of the oxidised compound 101 could be isolated. Due to the low yield and 
high toxicity of chromium(VI) compounds, manganese(IV) oxide was tested as an 
alternative (Scheme 4.6, B).[226] MnO2 is a weak to moderate oxidant and reacts 
preferably with allylic and benzylic hydroxyl groups to form aldehydes or ketones. 
Further oxidation to carboxylic acids does not occur. 
The secondary alcohol 100 and MnO2 were dissolved in DCM and stirred at r.t. for 2 h. 
The mixture was filtrated through Celite® and standard workup procedure was 
applied. It turned out that the usage of MnO2 as an oxidising agent had two major 
advantages: the yield of 61 % was considerably greater utilising MnO2 than Jones 
reagent and highly toxic chromium waste was avoided. 
After successful isolation of the keto-moiety bearing compound 101, the next step 
included the introduction of two fluorine atoms (Scheme 4.7). As fluorination reagent 
the aminosulphurane diethylaminosulphur trifluoride (DAST) was chosen and four 
different reaction conditions were tested (Table 4.1). 
 
Scheme 4.6 Oxidation approaches for the synthesis of 101 using Jones reagent (A) and manganese(IV) 
oxide (B). 




Table 4.1 Overview of tested fluorination condition. 
Condition No. Temperature Time Duration Admixture 
1. [227] 0 °C - r.t. over night ‒ 
2. [228] 45 °C 6 d ‒ 
3. [229] 60 °C 6 h 2 drops ethanol 
4. [230] r.t. 8 d ‒ 
 
Scheme 4.7 General fluorination reaction using DAST as fluorination reagent. 
None of these conditions led to the formation of the gem-fluorinated product 102. To 
overcome the obstacle of fluorine insertion a different synthetic approach had to be 
devised. In 1987 KWOK et al. published a strategy for the total synthesis of 7,7-, 10,10- 
and 13,13-difluoroarachidonic acids[231], in which incorporation of the fluorine atoms is 
conducted in an early stage of the synthesis (Scheme 4.8). 
The new route was adapted to the system used in this work and started with insertion 
of the fluorine atoms. KWOK et al. used the at r.t. gaseous bromochlorodifluoromethane 
(CBrClF2), which needs to be condensed at ‒78 °C prior usage. This prohibits working 
with precise stoichiometry, complicates handling and requires special technical setups. 
To avoid working with this gaseous reagent an alternative was found in 
dibromodifluoromethane (CBr2F2), which is a liquid with a boiling point of 22.8 °C. To 
incorporate the fluorine carrying moiety, the alkyne 1-heptyne was deprotonated by 
dropwise addition of n-BuLi (2.5 M) at ‒90 °C. Pre-cooled CBr2F2 was slowly added at 
‒110 °C and the reaction mixture stirred for 1 h at ‒50 °C. Standard workup procedure 
yielded the pure product 103 without further purification steps with a yield of 68 % 
(Scheme 4.9). Several publications state the formation of a brominated side product for 
this reaction[232–234] but interestingly, no formation of this compound (105) could be 
detected. 
 
Scheme 4.8 Retrosynthetic analysis of 11,11-difluorolinoleic acid based on the work of KWOK et al. 






Scheme 4.9 Incorporation of the fluorine moieties and the literature stated side product 105. 
Another observation was that, when 1-hexyne instead of 1-heptyne was subjected to 
this reaction condition, no product formation took place but various side reactions 
could be observed. 19F-NMR spectroscopy revealed formation of several fluorine 
containing compounds, which could not be identified. 
After successful introduction of the fluorine atoms, the next short-term objective was 
to achieve the desired chain length. For attachment of the second alkynyl moiety, the 
terminal alkyne of 93 was deprotonated using n-BuLi and treated dropwise with a 
solution 103 in THF at ‒78 °C (Scheme 4.10).  
 
Scheme 4.10 Attachment of the second alkyne to obtain the desired carbon chain length using the 
brominated compound 103. 
Using these conditions no product was formed. Therefore, a Nicholas-like reaction was 
tested.[235–237] Addition of dicobalt octacarbonyl (Co2(CO8)) should lead to a complex 
formation under release of two carbon monoxide molecules (Scheme 4.11). The formed 
cobalt–alkyne complex should protect the alkynyl moiety and stabilise the generated 
cation in the following nucleophilic substitution reaction. 
The complexation reaction using dicobalt octacarbonyl was tested in DCM and toluene 
as solvents but in both cases no signal shift in the 13C-NMR spectra was observed. A 
reason that no cobalt–alkyne complex was formed could be the instability of Co2(CO)8 
to air exposure followed by possible decomposition before the reaction could start. 
 
Scheme 4.11 Formation of cobalt–alkyne complex 106. 
 




Since a Nicholas-like approach was unsuccessful, it was decided to perform a halogen 
exchange reaction to substitute the bromine of compound 103 with an iodine, which 
represents a better leaving group.[231] Heating 103 in acetone in presence of sodium 
iodide yielded the iodinated compound 104 in equilibrium (Scheme 4.12). The 
equilibrium was shifted to the product side, because the generated sodium bromide 
was insoluble in acetone and therefore precipitated. 
 
Scheme 4.12 Substitution of bromine with iodine by halogen exchange reaction. 
The reaction conditions depicted in Scheme 4.10 were then applied to the iodised 
compound 104 (Scheme 4.13). This resulted in formation of product traces, which were 
detected in mass spectrometry, but could not be isolated. Optimisation attempts by 
varying n-BuLi concentrations (1.6 M or 2.5 M), changing the organolithium reagent to 
t-uLi (1.7 M) or shifting to another deprotonation agent like NaH or t-BuOK showed 
no increase in product yield. An overview about the tested bases and temperatures for 
carbon-carbon coupling of 93 and 104 is shown in Table 4.2 Conditions tested for 
carbon-carbon coupling of 93 and 104.. 
 
Scheme 4.13 Attachment of the second alkyne (93) to obtain the desired carbon chain length using the 
iodised compound 104. 
Table 4.2 Conditions tested for carbon-carbon coupling of 93 and 104. 
Condition No. Base Temperature Product Traces 
1.a n-BuLi (1.6 M) ‒78 °C ‒ 
1.b n-BuLi (1.6 M) 0 °C  
1.c n-BuLi (1.6 M) ‒20 °C 
2.a n-BuLi (2.5 M) ‒78 °C ‒ 
2.b n-BuLi (2.5 M) 0 °C  
3 t-BuLi (1.7 M) ‒78 °C 
4 NaH ‒78 °C ‒ 
5 t-BuOK ‒78 °C ‒ 
 
 





Due to the fact that these efforts led to no constructive route for the synthesis of 11,11-
difluorolinoleic acid (89), another strategy was necessary. Since the carbon-carbon 
coupling via organocerium(III) compounds has proven to be a useful synthetic tool 
(Scheme 4.5), it was applied to the fluorinated alkyne 103 as well. Alkyne 93 was 
deprotonated using n-BuLi and converted into an organocerium(III) compound by 
treatment with a cerium(III) iodide suspension. Addition of 103 was then supposed to 
lead to formation of product 102 (Scheme 4.14). The analysis with mass spectrometry 
revealed no formation of product 102. The individual components of the reaction 
mixture were isolated by FC and analysed to reveal that compound 93 was recovered 
while the gem-fluorinated alkyne 103 seemed to be decomposed. A third substance was 
isolated and identified by HSQC, HMBC and DOSY as a dimerisation product (107) of 
93, shown in Scheme 4.14. 
It was reported by XU and HAMMOND that the nucleophilic substitution (SN2) of 
RCF2Nu from RCF2X is a non-trivial challenge due to the carbon atom being shielded 
by the encircling fluorine atoms.[238] This hinders nucleophilic substitution reactions, 
which is why they developed a two-step synthesis consisting of an indium-mediated 
SE2’ bromide substitution followed by a SN2’ reaction (Scheme 4.15).  
To test the reported strategy, 103 was treated with ammonium chloride and 
elementary indium at 5‒10 °C for 7 h in an ultrasonic bath. After standard workup 
procedure, bromine was added to the crude product at ‒78 °C and stirred for 30 min at 
‒20 °C (Scheme 4.16, A). NMR spectroscopy could not unambiguously show formation 
of the difluoroallenyl compound 108. Nevertheless, it was used to try the following 
nucleophilic substitution reaction. Alkyne 93 was deprotonated by addition of n-BuLi 
at ‒78 °C and difluoroallene 108 was appended (Scheme 4.16, B).  
 
Scheme 4.14 Synthetic route to form 102 using CeI3 with in lieu thereof observed reaction. 





Scheme 4.15 From XU and HAMMOND designed strategy for SN2-like substitution.[238] 
Applying these conditions no product formation was detected but the mass spectrum 
showed unreacted starting material 93. Therefore, the deprotonation step was varied 
by addition of NaH at 0 °C instead of n-BuLi and the overall reaction time increased 
(Scheme 4.16, C). Under these conditions no product could be generated, too. 
Another attempt to synthesise the desired gem-difluorinated fatty acid 89 was to 
incorporate a better leaving group into 93 by exchanging the terminal hydrogen atom 
by a TMS group (Scheme 4.17).[239] A solution of 93 in THF was treated with 
magnesium swarf and trimethylsilyl chloride (TMSCl) at 0 °C for 30 min but no 
conversion took place. Since the hydrogen–TMS substitution reaction led to no product 
formation, the exchange of reactivities of the two alkyne compounds 93 and 103 aimed 
for and adapted from literature-known procedures for gem-difluorinated alkynes.[239] 
 
Scheme 4.16 Generation of difluoroallene 108 (A) with subsequent substitution reaction using n-BuLi (B) 
or NaH (C). 






Scheme 4.17 Approach to functionalise alkyne 93 with TMS. 
To achieve a reactivity exchange of terminal alkyne 93, the proton was substituted by a 
bromine via treatment of 93 with N-bromosuccinimide (NBS) and silver nitrate 
(Scheme 4.18, A).[240] The hydrogen–bromine substitution reacted smoothly to 
compound 110 within 45 min with a high yield of 82 %. In case of gem-fluorinated 
alkyne 103 the bromine was exchanged by applying the reaction conditions depicted in 
Scheme 4.18, B.[239] After 30 min at 0 °C the compound 111 was obtained in moderate 
yield of 51 %. The following reaction using potassium fluoride and copper iodide[239] to 
generate a carbon-carbon bond between nucleophilic 111 and electrophilic 110 did not 
produce the desired molecule 102 (Scheme 4.18, C). 
Since in the literature no synthesis of a compound with two geminal positioned 
fluorine atoms along with two geminal stationed alkynyl moieties on the same carbon 
atom has been described so far, it was considered that the reduction of 103 to the 
alkene 112 might enable the coupling reaction. It was crucial in this step to ensure the 
generation of a cis-alkene and to stop the reduction on the level of alkene formation. 
Therefore, compound 103 was treated with a Lindlar catalyst poisoned with quinoline 
under a hydrogen atmosphere (Scheme 4.19, A).[241] NMR spectroscopy revealed that 
no reaction took place, and 103 was regained. Another option to generate cis-alkenes is 
the utilisation of palladium on barium sulphate (5 % Pd‒BaSO4), shown in Scheme 
4.19, B.[242] This was tested using 103, which was stirred for 24 h with 5 % Pd‒BaSO4 in 
pyridine but no product was formed. 
 
Scheme 4.18 Substitution of terminal proton by bromine (A); substitution of bromine by TMS-group (B); 
coupling attempt of 110 and 111 (C). 





Scheme 4.19 Attempts of selective hydration for cis-alkene preparation using a Lindlar catalyst poisoned 
with quinoline (A) or 5 % Pd adsorped to BaSO4 (B). 
The synthetic approaches performed so far could not lead to the final compound 11,11-
difluorolinoleic acid (89). Further investigations with other strategies should be tested. 
Therefore, palladium catalysed coupling conditions could be considered featuring zinc 






Communication between cells represents a crucial process, which enables organisms to 
respond to environmental influences. For interaction of cells with the surrounding or 
with neighbouring cells, the plasma membrane as a special organelle is necessary. The 
plasma membrane serves as an active interface by carrying a multitude of receptors 
and sensors for signal transduction and regulates import and export of a variety of 
compounds.[129] To transmit signals, messenger agents are required. One of the most 
ubiquitous and versatile second messenger is calcium in its ionic form.[39,67] Typical 
processes regulated by Ca2+ are fertilisation[42], cell growth[43], apoptosis[38] and many 
more. 
Due to the importance of Ca2+ as a signalling agent, a high demand for fluorescent Ca2+ 
sensors evolved, which led to the development of a multitude of sensors with diverse 
fluorescent properties and sensitivities.[11,12] A major drawback of most commercially 
available sensors is, however, their unequal distribution within cells and occasionally 
rapid exclusion from the cell. To overcome this obstacle, several sensors have been 
modified by incorporation of an azide-carrying alkyl linker to enable the labelling of 
alkynes via a HUISGEN reaction.[13] In the first part of this work, two of these modified 
Ca2+ sensors (Fluo-Azide and X-Rhod-Azide) were applied to label membrane 
compartments. Therefore, the lipid DOPE, a frequently existing lipid in the plasma 
membrane, and the sterol cholesteryl hemisuccinate were coupled with alkyne-
carrying linker compounds. Furthermore, a small library of four peptides with the 
artificial amino acid propargyl glycine at the N-terminus was generated, including a 
transmembrane WALP25 peptide. After intensive condition screening, HUISGEN 
reactions were successfully performed using the cholesterol derivative and one of the 
DOPE derivatives. As products the Fluo-Azide labelled compounds 15 and 22, as well 
as the X-Rhod-Azide labelled compound 23 were obtained (Figure 5.1). 
Since an increase of fluorescence will occure only if Ca2+ is bound by a sensor, the 
labelled membrane components were thought to serve as a useful system for 
monitoring membrane fusion. Therefore, fusion experiments were performed using 
two different systems of SNARE analoga. Fluorescence measurements of fusion 
experiments utilising modified SNARE peptides with a PNA recognition motif 
revealed no fusion occurring. Substitution of the fusion proteins by modified SNARE 
peptides exhibiting a coiled-coil recognition unit resulted in a slight fluorescence 
increase. Due to the low increase, this result needs to be treated with caution but 






Figure 5.1 Synthesised membrane components 15 and 22 labelled with Fluo-Azide, and 23 labelled with 
X-Rhod-Azide. 
After verification of the outcome via further experiments, the usage of sensor labelled 
membrane compartments might present a useful system to follow fusion processes, 
taking the importance of Ca2+ for fusion in natural systems into account. 
Besides Ca2+ other important signalling agents are IP3 and DAG. The source of both 
messengers is the rare plasma membrane lipid PIP2.[14] During fusion processes, such as 
neuronal exocytosis, PIP2 was found to locally increase its concentration to form PIP2 
and cholesterol enriched domains. These rafts are thought to serve as binding 
platforms for fusion proteins.[16,127] The utilisation of a suited fluorophore for the 
observation of PIP2 raft formation should enable further insights into the protein 
mediated membrane fusion. Therefore, the ultimate goal of the second part of this 
work was to synthesise a labelled PIP2 derivative. Since the synthesis of the PIP2 head 
group requires expensive starting materials, a simplified PC lipid was targeted during 
the synthesis planning. As fluorophore, 7-azaindole was utilised, which is a well 
studied and highly environment sensitive labelling compound. The commercially 
available 7-azaindole was modified by incorporation of two different linkers, which 
yielded compounds 25 and 40, to allow subsequent covalent labelling of lipid 
derivative. Applying several strictly synthetic strategies as well as semi-enzymatic and 
full-enzymatic approaches to synthesise a 7-azaindole labelled PC lipid, the successful 
synthesis of a labelled lipid precursor lacking a head group was achieved. 





membranes revealed that the fluorophore does not insert into the membrane but is 
oriented in the polar head group region of the membrane. For this reason no further 
experiments were performed. 
Lipophilic signalling molecules in plants, like jasmonic acid, are generated by 
oxidation of polyunsaturated fatty acids, starting with hydroperoxide formation. The 
enzymatic dioxidation of the fatty acids is mainly performed by LOX enzymes.[22] So 
far, many details about the mechanism of hydroperoxidation have been learned but 
the exact orientation of the substrate within the active site of the enzyme remains to be 
discovered. As a result, the goal of the third part was to synthesise a substrate-like 
inhibitor that can be bound by the enzyme but cannot be digested. The target 
compound was 11,11-difluorolinoleic acid, which mimics the substrate linoleic acid. 
Substitution of both hydrogen atoms by fluorine atoms at C-11 inhibits the hydrogen 
abstraction step and no conversion can take place. To synthesise the target compound 
a multitude of approaches was made but none of them yielded the desired product. 
Other strategies to generate the target compound, which still have to be tested, are 










6 Experimental Part 
6.1 Materials and General Methods 
Solvents 
Technical solvents were distilled before usage. Solvents of “analytical” or “puriss. p. 
a.” Grade supplied by Acros Organics, Fisher Chemical, Merck, Sigma-Aldrich and VWR 
were used without further purification. Anhydrous solvents were purchased as 
“puriss, absolute, over molecular sieves” from Acros-Organics, Fluka and Sigma-Aldrich 
and were stored under argon atmosphere. For HPLC purification methanol and 
acetonitrile in “HPLC grade” were obtained from Fisher Scientific, Sigma-Aldrich and 
VWR. Demineralised water for HPLC and buffers was purified using as arium mini 
purification system from Satorius. 
Reagents 
All utilised reagents were ordered with the quality “for synthesis” or “analytical 
grade” and were purchased from ABCR, Acros Organics, Alfa Aesar, Bachem, Carl Roth, 
Fisher Scientific, Fluka, fluorchem, Merck, Nova Biochem, Sigma-Aldrich, TCI and VWR. 
Resins, amino acids and coupling reagents were obtained from the companies ABCR, 
Bachem, GL Biochem, IRIS Biotech and Nova Biochem. Polyethylenglycol (PEG) conjugates 
were purchased from Iris Biotech and fluorescent dyes from ATTO-TEC, Eurogentec and 
Invitrogen. 
Reactions 
Air- or moisture-sensitive reactions were carried out under inert atmosphere using 
anhydrous solvents. Small scale reactions were performed in non-heatable reaction 
tubes made of polypropylene using a purge and flush procedure. Reactions of larger 
scale were conducted in under vacuum flame-dried glassware. Addition of solid 
compounds was performed under counter flow. Light sensitive reactions were carried 
out under light exclusion. 
Lyophilisation 
For lyophilisation thecompounds dissoleved in water or dioxane with minimal 
amounts of methanol, acetonitrile or DMF were frozen with liquid nitrogen. The 





vacuum pump from Vakuubrand. Freeze-drying of small amounts filled in centrifuge 
caps were performed using the speed vac Christ RVC-2-18 linked to the lyophiliser. 
Chromatography 
 Thin Layer Chromatography (TLC) 
To follow reactions and as purity control silica gel 60 F254 coated aluminium plates with 
an absorbent layer thickness of 0.25 mm from Merck were used. TLC plates with a 
reverse phase surface were obtained from Macherey Nagel. The Alugram RP-18 W/UV254 
plates were pre-coated aluminium sheets with a layer thickness of 0.15 mm of C18 silica 
gel containing a fluorescent indicator. To detect UV active substances fluorescence 
elimination at wavelengths 254 and 366 nm were applied, while UV inactive 
substances were dyed with potassium permanganate solution (2.0 g KMnO4, 3.3 mL 
5 % (w/w) aqueous NaOH, 13.3 g K2CO3, 200 mL H2O) or sulfuric acid solution (20 mL 
sulfuric acid, 80 mL ethanol). 
 Preparative Thin Layer Chromatography (PLC) 
PLC plates were ordered from Carl Roth with glass plates carrying silica gel 60 
(thickness: 2 mm, size: 20 cm  20 cm). For detection the PLC sheet was dipped into an 
aqueous solution of copper sulphate and then heated to 120 °C for approximately 
30 min. This chares the organic substances on the plate and makes them visible. Since 
the substances are destroyed in this process, the stained PLC plate was used as 
reference for further PLC. 
 Flash Column Chromatography (FC) 
Silica gel 60 with a particle size of 40‒63 µm (230‒400 mesh particle size) from Merck 
was used. The silica gel was suspended in the eluent system and filled into the glass 
column. An excess of silica gel to crude product (50‒200 times) was conducted. The 
crude product was added to the column as a solid adsorbed to silica gel or as a 
concentrated solution in the employed eluent system. Separation of substances on the 
column occurred via 0.2‒1.0 bar applied pressure. 
 Reverse Phase Chromatography (RPC) 
Purification via RPC was carried out using RP silica gel from YMC (ODS-A, AA06S50, 
60 Å, S-50 µm, C18). Substances were dissolved in the respective eluent system and 
added to the column. Separation of substances occurred without additional pressure. 
 High Performance Liquid Chromatography (HPLC) 
Analytical and semi-preparative HPLC for peptide purification was performed on 






variable UV detector UV-900). The isolation of labelled compounds was achieved on a 
HPLC device from Jasco connected to a MD-2010 plus multi wavelength UV detector, a 
DG-2080-53 degasser, two PU-2080 pumps and a LC-NetII/ADC interface. The runs 
were executed with a linear gradient of eluent A to eluent B. An overview about 
utilised eluent systems is shown in Table 6.1. Detection of UV absorption took place at 
215, 254 and 280 nm for peptides and at 215 nm, 280 nm and the respective absorption 
maximum of the fluorophore (488 nm for Fluo-Azide and 580 nm for X-Rhod-Azide) 
for labelled compounds. Flow rates for analytical columns were 1 mL/min and 
3 mL/min for semi-preparative columns. Runs for purely analytical purposes with very 
small amounts were conducted on a Dionex UltiMate 3000 device from Thermo 
Scientific, containing a pump type P-3000 and a variable UV detector UV-3000. The 
flow rate was set to 0.4 mL/min. All samples were dissolved in purified water with 
minimum amounts of MeCN or MeOH and filtrated prior injection. 
Table 6.1 Overview about utilised eluent systems. 
 Eluent A Eluent B 
Variant 1 (V1) ultrapure H2O + 0.1 % TFA MeOH + 0.1 % TFA 
Variant 2 (V2) ultrapure H2O + 0.1 % TFA MeCN/ultrapure H2O (80:20, v/v) + 
0.1 % TFA 





Nuclear Magnetic Resonance Spectroscopy (NMR) 
NMR spectra were recorded at Bruker (AV401, AV300) and Varian instruments 
(INOVA500, INOVA600 and Mercury-VX 300).  The chemical shift is stated in ppm 
(TMS = 0 ppm) while remaining protons of deuterated solvents were used as internal 
standard. The following abbreviations were used for multiplicities in 1H-NMR signals: 
s = singlet, sb = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet. 
Coupling constant J is quoted in Hertz [Hz]. 13C-NMR spectra were recorded proton-








Mass Spectrometry (MS) 
Mass spectra were recorded at spectrometer from Bruker (micrOTOF (ESI-TOF-MS), 
maXis (ESI-QTOF-MS) and Apex IV (FT-ICR-MS)) using electron spray ionisation (ESI) 
as ionisation method. The signals were stated as mass to charge (m/z). Matrix-assisted 
laser desorption/ionisation (MALDI) spectra were recorded at MALDI-TOF Autoflex 
Speed from Bruker. 
 
 
6.3 Spectroscopic Methods 
UV/Vis Spectroscopy 
Absorption spectra were recorded at a Jasco system V-650 UV/Vis spectrophotometer at 
20 °C. Absorption spectra of calcium sensor-labelled compounds were measured in a 
Ca2+-free buffer (30 mM MOPS, 10 mM EGTA, 100 mM KCl, pH 7.2).  
Concentrations of peptides were calculated using the law of LAMBERT-BEER via 
absorption at specific wavelengths (see formula below). The extinction coefficient ε 
was calculated from of the extinction coeffients of tryptophan, tyrosine and 
phenylalanine at 280 nm.[243] 
   
 
    
 
A: absorption at specific wavelength, 
ε: molar extinction coefficient [cm-1M-1], 
d: layer thickness of the cuvette [cm]. 
 
Fluorescence Spectroscopy 
Fluorescence measurements were conducted at a Jasco FP-6200 spectrofluorometer 
connected to a temperature control unit Jasco ETC-272T. For Ca2+-dependent 
fluorescence measurements a commercially available buffer kit containing a Zero Free 
Calcium Buffer (30 mM MOPS, 10 mM EGTA, 100 mM KCl, pH 7.2, buffer A) and a 
39 µM Free Calcium Buffer (30 mM MOPS, 10 mM CaEGTA, 100 mM KCl, pH 7.2, buffer 
B) from Invitrogen was used. By mixing defined volumes of the buffer specific Ca2+ 
concentrations can be adjusted varying from 0 to 39 µM. All measurements for the 






sensor concentration constant. Employed parameters for fluorescence measurements 
are listed in Table 6.2. 
Table 6.2 Parameters applied for Ca2+-dependent fluorescence measurements. 
 Ex /nm Measuring range /nm Measurement Mode 
Fluo-Azide 488 500‒600 Emission 
X-Rhod-Azide 540 550‒650 Emission 
 
The employed procedure for Ca2+-dependent fluorescence measurements was based on 
the protocol stated by Invitrogen: 
1. The sensor-labelled compounds were dissolved as stock solution in DMF or 
MeOH with a resulting concentration of 0.2‒1 mM. 
2. One part of the respective stock solution was added to 2 mL of buffer A to 
obtain a 15/22/23 concentration of 2 µM (mixture C). 
3. Three parts of the stock solution was added to 6 mL of buffer B to gain the 
same concentration (2 µM, mixture D). 
4. 1.3 mL of mixture C was transferred to a fluorescence cuvette to detect the 
fluorescence spectrum of the labelled compound in absence of free Ca2+-ions. 
5. The following fluorescence measurements at varying Ca2+-concentration were 
performed by substitution of specific volumes of the mixture in the cuvette 
through the same volumes of mixture D (Table 6.3) while keeping the 
concentration of the sensor-labelled compound constant. 
Table 6.3 Serial dilution with resulting concentrations for Ca2+-dependent fluorescence measurements. 
c(CaEGTA) /mM c(Ca2+) /µM Replaced Volume* /µL 
0 0 - 
1.0 0.017 130 
2.0 0.038 144 
3.0 0.065 163 
4.0 0.100 186 
5.0 0.150 217 
6.0 0.225 260 
7.0 0.351 325 
8.0 0.602 433 
9.0 1.35 650 
9.3 2.00 390 
9.5 2.86 371 
10 39 Mixture D 





Circular Dichroism Spectroscopy (CD) 
CD measurements were performed at a Jasco J-810A spectropolarimeter connected to a 
PTC-423S Peltier element. To prevent ozone formation the sample chamber was 
flushed with nitrogen. The following parameters were adjusted during measurements: 
data mode: CD and absorption, band width: 1.0 nm, response: 2 s, datapitch: 0.1 nm, 
scanning speed: 50 nm/min, accumulations: 10. The spectra were corrected by sample 
concentration and layer thickness of the cuvette (0.1 cm). The curves were filtered 
following SAVITZKY-GOLAY. The molar ellipticity was calculated using the measured 
values (see formula below). 
           
  
   
 
Θmolar: molar ellipticity [deg·cm2/dmol], 
CD: measured ellipticity [mdeg], 
c: sample concentration [mol/cm3], 




6.4 General Protocols (GP) 
6.4.1 GP1: Peptide Synthesis 
GP1.1: Manuel Solid Phase Peptide Synthesis (SPPS) 
In this work the synthesis of peptides was achieved by applying SPPS with the 
standard Fmoc-protocol. For manual peptide coupling on solid support acid- and base-
resistant Becton Dickinson Discardit (BD)-syringes provided with a polyethylene filter 
were used. The Fmoc-loaded Rink-Amide MBHA resin (loading density 0.76 mmol/g) 
was swollen in DMF (~10 mL/g resin) for a minimum of 1 h. The batch size was varied 
for each peptide synthesis. The protocol stated below refers to 0.05 mmol (65.8 mg 
resin) in a 2 mL BD syringe. 
1. Deprotection: Removal of the Fmoc group was carried out by treatment with 
piperidine (20 % v/v) in DMF (2  1.5 mL) for 10 min each. Afterwards, the 
resin was washed with DMF (10  2 mL). 
 
2. Coupling: The respective amino acid (5.0 eq.), HBTU (4.5 eq.) and HOBt 
(5.0 eq.) were dissolved in DMF (1.5 mL). After addition of DIPEA (10.0 eq.) the 






30 min. For double coupling the resin was treated with the coupling mixture a 
second time. After coupling the resin was washed with DCM/DMF (1:1, 
3  2 mL), DCM (2  2 mL), DCM/DMF (1:1, 3  2 mL) and DMF (2  2 mL). 
 
3. Repetition: The steps 1 and 2 were repeated as often as required to obtain the 
desired sequence. In case of longer intermission during synthesis the resin was 
washed with DCM (10  2 mL) after step 2, dried and stored in vacuo.  
 
GP1.2: Automated Solid Phase Peptide Synthesis 
Automated solid phase peptide synthesis was performed using standard Fmoc-
protocol. The synthesis was conducted on a CEM (Kamp-Lintfort) microwave-
supported LibertyBlue peptide synthesiser. The Discover microwave was equipped with 
a reaction cavity connected to the LibertyBlue unit with all required reagents and 
solvents. Besides the positions for the 20 natural amino acids up to seven non-natural 
amino acids could be attached on the available external positions. The used amino 
acids were prepared as 2 M solutions in DMF. Standard reagents were used for 
coupling (0.5 M DIC in DMF, 1.0 M Oxyma in DMF), for deprotection (20 % (v/v) 
piperidine in DMF) and for washing (DMF). All reactions were carried out microwave-
assisted and under nitrogen. A standard cycle with a batch size of 0.1 mmol using 
double coupling on high-swelling resins was performed, which consisted of two 
deprotection steps (1. 15 s, 75 °C, 155 W; 2. 50 s, 90 °C, 35 W), two coupling steps (1. 
15 s, 75 °C, 170 W; 2. 110 s, 90 °C, 30 W) and washing with DMF between deprotection 
and coupling steps. After finishing the synthesis the resin was transferred from the 
reaction vessel into a 10 mL BD-syringe, washed with DCM (10  6 mL) and dried in 
vacuo. 
 
GP1.3: Cleavage from Solid-Support 
To cleave synthesised peptides from solid support the dry resin was treated with a 
solution of TFA, TIS and H2O (95:2.5:2.5, v/v/v, ~10 mL/g) and agitated for 2 h. The 
cleavage solution was collected and the resin washed with TFA (2  10 mL/g). The 
solvents were removed by a gentle nitrogen stream and the peptide precipitated with 
cold Et2O (4‒10 mL). The suspension was vortexed and centrifuged (9000 rpm, -10 °C, 
20 min). The solvent was decanted and the precipitation repeated twice. The crude 






6.4.2 GP2: Preparation of Vesicles 
GP2.1: Preparation of Lipid Films 
The lipids used in this work for vesicle preparation were 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanol-amine (DOPE) and 
cholesterol in the relation of DOPC/DOPE/cholesterol 50:25:25. The total lipid 
concentration was varied between 0.625 ‒ 2.50 µM. For lipid film preparation stock 
solution of each lipid in chloroform (20 mg/mL) was assembled, which were stored at -
20 °C. For each desired vesicle population one small reagent tube was provided. A 
specific volume of chloroform was added to the tubes that contained up to 500 µL after 
addition of lipid solution for vesicles without peptides and 250 µL for vesicles with 
peptides. Examples for both systems are shown in Table 6.4. The calculated amount of 
lipid stock solutions was pipetted into the prepared tubes. For vesicles containing 
peptides, a specific amount TFE was added, which is again supposed to sum up to 
250 µL after addition of peptide solution. The in TFE dissolved peptides were added to 
yield a peptide to lipid ratio varying from 1:200 to 1:750. The solutions were warmed 
up to r.t. and vortexed for 5 s each. The tubes were heated to 50 °C and after 5 min 
vortexed again. The solvents were slowly removed at 50 °C by nitrogen stream to 
obtain even lipid films. These films were further dried over night in a vacuum oven at 
45 °C. If the lipid films were not used on the next day they were stored under argon at 
-20 °C. 
Table 6.4 Exemplary composition of four different lipid films: VA and VC containing the Ca2+ sensor-
labelled 22. VB and CV do not comprise a sensor, while VA and VB hold SNARE fusion proteins E3-Syb 
and K3-Sx. 
 [µL] VA VB VC CV 
DOPC 24.24 24.24 24.24 24.24 
DOPE 17.21 17.21 17.21 17.21 
cholesterol 26.62 28.12 26.62 28.12 
22 14.28 - 14.28 - 
E3-Syb 2.13 - - - 
K3-Sx - 2.92 - - 
CHCl3 167.65 180.43 417.65 430.43 











GP2.2 Preparation of Large Unilamellar Vesicles (LUVs) 
For preparation of large unilamellar vesicles the prepared lipid films were incubated 
with 0.5 mL buffer, MOPS (30 mM MOPS, 10 mM CaEGTA/10 mM EGTA, 100 mM KCl, 
pH 7.2) or HEPES (20 mM HEPES, 1 mM EDTA, 100 mM KCl, pH = 7.4), at 40 °C for at 
least 2 h. To improve dissolution of the lipid films from the glass wall three small glass 
beads were given into each reaction tube. The tubes were closed with Parafilm and 
shaken at approximately 150 rpm. To produce LUVs the extrusion method[244] was 
used. In this method a multilamellar vesicle suspension is forced 31 times through a 
polycarbonate membrane from Avestin with a pore diameter of 100 nm. The employed 
extruder was a LiposoFast type from Avestin. Using this method vesicles with an 
average size of 80 nm were prepared.[244] The obtained vesicles were used immediately 
after extrusion for fluorescence spectroscopy. Vesicles containing the head labelled N-
(lyssamine rhodamine B sulfonyl)-1,2-dioleoyl-sn-3-phosphatidylethanol-amine (Rhod-






6.5.1 Synthesis of 11,11-Difluorolinoleic acid 
N-Methoxy-N-methyloct-2-ynamide (91) 
 
To a solution of 90 (300 mg, 330 µL, 1.95 mmol, 1.00 eq.) and N,O-
dimethylhydroxylamine hydrochloride (470 mg, 4.86 mmol, 2.50 eq.) in THF (3.5 mL) 
isopropylmagnesium chloride (2 M in THF, 2.43 mL, 4.86 mmol, 2.50 eq.) was added 
dropwise under argon atmosphere. The mixture was stirred for 30 min and treated 
with aqueous NH4Cl-solution (200 µL). The mixture was diluted with MTBE (1.2 mL) 
and filtrated through celite. The solvent was evaporated and the crude product 
purified via flash column chromatography (n-pentane/ethyl acetate, 4:1). The isolated 
product 91 (210 mg, 1.13 mmol, 58 %) was obtained as colourless oil. 
TLC (n-pentane/ethyl acetate, 4:1): Rf = 0.43. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 0.88 (t, J = 7.1 Hz, 3H, CH3), 1.28‒1.40 (m, 4H, 
2 CH2), 1.53‒1.64 (m, 2H, CH2), 2.35 (t, J = 7.0 Hz, 2H, CH2), 3.15‒3.28 (m, 3H, NCH3), 
3.74 (s, 3H, OCH3). 
13C-NMR (125 MHz, CDCl3): δ [ppm] = 13.75 (C-8), 18.79 (C-4), 21.91 (C-7), 27.27 (C-5), 
30.80 (C-6), 32.19 (NCH3), 61.77 (OCH3), 72.99 (C-2), 93.38 (C-3), 125.69 (C=O). 













Dec-9-ynoic acid (122) 
 
Dec-9-ynol (92, 1.50 g, 1.70 mL, 9.72 mmol, 1.00 eq.) was dissolved in acetone (70 mL), 
cooled to 0 °C and treated dropwise with Jones reagent (5.00 mL, 10.0 mmol, 1.14 eq.). 
The mixture was stirred for 2 h at 0 °C. The solvent was removed under reduced 
pressure and the residue dissolved in diethyl ether (250 mL), washed with saturated 
aqueous sodium chloride solution (200 mL) and dried over MgSO4. Evaporation of the 
solvent and purification via flash column chromatography (n-pentane/ethyl acetate, 
3:2) yielded 122 (1.49 g, 8.85 mmol, 91 %) as colourless oil. 
 TLC (n-pentane/ethyl acetate, 3:2): Rf = 0.63. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.25‒1.37 (m, 6H, 4-CH2, 5-CH2, 6-CH2), 
1.41‒1.50 (m, 2H, 7-CH2), 1.57 (dt, J = 14.8, 7.2 Hz, 2H, 3-CH2), 1.87 (t, J = 2.6 Hz, 1H, 
10-CH), 2.11 (td, J = 6.9, 2.6 Hz, 2H, 8-CH2), 2.28 (t, J = 7.5 Hz, 2H, 2-CH2), 9.54‒9.75 (m, 
1H, COOH). 
13C-NMR (125 MHz, CDCl3): δ [ppm] = 18.33 (C-8), 24.58, 28.34, 28.47, 28.68, 28.87 (C-3, 
C-4, C-5, C-6, C-7), 33.91 (C-2), 68.13 (C-10), 84.60 (C-9), 179.53 (C-1). 
ESI-MS m/z: 169.1 [M+H]+, 191.1 [M+Na]+, 359.2 [2M+Na]+, 167.1 [M-H]-, 335.2 [2M-H]-. 
HR-MS (ESI): calculated for [C10H17O2] ([M+H]+): 169.1223, found: 169.1220; calculated 
for [C10H16O2Na] ([M+Na]+): 191.1043, found: 191.1042; calculated for [C10H15O2] ([M-H]-















To a solution of dec-9-ynol (92, 1.31 g, 1.50 mL, 8.46 mmol, 1.00 eq.) in DCM (60 mL) 
imidazole (1.73 g, 25.4 mmol, 3.00 eq.), DMAP (41.3 mg, 338 µmol, 4 mol-%) and 
TIPSCl (1.63 g, 1.81 mL, 8.46 mmol, 1.00 eq.) was added. The reaction mixture was 
stirred at r.t. for 16 h. The solvent was evaporated, the residue dissolved in diethyl 
ether (30 mL) and washed with hydrochloric acid (1 M, 30 mL). The mixture was dried 
over MgSO4, the solvent was evaporated. After flash column chromatography 
(n-pentane/ethyl acetate, 8:1) the product (93, 2.63 g, 8.46 mmol, 100 %) was obtained 
as colourless oil. 
TLC (n-pentane/ethyl acetate, 6:1): Rf = 0.90. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.01‒1.06 (m, 21H, 6 CH3,TIPS, 3 CHTIPS), 
1.25‒1.39 (m, 8H), 1.45‒1.55 (m, 4H), 1.90 (t, J = 2.6 Hz, 1H, 10-CH), 2.15 (td, J = 7.0, 
2.6 Hz, 2H, 8-CH2), 3.64 (t, J = 6.6 Hz, 2H, 1-CH2). 
13C-NMR (125 MHz, CDCl3): δ [ppm] = 12.02 (3 CHTIPS), 18.01 (6 CH3,TIPS), 18.38 (C-8), 
25.77, 28.48, 28.69, 29.09, 29.31 (C-3, C-4, C-5, C-6, C-7), 33.00 (C-2), 63.45 (H2C-OTIPS), 
68.00 (C-10), 84.69 (C-9). 
ESI-MS m/z: 311.3 [M+H]+, 333.3 [M+Na]+. 
HR-MS (ESI): calculated for [C19H39OSi] ([M+H]+): 311.2765, found: 311.2762; calculated 














 ((10-Bromodec-9-yn-1-yl)oxy)triisopropylsilane (110) 
 
To a solution of 93 (1.38 g, 4.43 mmol, 1.00 eq.) in acetone (25 mL) NBS (920 mg, 
5.17 mmol, 1.17 eq.) and AgNO3 (75.2 mg, 440 µmol, 0.10 eq.) was added at r.t.. The 
mixture was stirred for 45 min, poured onto ice water and the resulting precipitate was 
filtered off. The precipitate was dissolved in ethyl acetate (20 mL) and washed with 
water (2  15 mL). The organic layer was dried over MgSO4 and the solvent was 
removed under reduced pressure. After flash column chromatography (n-pentane/ 
ethyl acetate, 10:1) the desired compound 110 (1.42 g, 3.64 mmol, 82 %) was obtained 
as brown oil. 
TLC (n-pentane): Rf = 0.76.  
1H-NMR (400 MHz, CDCl3): δ [ppm] = 1.02‒1.05 (m, 18H, 6 CH3,TIPS), 1.25‒1.39 (m, 9H, 
3 CHTIPS, 3 CH2), 1.43‒1.56 (m, 6H, 3 CH2), 2.17 (t, J = 7.1 Hz, 2H, Br-C≡C-CH2), 3.65 
(t, J = 6.6 Hz, CH2-OTIPS). 
13C-NMR (125 MHz, CDCl3): δ [ppm] = 12.01 (3 CHTIPS), 18.02 (6 CH3,TIPS), 19.66 (C-8), 
25.76, 28.27, 28.72, 29.06, 29.29, 32.99 (C-2), 37.40 (HC≡C), 63.45 (C-1), 80.44 (Br-C≡C). 
ESI-MS m/z: 389.2 [M+H]+, 411.2 [M+Na]+, 427.3 [M+K]+. 














18-((Triisopropylsilyl)oxy)octadeca-6,9-diyn-8-ol (100) — 1. Variant 
 
To a solution of 93 (1.00 g, 3.22 mmol, 1.25 eq.) in THF (6 mL) n-BuLi (2.5 M, 1.26 mL, 
3.14 mmol, 1.22 eq.) was added at ‒30 °C under dry conditions. The mixture was 
stirred at r.t. for 2 h. Oct-2-ynal (370 µL, 330 mg, 2.58 mmol, 1.00 eq.) was dissolved in 
THF (4 mL) and added dropwise to the prepared mixture at ‒78 °C. The reaction 
mixture was allowed to warm up slowly to r.t. and stirred for 15 h. The mixture was 
filtered through silica and the solvent was removed under reduced pressure. The 
product 100 (440 mg, 1.01 mmol, 31 %) was obtained after flash column 




To a solution of 93 (800 mg, 2.58 mmol, 1.05 eq.) in THF (5 mL) i-PrMgCl (2.0 M, 
1.41 mL, 2.81 mmol, 1.15 eq.) was added dropwise at -10 °C under dry conditions. The 
reaction mixture was stirred at ‒10 °C for 1 h. Oct-2-ynal (350 µL, 300 mg, 2.45 mmol, 
1.00 eq.) was dissolved in THF (5 mL), added dropwise to the mixture at ‒10 °C and 
then stirred at r.t. over night. The reaction was stopped by addition of water (20 mL) 
and washed with ethyl acetate (3  10 mL) and saturated aqueous sodium chloride 
solution (20 mL). The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash column 
chromatography (n-pentane/ethyl acetate, 6:1) to yield the pure 100 (360 mg, 840 µmol, 












Compound 93 (660 mg, 2.13 mmol, 2.20 eq.) was dissolved in THF (4.5 mL) under dry 
conditions, cooled to ‒30 °C and treated dropwise with n-BuLi (2.5 M, 850 µL, 
2.13 mmol, 2.20 eq.). The reaction mixture was stirred at r.t. for 2 h. In a second 
reaction vessel cerium (III) triiodide (1.01 g, 1.93 mmol, 2.00 eq.) was suspended in 
THF (6 mL) and cooled to ‒65 °C. The mixture of the first reaction vessel was added 
dropwise to the suspension and after stirring at ‒65 °C oct-2-ynal (170 µL, 120 mg, 
970 µmol, 1.00 eq.) was added. The suspension was stirred for 3 h at ‒65 °C. The 
reaction mixture was allowed to warm up to r.t., quenched with saturated aqueous 
ammonium chloride solution (10 mL) and extracted with chloroform (3  15 mL). The 
combined organic extracts were dried over MgSO4 and the solvent was evaporated. 
After flash column chromatography (n-pentane/ethyl acetate, 6:1) the pure product 100 
(320 mg, 730 µmol, 76 %) was obtained. 
TLC (n-pentane/ethyl acetate, 6:1): Rf = 0.49. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 0.82‒0.89 (m, 6H, CH3, 3 CHTIPS), 1.02 (t, 
J = 3.6 Hz, 18H, 6 CH3,TIPS), 1.36‒1.21 (m, 12H, 6 CH2), 1.47 (dd, J = 8.9, 3.0 Hz, 6H, 
3CH2), 2.18 (ddd, J = 7.1, 4.7, 2.1 Hz, 4H, 2 C≡C-CH2), 3.63 (t, J = 6.6 Hz, 2H, CH2-
OTIPS), 5.05 (dt, J = 4.0, 2.0 Hz, 1H CH-OH). 
13C-NMR (125 MHz, CDCl3): δ [ppm] = 11.97 (3 CHTIPS), 13.87 (C-1), 17.96 (6 CH3,TIPS), 
18.63, 18.65 (C-5, C-11), 22.12 (C-2), 25.72, 28.02, 28.31, 28.76, 29.04, 29.26, 30.98, 32.94 
(C-17), 52.43 (C-8), 63.43 (C-18), 78.07 (C-7, C-9), 84.94, 84.95 (C-6, C-10). 
ESI-MS m/z: 435.4 [M+H]+, 457.4 [M+Na]+, 433.4 [M-H]-. 
HR-MS (ESI): calculated for [C27H50O2SiNa] ([M+Na]+): 457.3572, found: 457.3573; 










18-((Triisopropylsilyl)oxy)octadeca-6,9-diyn-8-one (101) — 1. Variant 
 
To a solution of 100 (200 mg, 460 µmol, 1.00 eq.) in acetone (5 mL) Jones reagent (1.5 M, 
340 µL, 510 µmol, 1.10 eq.) was added dropwise at 0 °C. The reaction mixture was 
stirred at r.t. for 1 h. The After quenching the reaction by addition of 2-propanole 
(3 mL) the organic solvents were removed under reduced pressure and the 
concentrated solution was extracted with ethyl acetate (3  5 mL). The combined 
organic layers were washed with saturated aqueous sodium chloride solution (10 mL) 
and dried over MgSO4. The organic solvent was removed in vacuo and the purification 
via flash column chromatography (n-pentane/ethyl acetate, 8:1) yielded the desired 




Compound 100 (100 mg, 230 µmol, 1.00 eq.) and MnO2 (440 mg, 5.09 mmol, 22.1 eq.) 
were dissolved in anhydrous DCM (4.5 mL). The reaction mixture was stirred at r.t. for 
2 h and then filtrated through celite. The celite was washed with DCM (5  5 mL), the 
combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure. Flash column chromatography (n-pentane/ethyl acetate, 8:1) led to the pure 
product 101 (60.9 mg, 140 µmol, 61 %) as brown oil. 
TLC (n-pentane/ethyl acetate, 8:1): Rf = 0.75. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 0.79‒0.89 (m, 6H, CH3, 3 CHTIPS), 1.21-1.43 (m, 
28 H, 6 CH3,TIPS, 5 CH2), 1.46‒1.76 (m, 8H, 4 CH2), 2.26 (t, J = 7.1 Hz, 4H, 
2 C≡C-CH2), 4.32 (td, J = 6.1, 2.0 Hz, 2H, CH2-OTIPS). 






HR-MS (ESI): calculated for [C27H49O2Si] ([M+H]+): 433.3496, found: 433.3497; 
calculated for [C27H48O2SiNa] ([M+Na]+): 455.3316, found: 455.3318; calculated for 































1-Heptine (680 µL, 500 mg, 5.20 mmol, 1.00 eq.) was dissolved in dry THF (25 mL) and 
cooled to ‒90 °C. To the solution n-BuLi (2.08 mL, 2.5 M, 5.20 mmol, 1.00 eq.) was 
added dropwise. The mixture was stirred at ‒90 °C for 30 min and then cooled to 
‒110 °C. ‒78 °C cold dibromodifluoromethane (570 µL, 1.31 g, 6.24 mmol, 1.20 eq.) was 
slowly added and the mixture allowed to warm up to ‒50 °C. After stirring for 1 h at 
‒50 °C the reaction mixture was warmed up to r.t. and quenched with saturated 
aqueous ammonium chloride solution (5 mL). Diethyl ether (20 mL) was added and 
the mixture extracted with water (2  20 mL). The organic layer was dried over MgSO4 
and concentrated under reduced pressure. Without further purification the pure 
product (790 mg, 3.52 mmol, 68 %) was obtained as brown oil. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 0.87‒0.94 (m, 3H, CH3), 1.27‒1.41 (m, 4H, 6-CH2, 
7-CH2), 1.52‒1.61 (m, 2H, 5-CH2), 2.29‒2.36 (m, 2H, 4-CH2). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = 13.83 (CH3), 18.47 (t, J = 1.9 Hz, C-4), 22.03 (s, 
C-7), 26.94 (t, J = 1.5 Hz, C-5), 30.88 (s, C-6), 73.95 (t, J = 37.7 Hz, C-2), 93.20 (t, J = 5.7 Hz, 
C-3), 101.47 (t, J = 288.6 Hz, CBrF2). 
19F-NMR (376 MHz, CDCl3): δ [ppm] = -29.97 (t, J = 4.7 Hz, 2F). 














 (1,1-Difluorooct-2-yn-1-yl)trimethylsilane (111) 
 
Magnesium cuttings (430 mg, 17.8 mmol, 8.00 eq.) and TMSCl (1.12 mL, 970 mg, 
8.89 mmol, 4.00 eq.) were suspended in dry THF (22 mL). The suspension was cooled 
to 0 °C and 103 (500 mg, 2.22 mmol, 1.00 eq.) was added dropwise. After stirring at 
0 °C for 30 min the suspension was decanted, the filtrate washed with water (10 mL) 
and the aqueous layer extracted with n-pentane (3   12 mL). The combined organic 
layers were dried over MgSO4 and the organic solvents removed under reduced 
pressure. After flash column chromatography (n-pentane) compound 111 (250 mg, 
1.13 mmol, 51 %) was obtained as brown oil. 
TLC (n-pentane): Rf = 0.74. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 0.18‒0.21 (m, 6H, 3 CH3,TMS), 0.84‒0.92 (m, 3H, 
CH3), 1.23‒1.46 (m, 4H, 6-CH2, 7-CH2), 1.46‒1.59 (m, 2H, 5-CH2), 2.23‒2.34 (m, 2H, 
4-CH2). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = -2.09 (s, 3 CH3,TMS), 13.98 (s, C-8, CH3), 18.72 (t, 
J = 3.4 Hz, C-4), 22.16 (s, C-7), 27.79 (t, J = 3.0 Hz, C-5), 30.98 (s, C-6), 74.41 (t, 
J = 31.0 Hz, C-2), 93.01 (t, J = 9.2 Hz, C-3), 120.34 (t, J = 251.7 Hz, CF2TMS). 
19F-NMR (376 MHz, CDCl3): δ [ppm] = -103.02 (t, J = 6.9 Hz, 2F). 















Compound 103 (850 mg, 3.77 mmol, 1.00 eq.) was dissolved in NaI in acetone (1 M, 
21 mL, 3.21 g, 21.4 mmol, 5.68 eq.) and heated to reflux for 2 h. After cooling down to 
r.t. the reaction mixture was added to a mixture of n-pentane and water (20 mL, 1:1). 
After extraction with n-pentane (2  10 mL) the organic solvent was removed under 
reduced pressure. The product 104 (380 mg, 1.41 mmol, 37 %) was obtained as brown 
oil. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 0.84‒0.95 (m, 3H, CH3), 1.25‒1.43 (m, 4H, 6-CH2, 
7-CH2), 1.57 (dt, J = 14.1, 7.0 Hz, 2H, 5-CH2), 2.27‒2.38 (m, 2H, 4-CH2). 
13C-NMR (126 MHz, CDCl3): δ [ppm] = 13.92 (s, CH3), 18.56 (t, J = 1.9 Hz, C-4), 22.11 (s, 
C-7), 27.01 (t, J = 1.8 Hz, C-5), 30.95 (s, C-6), 73.95 (t, J = 38.0 Hz, C-2), 93.17 (t, J = 5.9 Hz, 
C-3), 101.43 (t, J = 288.1 Hz, C-1). 


















 ((11,11-Difluorooctadeca-9,12-diyn-1-yl)oxy)triisopropylsilane (102) 
 
To a solution of 93 (750 mg, 1.40 mmol, 2.00 eq.) in THF (16 mL) n-BuLi (2.5 M, 960 µL, 
2.40 mmol, 2.00 eq.) was added dropwise at 0 °C under argon atmosphere. The mixture 
was allowed to warm up to r.t. and stirred for 1 h. After cooling the reaction mixture to 
‒15 °C 104 (330 mg, 1.20 mmol, 1.00 eq.) in THF (4 mL) was added and the mixture was 
stirred for 2 h. Water (20 mL) was added and the mixture extracted with pentane 
(3x15 mL). The combined organic layers were dried over MgSO4 and solvents were 
removed under reduced pressure. Mass spectrometry revealed that product traces 
were formed, which could not be isolated. 
ESI-MS m/z: 455.3 [M+H]+, 477.4 [M+Na]+, 453.3 [M-H]-. 



















6.5.2 Synthesis of 7-Azaindole Derivatives 
7-Azagramine (24) 
 
To a mixture of dimethylamine in ethanol (33 wt-%, 9.80 mL, 55.0 mmol, 1.30 eq.), 
concentrated acetic acid (2.70 mL, 47.8 mmol, 1.13 eq.) and water (10 mL) 
formaldehyde (3.60 mL, 47.8 mmol, 1.13 eq.) was added at 0 °C. The mixture was 
stirred for 30 min and then treated with 7-azaindole (5.00 g, 42.3 mmol, 1.00 eq.) in 
ethanol (20 mL). After further stirring at 0 °C for 30 min the reaction mixture was 
heated to 100 °C for 18‒20 h. The mixture was allowed to cool to r.t. and treated with 
water (40 mL). Before extraction with DCM (3  30 mL) a pH of 11 was adjusted using 
aqueous sodium hydroxide solution (50 wt-%). The combined organic extracts were 
dried over MgSO4 and concentrated under reduced pressure. The product 24 (7.33 g, 
41.8 mmol, 99 %) was obtained as yellow solid. 
TLC (ethyl acetate/MeOH, 4:1): Rf = 0.26. 
1H-NMR (301 MHz, CDCl3): δ [ppm] = 2.26 (s, 6 H, 2 CH3), 2.61 (s, 2H CH2), 7.06 (dd, 
J = 7.8, 4.8 Hz, 1H, 5-CH), 7.27 (s, 1H, 2-CH), 8.03 (dd, J = 7.9, 1.6 Hz, 1H, 6-CH), 8.30 
(dd, J = 4.8, 1.5 Hz, 1H, 4-CH), 11.41 (s, 1H, NH). 
13C-NMR (76 MHz, CDCl3): δ [ppm] = 45.16 (2 CH3), 54.72 (CH2), 111.38 (C-3), 115.42 
(C-5), 120.57 (C-9), 124.44 (C-2), 127.89 (C-4), 142.35 (C-6), 149.07 (C-8). 
ESI-MS m/z: 176.1 [M+H]+, 174.1 [M-H]-. 
HR-MS (ESI): calculated for [C10H14N3] ([M+H]+): 176.1182, found: 176.1183; calculated 












Diethyl 2-((1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)malonate (26) 
 
Compound 24 (200 mg, 1.14 mmol, 1.00 eq.) was dissolved in diethyl malonate (520 µL, 
550 mg, 3.42 mmol, 3.00 eq.) under dry conditions and heated to 120 °C. A catalytically 
amount of sodium was added to the reaction mixture and then stirred for 6 h at 120 °C. 
The mixture was cooled to r.t., treated with hydrochloric acid (5 v/v-%, 2 mL) and 
extracted with diethyl ether (2  10 mL). After basification with sodium carbonate the 
aqueous layer was extracted with diethyl ether (2  10 mL), dried over MgSO4 and 
concentrated under reduced pressure. The pure product (2.88 g, 9.92 mmol, 58 %) was 
obtained as yellow solid. 
1H-NMR (400 MHz, CDCl3): δ [ppm] = 1.16 (t, J = 7.1 Hz, 6H, 2 CH3), 3.36 (d, 
J = 7.7 Hz, 2H, CH2), 3.71 (t, J = 7.7 Hz, 1H, CH-(COOEt)2), 4.04‒4.19 (m, 4H, 2 CH2), 
7.07 (dd, J = 7.8, 4.8 Hz, 5-CH), 7.95 (dd, J = 7.8, 1.0 Hz, 1H, 6-CH), 8.29 (d, J = 4.2 Hz, 
1H, 4-CH), 11.44 (sbr, 1H, NH).  
13C-NMR (101 MHz, CDCl3): δ [ppm] = 13.99 (2 CH3), 24.57 (CH2), 53.11 
(CH-(COOEt)2), 61.25 (2 CH2), 110.46 (C-3), 115.31 (C-5), 120.19 (C-9), 123.74 (C-2), 
127.53 (C-4), 142.11 (C-6), 148.63 (C-8), 169.12 (2 C(O)OEt). 
ESI-MS (m/z): 291.1 [M+H]+, 313.1 [M+Na]+. 329.1 [M+K]+. 
HR-MS (ESI): calculated for [C15H19N2O4] ([M+H]+): 291.1339, found: 291.1341; 
calculated for [C15H18N2O4Na] ([M+Na]+): 313.1159, found: 313.1155; calculated for 












3-(1H-Pyrrolo[2,3-b]pyridin-3-yl)propanoic acid (25) 
 
Compound 26 (1.90 g, 6.55 mmol, 1.00 eq.) was dissolved in hydrochloric acid (37 %, 
28.2 mL) and heated to reflux for 7 h. The mixture was concentrated in vacuo to 
dryness. A few milliliters of water were added to the solid and a pH of 7 was adjusted 
by treating with aqueous Na2CO3-solution (5 wt-%). The solvent was removed under 
reduced pressure and recrystallisation from water yielded the pure product 25 (1.23 g, 
6.48 mmol, 99 %) as yellow solid. 
1H-NMR (500 MHz, DMSO): δ [ppm] = 2.60 (t, J = 7.4 Hz, 2H, CH2-COOH), 2.93 (t, 
J = 7.5 Hz, 2H, CH2-CAr), 7.01 (dd, J = 7.5, 4.6 Hz, 1H, 5-CH), 7.22 (s, 1H, 2-CH), 7.94 (d, 
J = 7.6 Hz, 1H, 6-CH), 8.17 (d, J = 3.4 Hz, 1H, 4-CH), 11.28 (s, 1H, NH), 12.06 (sbr, 1H, 
COOH). 
13C-NMR (126 MHz, DMSO): δ [ppm] = 20.28 (CH2-CAr), 34.43 (CH2-COOH), 112.23 
(C-3), 114.48 (C-5), 118.98 (C-9), 122.55 (C-2), 126.28 (C-4), 142.13 (C-6), 148.35 (C-8), 
173.79 (COOH). 
ESI-MS (m/z): 191.1 [M+H]+, 189.1 [M-H]-. 
HR-MS (ESI): calculated for [C10H11N2O2] ([M+H]+): 191.0815, found: 191.0819; 















Methyl 10-oxo-10-(1H-pyrrolo[2,3-b]pyridin-3-yl)decanoate (43) 
 
Aluminium chloride (2.26 g, 16.9 mmol, 4.00 eq.) was suspended in anhydrous DCM 
(35 mL), 7AI (500 mg, 4.23 mmol, 1.00 eq.) was added and the suspension was stirred 
at r.t. for 1 h. Sebacoyl chloride (3.61 mL, 4.05 g, 19.9 mmol, 4.00 eq.) was added 
dropwise and the reaction mixture was stirred for 18 h. The suspension was cooled to 
0 °C and treated dropwise with methanol (30 mL). After stirring for 1 h solid 
components were filtered off and the organic solvent was removed under reduced 
pressure. Flash column chromatography (ethyl acetate/n-pentane, 3:1) yielded the pure 
product 43 (570 mg, 1.80 mmol, 43 %) as yellow solid. 
TLC (ethyl acetate/n-pentane 3:1): Rf = 0.51. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 1.17‒1.45 (m, 12 H, 6 CH2), 1.48‒1.67 (m, 2H, 
3-CH2), 1.69‒1.85 (m, 2H, 8-CH2), 2.21‒2.34 (m, 2H, 2-CH2), 2.81‒2.93 (m, 2H, 9-CH2), 
3.61 (s, 3H, OCH3), 7.32 (dd, J = 7.9, 5.0 Hz, 1H, 5’-CH), 8.08 (s, 1H, 2’-CH), 8.39 (dd, 
J = 5.0, 1.2 Hz, 6’-CH), 8.80 (dd, J = 7.9, 1.5 Hz, 4’-CH). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = 24.92 (C-3), 28.98 (C-8), 29.05 (C-4, C-5, C-6, 
C-7), 34.07 (C-2), 39.45 (C-9), 51.44 (OCH3), 101.37 (C-3’), 116.40 (C-5’), 126.80 (C-9’), 
132.03 (C-4’), 132.18 (C-2’), 142.92 (C-6’), 148.52 (C-8’), 173.89 (C-1), 196.42 (C-10). 
ESI-MS (m/z): 317.2 [M+H]+, 339.2 [M+Na]+, 355.2 [M+K]+, 315.2 [M-H]-. 
HR-MS (ESI): calculated for [C18H25N2O3] ([M+H]+): 317.1860, found: 317.1863; 
calculated for [C18H24N2O3Na] ([M+Na]+): 339.1679, found: 339.1680; calculated for 











Methyl 10-(1H-pyrrolo[2,3-b]pyridin-3-yl)decanoate (41) 
 
To a solution of 43 (150 mg, 476 µmol, 1.00 eq.) in TFA (1.7 mL) TES (470 µL, 350 mg, 
2.97 mmol, 6.25 eq.) was added. The reaction mixture was stirred at r.t. for 18 h. TFA 
was removed under reduced pressure and the residue was diluted with aqueous KOH 
(2 M, 3 mL). The mixture was extracted with DCM (3  5 mL) and the combined 
organic extracts were dried over MgSO4. After filtration the organic solvent was 
removed in vacuo and purification via flash column chromatography (ethyl 
acetate/n-pentane, 3:1) yielded the pure product 41 (110 mg, 363 µmol, 76 %) as yellow 
solid. 
TLC (ethyl acetate/n-pentane, 3:1): Rf = 0.50. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 1.24‒1.36 (m, 10H, 5 CH2), 1.58 (d, J = 7.1 Hz, 
2H, 9-CH2), 1.75 (d, J = 7.5 Hz, 2H, 3-CH2), 2.26 (dd, J = 14.4, 7.1 Hz, 2H, 2-CH2), 
2.82‒2.88 (m, 2H, 10-CH2), 3.62 (s, 3H, CH3), 7.94‒8.00 (m, 1H, 5’-CH), 8.05 (s, 1H, 
2’-CH), 8.34‒8.42 (m, 1H, 6’-CH), 8.70 (dd, J = 7.9, 1.5 Hz, 1H, 4’-CH). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = 25.02 (C-3), 29.09, 29.12, 29.31, 29.35, 29.45 
(C-4, C-5, C-6, C-7, C-8), 34.36 (C-9), 39.47 (C-2), 45.79 (C-10), 49.89 (OCH3), 100.81 
(C-3’), 116.41 (C-5’), 118.35 (C-9’), 125.57 (C-2’), 129.66 (C-4’),  143.51 (C-6’), 149.18 
(C-8’), 173.92 (C-1’). 
ESI-MS (m/z): 303.2 [M+H]+, 325.2 [M+Na]+. 
HR-MS (ESI): calculated for [C18H27N2O2] ([M+H]+): 303.2067, found: 303.2073; 













10-(1H-Pyrrolo[2,3-b]pyridin-3-yl)decanoic acid (40) 
 
To a solution of 41 (110 mg, 363 µmol, 1.00 eq.) in methanol (300 µL) water (500 µL) 
and NaOH (28.0 mg, 697 µmol, 1.92 eq.) were added. The mixture was heated to reflux 
for 4 h. After cooling down to r.t. the mixture was neutralised using 2 M hydrochloric 
acid and extracted with DCM (3  2 mL). The combined organic extracts were dried 
over MgSO4 and solvents were removed under reduced pressure. Flash column 
chromatography yielded the pure product (49.0 mg, 170 µmol, 47 %) as yellow solid. 
TLC (ethyl acetate/n-pentane, 3:1): Rf = 0.49. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 1.15‒1-38 (m, 10H, 5 CH2), 1.59 (d, J = 4.8 Hz, 
4H, 3-CH2, 9-CH2), 2.29 (t, J = 7.5 Hz, 2H, 2-CH2), 2.64 (t, J = 7.5 Hz, 2H, 10-CH2), 6.53 (d, 
J = 3.5 Hz, 1H, 2’-CH), 7.39 (d, J = 3.5 Hz, 1H, 5’-CH), 8.04 (dt, J = 7.8, 1.5 Hz, 1H, 
6’-CH), 8.24‒8.29 (m, 1H, 4’-CH), 11.13 (sbr, COOH). 
13C-NMR (76 MHz, CDCl3): δ [ppm] = 24.90 (C-3), 28.95, 29.11, 29.22, 29.91 (C-4, C-5, 
C-6, C-7, C-8), 34.60 (C-9), 39.24 (C-2), 45.49 (C-10), 101.11 (C-3’), 115.70 (C-5’), 121.56 
(C-9’), 125.99 (C-2’), 130.50 (C-4’), 140.40 (C-6’), 147.04 (C-8’), 179.13 (C-1). 
ESI-MS (m/z): 289.2 [M+H]+, 287.2 [M-H]-. 













Ethyl 10-oxo-10-(1H-pyrrolo[2,3-b]pyridin-3-yl)decanoate (44) 
 
Aluminium chloride (2.26 g, 16.9 mmol, 4.00 eq.) was suspended in anhydrous DCM 
(35 mL), 7AI (500 mg, 4.23 mmol, 1.00 eq.) and triethylamine (290 µL, 210 mg, 
2.12 mmol, 0.50 eq.) were added and the suspension was stirred at r.t. for 1 h. Sebacoyl 
chloride (3.61 mL, 4.05 g, 19.9 mmol, 4.00 eq.) was added dropwise and the reaction 
mixture was stirred for 18 h. The suspension was cooled to 0 °C and treated dropwise 
with ethanol (30 mL). After stirring for 1 h solid components were filtered off and the 
organic solvent was removed under reduced pressure. Flash column chromatography 
(ethyl acetate/n-pentane, 3:1) yielded the pure product 44 (420 mg, 1.26 mmol, 30 %) as 
yellow solid. 
TLC (ethyl acetate/n-pentane, 3:1): Rf = 0.44. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 1.20‒1.42 (m, 15H, 6 CH2, CH3), 1.51‒1.65 (m, 
2H, CH2), 1.71‒1.82 (m, 2H, CH2), 2.22‒2.32 (m, 2H, CH2), 2.82‒2.92 (m, 2H, CH2), 
4.06‒4.19 (m, 2H, OCH2CH3), 7.32 (dd, J = 7.9, 5.0 Hz, 1H, 5’-CH), 8.08 (s, 1H, 2’-CH), 
8.39 (dd, J = 5.0, 1.2 Hz, 1H, 6’-CH), 8.80 (dd, J = 7.9, 1.5 Hz, 1H, 4’-CH). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = 14.25 (CH3), 24.95 (C-3), 29.09, 29.12, 29.31, 
29.45 (C-4, C-5, C-6, C-7, C-8), 34.36 (C-2), 60.17 (OCHCH3), 100.81 (C-3’), 116.40 (C-5’), 
118.35 (C-9’), 131.35 (C-4’), 131.80 (C-2’), 143.51 (C-6’), 149.18 (C-8’), 173.92 (C-1’), 
196.43 (C-10). 
ESI-MS (m/z): 331.2 [M+H]+, 329.2 [M-H]-. 
HR-MS (ESI): calculated for [C19H27N2O3] ([M+H]+): 331.2016, found: 331.2020; 












Ethyl 10-(1H-pyrrolo[2,3-b]pyridin-3-yl)decanoate (42) 
 
To a solution of 44 (200 mg, 605 µmol, 1.00 eq.) in TFA (2 mL) TES (610 µL, 440 mg, 
3.78 mmol, 6.25 eq.) was added. The reaction mixture was stirred at r.t. for 18 h. TFA 
was removed under reduced pressure and the residue was diluted with aqueous KOH 
(2 M, 3 mL). The mixture was extracted with DCM (3  5 mL) and the combined 
organic extracts were dried over MgSO4. After filtration the organic solvent was 
removed in vacuo and purification via flash column chromatography (ethyl acetate/n-
pentane, 3:1) yielded the pure product 42 (93.8 mg, 296 µmol, 49 %) as yellow solid. 
TLC (ethyl acetate/n-pentane, 2:1): Rf = 0.41. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 1.22 (t, J = 7.1 Hz, 3H, CH3), 1.24‒1.36 (m, 10H, 
5 CH2), 1.58 (d, J = 7.1 Hz, 2H, 9-CH2), 1.75 (d, J = 7.5 Hz, 2H, 3-CH2), 2.26 (dd, J = 14.4, 
7.1 Hz, 2H, 2-CH2), 2.82‒2.88 (m, 2H, 10-CH2), 4.09 (q, J = 7.1 Hz, 2H, OCH2CH3), 
7.94‒8.00 (m, 1H, 5’-CH), 8.05 (s, 1H, 2’-CH), 8.34‒8.42 (m, 1H, 6’-CH), 8.70 (dd, J = 7.9, 
1.5 Hz, 1H, 4’-CH). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = 14.25 (CH3), 25.02 (C-3), 29.09, 29.12, 29.31, 
29.35, 29.45 (C-4, C-5, C-6, C-7, C-8), 34.36 (C-9), 39.47 (C-2), 45.79 (C-10), 60.17 
(OCH2CH3), 100.81 (C-3’), 116.41 (C-5’), 118.35 (C-9’), 125.57 (C-2’), 129.66 (C-4’),  
143.51 (C-6’), 149.18 (C-8’), 173.92 (C-1). 
ESI-MS (m/z): 317.2 [M+H]+. 












10-(1H-Pyrrolo[2,3-b]pyridin-3-yl)decanoic acid (40) 
 
To a solution of 42 (700 mg, 2.21 mmol, 1.00 eq.) in methanol (1.8 mL) water (2.7 mL) 
and NaOH (1.77 g, 44.1 mmol, 20.0 eq.) were added. The mixture was heated to reflux 
for 4 h. After cooling down to r.t. the mixture was neutralised using 2 M hydrochloric 
acid and extracted with DCM (3  10 mL). The combined organic extracts were dried 
over MgSO4 and solvents were removed under reduced pressure. Flash column 
chromatography yielded the pure product 40 (270 mg, 717 µmol, 33 %) as yellow solid. 
 





















10-(1-(tert-Butoxycarbonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)decanoic acid (113) 
 
To a solution if 40 (100 mg, 347 µmol, 1.00 eq.) in THF (500 µL) DMAP (400 µg, 
3.46 µmol, 0.01 eq.) and Boc anhydride (80.0 mg, 375 µmol, 1.08 eq.) were added. The 
mixture was stirred at r.t. for 1 h and treated with a second portion of Boc anhydride 
(8.00 mg, 37.5 µmol, 0.11 eq.). After stirring for another hour water (8 µL) was added 
and the mixture was stirred for 30 min. The mixture was concentrated under reduced 
pressure and coevaporated with toluene (2  1 mL). Purification via flash column 
chromatography (DCM/MeOH, 98:2) yielded the product 113 (128 mg, 330 µmol, 95 %) 
as yellow solid. 
TLC (DCM/MeOH, 98:2): Rf = 0.49. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 1.20‒1.37 (m, 14H, 7 CH2), 1.61 (s, 9H, 
3 CH3,Boc), 2.32 (t, J = 7.5 Hz, 2H, CH2), 2.66 (t, J = 7.4 Hz, 2H, CH2), 7.05 (s, 1H, 2’-CH), 
7.29‒7.33 (m, 1H, 5’-CH), 8.11 (d, J = 3.6 Hz, 1H, 6’-CH), 8.46 (d, J = 5.1 Hz, 1H, 4’-CH). 
ESI-MS (m/z): 389.2 [M+H]+, 411.2 [M+Na]+, 387.3 [M-H]-. 

















Compound 40 (100 mg, 347 µmol, 1.00 eq.) was dissolved in aqueous NaHCO3-
solution (10 w/w-%, 1 mL). The solution was cooled down to 0 °C and treated 
dropwise with Fmoc-Cl (110 mg, 409 µmol, 1.18 eq.) in dioxane (1 mL). The mixture 
was stirred at 0 °C for 1 h, warmed up to r.t. and stirred for 7 d. After dilution with 
water (10 mL) the mixture was extracted with diethyl ether (2   10 mL). The combined 
organic extracts were dried over MgSO4 and concentrated under reduced pressure. 
The obtained yellow solid was a mixture of Fmoc-protected 85 and 40. Attempts to 
purify the crude were unsuccessful.  
TLC (n-pentane/ethyl acetate, 3:1): Rf = 0.40. 
ESI-MS (m/z): 533.2 [M+Na]+. 




















A solution of 47 (2.00 g, 6.44 mmol, 1.00 eq.) in anhydrous THF (20 mL) was cooled to 
‒78 °C, treated dropwise with n-BuLi (2.5 M, 2.78 mL, 6.95 mmol, 1.08 eq.) and stirred 
for 30‒40 min. TESCl (1.17 mL, 1.05 g, 6.95 mmol, 1.08 eq.) was slowly added and the 
reaction mixture stirred at ‒78 °C stirred for 60 min. The mixture was warmed up to r.t. 
and diluted with aqueous NaHCO3-solution (5 w/w-%, 15 mL). After extraction with 
n-pentane (3  20 mL) the combined organic extracts were washed with water 
(2   45 mL), dried over MgSO4 and concentrated in vacuo. Purification via flash column 
chromatography (n-pentane/ethyl acetate, 6:1) yielded the pure product 48 (2.48 g, 
5.84 mmol, 91 %) as colourless oil. 
TLC (n-pentane/ethyl acetate 6:1): Rf = 0.92. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 0.55 (q, J = 8.1 Hz, 6H, 3 CH2,TES), 0.96 (t, 
J = 7.9 Hz, 9H, 3 CH3,TES), 1.02‒1.07 (m, 18H, 6 CH3,TIPS), 1.24‒1.42 (m, 10H, 5 CH2), 
1.45‒1.55 (m, 5H, 3 CHTIPS, 9-CH2), 2.21 (t, J = 7.0 Hz, 2H, 3-CH2), 3.64 (t, J = 6.6 Hz, 2H, 
10-CH2).  
13C-NMR (101 MHz, CDCl3): δ [ppm] = 4.58 (3 CH2,TES), 7.45 (3 CH3,TES), 18.02 
(6 CH3,TIPS), 19.85 (C-3), 25.77 (3 CHTIPS), 28.69, 28.76, 29.08, 29.35 (C-4, C-5, C-6, C-7, 
C-8), 33.02 (C-9), 63.48 (C-10), 81.33 (C-2), 108.82 (C-1). 
ESI-MS (m/z): 425.4 [M+H]+, 447.4 [M+Na]+. 












2-(Triethylsilyl)-3-(8-((triisopropylsilyl)oxy)octyl)-1H-pyrrolo[2,3-b] pyridine 49 
 
A Schlenk flask was furnished with palladium(II) acetate (10.2 mg, 45.5 µmol, 0.05 eq.), 
Na2CO3 (480 mg, 4.55 mmol, 5.00 eq.), 2-amino-3-iodopyridine (200 mg, 909 µmol, 
1.00 eq.) and 48 (500 mg, 1.18 mmol, 1.30 eq.). Triphenylphosphine (11.9 mg, 45.5 µmol, 
0.05 eq.) and tetra-n-butylammonium chloride (250 mg, 909 µmol, 1.00 eq.) were 
added. The solids were dissolved in anhydrous DMF (20 mL) and the flask was 
provided with a reflux condenser. The reaction mixture was stirred at 100 °C for 15 h. 
The mixture was allowed to cool down to r.t., diluted with water (30 mL) and extracted 
with DCM (3  20 mL). The combined organic layers were dried over MgSO4 and the 
solvent was removed under reduced pressure. Flash column chromatography 
(n-pentane/ethyl acetate, 5:1) provided the product 49 (200 mg, 386 µmol, 21 %) as 
brown oil. 
TLC (n-pentane/ethyl acetate, 5:1): Rf = 0.41. 
ESI-MS (m/z): 517.4 [M+H]+, 1033.9 [2M+H]+, 515.4 [M-H]-. 
HR-MS (ESI): calculated for [C30H57N2OSi2] ([M+H]+): 517.4004, found: 517.4003; 


















To a solution of 49 (170 mg, 320 µmol, 1.00 eq.) in concentrated hydrochloric acid 
(2.4 mL) methanol (2.4 mL) was added and stirred under reflux for 24 h. The reaction 
mixture was diluted with isopropyl acetate (6.4 mL) and water (1.1 mL). The layers 
were separated and the organic layer was concentrated under reduced pressure. 
Purification via flash column chromatography (n-pentane/ethyl acetate, 3:1) yielded 
the product 52 (32.4 mg, 132 µmol, 41 %) as yellow solid. 
TLC (n-pentane/ethyl acetate 3:1): Rf = 0.46. 
ESI-MS (m/z): 247.2 [M+H]+, 245.2 [M-H]-. 
HR-MS (ESI): calculated for [C15H23N2O] ([M+H]+): 247.1805, found: 247.1805; 

















6.5.3 Synthesis of Phospholipids 
3-((4-Methoxybenzyl)oxy)propane-1,2-diol (32) 
 
To a solution of solketal (2.34 mL, 2.50 g, 18.9 mmol, 1.00 eq.) in dry DMF (250 mL) 
sodium hydride (60 %, 1.14 g, 28.4 mmol, 1.50 eq.) and p-methoxybenzyl chloride 
(3.08 mL, 3.56 g, 22.7 mmol, 1.20 eq.) were added. The reaction mixture was stirred 
under inert gas at r.t. for 18 h.  Excess of sodium hydride was quenched by addition of 
methanol. The mixture was extracted with DCM (3  200 mL), and the combined 
organic extracts were washed with water and brine. After drying over MgSO4 the 
solvent was removed under reduced pressure. 
The obtained oil was dissolved in THF (50 mL), hydrochloric acid (1 M, 50 mL) was 
added and the mixture was stirred at r.t. for 20 h. The mixture was neutralised using 
saturated aqueous sodium hydrogen carbonate solution. The organic solvent was 
removed in vacuo and the aqueous layer was extracted with ethyl acetate (3  40 mL) 
added. The mixture was dried over MgSO4 and concentrated under reduced pressure. 
Flash column chromatography (ethyl acetate/n-pentane, 3:1) yielded the product 32 
(2.70 g, 12.7 mmol, 67 %) as white solid. 
TLC (ethyl acetate): Rf = 0.49. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 3.39‒3.60 (m, 2H, 1-CH2), 3.72 (d, J = 4.6 Hz, 2H, 
3-CH2), 3.74 (s, 3H, OCH3), 3.80 (dd, J = 6.3, 2.5 Hz, 1H, 2-CH), 4.41 (s, 2H, CH2-CAr), 
6.80‒6.86 (m, 2H, 2 CHAr), 7.17‒7.23 (m, 2H, CHAr). 
13C-NMR (126 MHz, CDCl3): δ [ppm] = 55.06 (OCH3), 63.81 (C-1), 70.69 (C-2), 71.14 
(C-3), 72.93 (CH2-CAr), 113.66 (2 CHAr), 129.28 (2 CHAr), 129.69 (CAr-CH2), 159.12 
(CAr-OCH3). 
ESI-MS (m/z): 235.1 [M+Na]+, 251.1 [M+K]+, 211.1 [M-H]-. 
HR-MS (ESI): calculated for [C11H16O4Na] ([M+Na]+): 235.0941, found: 235.0943; 












A solution of 32 (4.82 g, 22.7 mmol, 1.04 eq.) and Z-6-aminohexanoic acid (5.79 g, 
21.8 mmol, 1.00 eq.) in DCM (200 mL) was treated dropwise at 0 °C with a solution of 
DCC (5.40 g, 26.2 mmol, 1.20 eq.) and DMAP (3.20 g, 26.2 mmol, 1.20 eq.) in DCM 
(50 mL) under dry conditions. The reaction mixture was stirred at 0 °C for 16 h, 
concentrated under reduced pressure and redissolved in ethyl acetate (100 mL). The 
resulting solid was filtered off and the filtrate was concentrated in vacuo. The pure 
product 31 (9.41 g, 20.5 mmol, 90 %) was obtained after flash column chromatography 
(DCM/ethyl acetate, 3:1). 
TLC (DCM/ethyl acetate, 3:1): Rf = 0.41. 
1H-NMR (301 MHz, CDCl3): δ [ppm] = 1.46 (dd, J = 14.3, 7.2 Hz, 2H, 4’-CH2), 1.58 (dt, 
J = 15.4, 7.9 Hz, 4H, 3’-CH2, 5’-CH2), 2.29 (t, J = 6.2 Hz, 2H, 2’-CH2), 3.15 (dd, J = 13.0, 
6.7 Hz, 2H, 6’-CH2), 3.49‒3.55 (m, 2H, 3-CH2), 3.76 (s, 3H, OCH3), 4.09‒4.18 (m, 1H, 
2-CH), 4.31 (dd, J = 11.9, 3.8 Hz, 2H, 1-CH2), 4.37‒4.49 (m, 2H, CH2-CPMB), 4.89 (s, 1H 
NH), 5.06 (s, CH2,Z), 6.81‒6.87 (m, 2H, 2 CHPMB), 7.17‒7.23 (m, 2H, 2 CHPMB), 7.31 (s, 
5H, 5 CHZ). 
13C-NMR (125 MHz, CDCl3): δ [ppm] = 24.52 (C-3’), 26.18 (C-4’), 29.62 (C-5’), 33.89 
(C-2’), 40.83 (C-6’), 55.26 (OCH3), 62.76 (C-2), 66.53 (CH2,Z), 67.82 (C-3), 70.09 (C-1), 
72.89 (CH2-CPMB), 113.72 (2 CHPMB), 127.93 (2 CHZ), 127.96 (CHZ), 128.36 (2xCHZ), 
129.20 (2 CHPMB), 129.58 (CPMB-CH2), 136.51 (CZ-CH2), 156.24 (N-C(O)OZ), 159.14 
(CPMB-OCH3), 172.88 (C-1’). 
ESI-MS (m/z): 460.2 [M+H]+, 477.3 [M+NH4]+, 482.2 [M+Na]+. 
HR-MS (ESI): calculated for [C25H34NO7] ([M+H]+): 460.2330, found: 460.232; calculated 













To a solution of 31 (1.20 g, 2.61 mmol, 1.00 eq.) and stearic acid (950 µL, 890 mg, 
3.13 mmol, 1.20 eq.) in anhydrous DCM (14.4 mL) a solution of DCC (650 mg, 
3.13 mmol, 1.20 eq.) and DMAP (180 mg, 1.44 mmol, 0.55 eq.) in anhydrous DCM 
(7.2 mL) was added dropwise. The reaction mixture was stirred for 24 h at r.t.. After 
reducing the mixture under reduced pressure the residue was dissolved in ethyl 
acetate (12 mL), filtrated and concentrated again under reduced pressure. The crude 
product was purified via flash column chromatography (n-pentane/ethyl acetate, 4:1) 
to yield the pure product 34 (1.66 g, 2.29 mmol, 88 %) as white crystals. 
TLC (n-pentane/ethyl acetate, 4:1): 0.55. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 0.86 (t, J = 6.7 Hz, 3H, CH3), 1.23 (s, 30H, 
15 CH2), 1.46 (dd, J = 14.3, 7.2 Hz, 2H, CH2), 1.52‒1.66 (m, 4H, 2 CH2), 2.27 (dt, 
J = 12.0, 7.4 Hz, 4H, 2’-CH2, 2’’-CH2), 3.15 (dd, J = 13.0, 6.7 Hz, 2H, 6’-CH2), 3.52 (dd, 
J = 5.1, 2.1 Hz, 2H, 3-CH2), 3.76 (s, 3H, OCH3), 4.13 (dd, J = 11.9, 6.5 Hz, 1H, 1-CH2,a), 
4.31 (dd, J = 11.9, 3.8 Hz, 1H, 1-CH2,b), 4.36‒4.50 (m, 2H, C-CH2,PMB), 4.89 (sbr, 1H, NH), 
5.06 (s, 2H, CH2,Z), 5.15‒5.26 (m, 1H, 2-CH), 6.81‒6.88 (m, 2H, 2 CHPMB), 7.16‒7.23 (m, 
2H, 2 CHPMB), 7.26‒7.34 (m, 5H, 5 CHZ). 
13C-NMR (126 MHz, CDCl3): δ [ppm] = 14.02 (C-18’’), 22.59 (C-17’’), 24.30, 24.85, 26.05, 
28.98, 29.19, 29.26, 29.39, 29.53, 29.56, 29.60, 31.82, 33.75, 34.21, 40.72 (C-6’), 55.13 
(OCH3), 62.72 (C-2), 66.43 (CH2,Z), 67.78 (C-3), 69.91 (C-1), 72.84 (CH2-CPMB), 113.71 
(2 CHPMB), 127.93 (2 CHZ), 127.96 (CHZ), 128.37 (2 CHZ), 129.18 (2 CHPMB), 129.65 
(CPMB-CH2), 136.58 (CZ-CH2), 156.28 (N-C(O)OZ), 159.21 (CPMB-OCH3), 172.94 (C(O)O), 
173.00 (C(O)O). 
ESI-MS (m/z): 726.5 [M+H]+, 743.5 [M+NH4]+, 748.5 [M+Na]+, 724.5 [M-H]-. 
HR-MS (ESI): calculated for [C43H68NO8] ([M+H]+): 726.4939, found: 726.4918; 
calculated for [C43H67NO8Na] ([M+Na]+): 748.4759, found: 748.4765; calculated for 
[C43H71N2O8] ([M+NH4]+): 743.5205, found: 743.5204; calculated for [C43H66NO8] 







1-((6-(((Benzyloxy)carbonyl)amino)hexanoyl)oxy)-3-hydroxypropan-2-yl stearate (30) 
 
A solution of 34 (1.10 g, 1.52 mmol, 1.00 eq.) in DCM (50 mL) was treated with DDQ 
(720 mg, 3.17 mmol, 2.09 eq.) and stirred at r.t. for 24 h. The mixture was diluted with 
DCM (20 mL), washed with aqueous NaHCO3 solution (10 w/w-%, 60 mL) and dried 
over MgSO4. After removal of the organic solvent under reduced pressure the product 
was purified using flash column chromatography (n-pentane/ethyl acetate, 7:3). The 
pure product (880 mg, 1.45 mmol, 96 %) was obtained as white crystals. 
TLC (n-pentane/ethyl acetate, 7:3): Rf = 0.73. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 0.86 (t, J = 6.7 Hz, 3H, 18’-CH3), 1.23 (s, 30H, 
15 CH2), 1.43‒1.65 (m, 6H, 3 CH2), 2.22‒2.39 (m, 4H, 2’-CH2, 2’’-CH2), 3.16 (dt, J = 11.7, 
5.8 Hz, 2H, 6’’-CH2), 3.53‒3.72 (m, 2H, 3-CH2), 4.14‒4.35 (m, 2H, 1-CH2), 5.02‒5.10 (m, 
1H, 2-CH), 5.21 (s, 2H, CH2,Z), 6.82 (sbr, 1H, NH), 7.29‒7.39 (m, 5H, CHZ). 
ESI-MS (m/z): 606.4 [M+H]+, 623.5 [M+NH4]+, 628.4 [M+Na]+. 
HR-MS (ESI): calculated for [C35H60NO7] ([M+H]+): 606.4364, found: 606.4353; 
















amino)hexanoyl)oxy)propan-2-yl stearate (29) 
 
To a solution of phosphoryl trichloride (270 µL, 450 mg, 2.93 mmol, 3.09 eq.) in 
anhydrous THF (3.3 mL) a mixture of 30 (580 mg, 958 µmol, 1.00 eq.) and triethylamine 
(410 µL, 300 mg, 2.92 mmol, 3.05 eq.) in anhydrous THF (5 mL) was added over 15 min 
at 0 °C. The reaction mixture was stirred at 0 °C for 10 min and for 45 min at r.t.. The 
mixture was cooled down again to 0 °C and treated with a mixture of ethanolamine 
(180 µL, 180 mg, 2.93 mmol, 3.06 eq.) and triethylamine (810 µL, 590 mg, 5.84 mmol, 
6.10 eq.) in THF (8.5 mL) dropwise over 15 min. After stirring for 10 min at 0 °C the 
reaction mixture was stirred at r.t. over night. The mixture was filtered and the filtrate 
concentrated under reduced pressure. The residue was dissolved in a mixture of acetic 
acid (8.3 mL) and water (3.5 mL) and heated to 70 °C for 1 h. After extraction with 
chloroform (3  15 mL) the combined organic extracts were washed with water 
(2   20 mL) and concentrated under reduced pressure. Flash column chromatography 
(n-pentane/ethyl acetate, 7:3) yielded the pure product 29 (56.0 mg, 77.2 µmol, 8 %) as 
yellow solid. 
TLC (n-pentane/ethyl acetate, 7:3): Rf = 0.81. 
1H-NMR (400 MHz, CDCl3): δ [ppm] = 0.86 (t, J = 6.8 Hz, 3H, 18’-CH3), 1.23 (s, 30H, 
15 CH2), 1.44‒1.68 (m, 6H, 3 CH2), 2.25‒2.36 (m, 4H, 2’-CH2, 2’’-CH2), 3.14‒3.21 (m, 
2H, 6’-CH2), 3.56‒3.68 (m, 2H, 2’’’-CH2), 3.70‒3.75 (m, 2H, 1’’’-CH2), 3.86 (s, 2H, NH2), 
4.01‒4.34 (m, 4H, 1-CH2, 3-CH2), 4.78 (sbr, 1H, OH), 5.08 (s, 2H, CH2,Z), 5.16‒.24 (m, 1H, 
2-CH), 6.76 (s, 1H, NH) 7.33 (s, 5H, 5 CHZ). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = 14.12 (C-18’’), 22.69 (C-17’’), 24.44, 24.89 (C-3’, 
C-3’’), 25.61, 26.14, 29.06, 29.25, 29.36, 29.47, 29.61, 29.66, 29.70, 31.93 (C-16’’), 33.80 






67.97 (C-3), 70.17 (C-1), 128.11 (CHZ), 128.52 (2 CHZ), 132.02 (CZ-CH2), 132.33 (2 CHZ), 
164.00 (N-C(O)OZ), 172.87, 172.93 (C-1’, C-1’’). 
ESI-MS (m/z): 729.5 [M+H]+, 751.4 [M+Na]+, 727.4 [M-H]-. 
HR-MS (ESI): calculated for [C37H66N2O10P] ([M+H]+): 729.4450, found: 729.4440; 



























(trimethylammonio)ethyl) phosphate (28) 
 
Compound 29 (300 mg, 412 µmol, 1.00 eq.) was dissolved in 2-propanole (7 mL) and 
DCM (2.4 mL) and heated afterwards to 35‒40 °C. The mixture was treated dropwise 
with K2CO3 (280 mg, 2.06 mmol, 5.00 eq.) in water (1.4 mL) over 5 min. A solution of 
dimethylsulfate (200 µL, 270 mg, 2.10 mmol, 5.11 eq.) in 2-propanole (1.4 mL) was 
added over 10 min at 40 °C. The reaction mixture was stirred at 40 °C for 90 min, 
diluted with water (5 mL) and extracted with chloroform (2  10 mL). The combined 
organic extracts were washed with water (20 mL) and the organic solvent was 
removed under reduced pressure. Product traces were found in mass spectrometry, 
but isolation of the pure product 28 was unsuccessful. Furthermore, the mass spectrum 
showed formation of a methylphosphate ester (35). 















1-((6-Aminohexanoyl)oxy)-3-((4-methoxybenzyl)oxy)propan-2-yl stearate (36) 
 
To a solution of 34 (500 mg, 689 µmol, 1.00 eq.) in anhydrous methanol (20 mL) Pd/C 
(10 %, 140 mg) and ammonium formate (220 mg, 3.45 mmol, 5.00 eq.) were added. The 
mixture was heated to reflux for 2.5 h, cooled down to r.t. and solid components were 
filtered off. The filtrate was concentrated under reduced pressure. Without further 
purification the pure product 36 (360 mg, 603 µmol, 88 %) was yielded as yellow solid. 
TLC (DCM/MeOH, 9:1): Rf = 0.62. 
1H-NMR (301 MHz, CHCl3): δ [ppm] = 0.85 (t, J = 6.7 Hz, 3 H, CH3), 1.22 (s, 30 H, 
15 CH2), 1.53‒1.77 (m, 6H, 3 CH2), 2.22‒2.46 (m, 4H, 2’-CH2, 2’’-CH2), 3.19 (dd, 
J = 11.7, 5.7 Hz, 2H, 6’-CH2), 3.39‒3.59 (m, 2H, 3-CH2), 3.77 (s, 3H, OCH3), 4.04‒4.17 (m, 
2H, 1-CH2), 4.45 (s, 2H, C-CH2,PMB), 5.14‒5.24 (m, 1H, 2-CH), 6.85 (dt, J = 4.9, 2.9 Hz, 2H, 
2 CHPMB), 7.17‒7.24 (m, 2H, 2 CHPMB). 
13C-NMR (76 MHz, CDCl3): δ [ppm] = 14.07 (CH3,FA), 22.64 (C-17’’), 24.86, 26.33, 29.09, 
29.21, 29.31, 29.41, 29.56, 29.61, 29.64, 30.52, 30.86, 31.87, 32.77, 33.85, 34.11, 36.53, 42.86 
(C-6’), 55.21 (OCH3), 63.37 (C-2), 68.82 (C-3), 70.20 (C-1), 73.11 (CH2-CPMB), 113.80 
(2 CHPMB), 129.37 (2 CHPMB), 129.40 (CPMB-CH), 159.31 (CPMB-OCH3), 173.92 (C(O)O), 
174.20 (C(O)O). 
ESI-MS (m/z): 592.4 [M+H]+, 1183.9 [2M+H]+. 












methoxybenzyl)oxy)propan-2-yl stearate (39) 
 
A solution of 25 (60.0 mg, 318 µmol, 1.00 eq.) in anhydrous DCM (10 mL) was treated 
with NHS (36.0 mg, 312 µmol, 0.98 eq.) and DCC (66.0 mg, 318 µmol, 1.00 eq.) and 
stirred for 1 h at 0 °C. The mixture was allowed to warm up to r.t. and stirred for 
additional 12 h. The resulting solid was filtered off, 36 (200 mg, 338 µmol, 1.06 eq.) and 
triethylamine (154 µL, 112 mg, 3.49 eq.) were added to the filtrate and the mixture was 
stirred for 1 h. The mixture was diluted with ethyl acetate (5 mL) and washed with 
aqueous citric acid (10 w/w-%, 3  5 mL). The organic extract was washed with water 
(1   5 mL), saturated aqueous sodium hydrogen carbonate solution (3  4 mL) and 
saturated aqueous sodium chloride solution (1  5 mL). The organic layer was dried 
over MgSO4 and concentrated under reduced pressure. Traces of product 39 were 
observed in mass spectrometry but isolation attempts were unsuccessful. 
TLC (n-pentane/ethyl acetate, 3:1): Rf = 0.53. 
ESI-MS (m/z): 764.5 [M+H]+. 

















Compound 32 (1.50 g, 7.07 mmol, 1.00 eq.) and imidazole (1.07 g, 15.7 mmol, 2.22 eq.) 
were dissolved in anhydrous DMF (5 mL) and the mixture was cooled to 0 °C. In a 
second flask TBSCl (1.24 g, 8.20 mmol, 1.16 eq.) was dissolved in anhydrous DMF 
(3.5 mL) and added to the previously prepared mixture dropwise over a period of 1 h. 
The reaction mixture was stirred at 4 °C over night followed by stirring at r.t. for 
additional 8 h. The reaction was stopped by addition of water (5 mL). After extraction 
with n-pentane/ethyl acetate (4:1, 5 mL) and diethyl ether (5 mL) the combined organic 
layers were washed with hydrochloric acid (0.5 M, 10 mL), saturated aqueous 
NaHCO3-solution and saturated aqueous sodium chloride solution (10 mL). The pure 
product 56 (2.29 g, 6.98 mmol, 99 %) was obtained after flash column chromatography 
(n-pentane/ethyl acetate, 5:1) as white solid. 
TLC (n-pentane/ethyl acetate, 5:1): Rf = 0.21. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 0.04 (s, 6H, 2 CH3), 0.87 (s, 9H, 3 CH3,t-Bu), 
3.42‒3.51 (m, 2H, 1-CH2), 3.58‒3.66 (m, 2H, 3-CH2), 3.78 (s, 3H, OCH3), 3.79‒3.83 (m, 
1H, 2-CH), 4.46 (s, 2H, CH2,PMB), 6.84‒6.88 (m, 2H, 2 CHPMB), 7.21‒7.25 (m, 2H, 
2 CHPMB). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = -5.41 (2 CH3), 18.29 (Cq,t-Bu), 25.88 (3 CH3,t-Bu), 
55.26 (OCH3), 64.06 (C-1), 70.70 (C-2, CH2-CPMB), 73.10 (C-3), 113.83 (2 CHPMB), 129.38 
(2 CHPMB), 130.19 (CPMB-CH2), 159.28 (CPMB-OCH3). 
ESI-MS (m/z): 349.2 [M+Na]+, 365.2 [M+K]+. 
HR-MS (ESI): calculated for [C17H30O4SiNa] ([M+Na]+): 349.1806, found: 349.1809; 










1-((tert-Butyldimethylsilyl)oxy)-3-((4-methoxybenzyl)oxy)propan-2-yl stearate (57) 
 
Stearic acid (92.8 mg, 326 µmol, 1.21 eq.) and 56 (88.6 mg, 270 µmol, 1.00 eq.) were 
dissolved in anhydrous DCM (500 µL). In a second flask DCC (71.8 mg, 348 µmol, 
1.29 eq.) and DMAP (42.5 mg, 348 µmol, 1.29 eq.) were dissolved in anhydrous DCM 
(2 mL) and added to the first flask. The reaction mixture was stirred at r.t. for 24 h, 
solid components were filtered off and the organic solvent was removed under 
reduced pressure. The pure product 57 (70.6 mg, 119 µmol, 44 %) was obtained after 
flash column chromatography (n-pentane/ethyl acetate, 50:1) as white solid. 
TLC (n-pentane/ethyl acetate, 50:1): Rf = 0.25. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 0.01 (s, 6H, 2 SiCH3), 0.84 (s, 9H, 3 CH3,t-Bu), 
0.85 (t, J = 1.6 Hz, 3H, 18’-CH3), 1.21‒1.28 (m, 28H, 4’-17’-CH2), 1.53‒1.63 (m, 2H, 
3’-CH2), 2.25‒2.31 (m, 2H, 2’-CH2), 3.52‒3.60 (m, 2H, 1-CH2), 3.70 (dd, J = 5.3, 1.7 Hz, 
2H, 3-CH2), 3.78 (s, 3H, OCH3), 4.40‒4.48 (m, 2H, CH2,PMB), 4.98‒5.04 (m, 1H, 2-CH), 6.50 
(dd, J = 5.2, 1.6 Hz, 2H, 2 CHPMB), 6.82‒6.86 (m, 2H, 2 CHPMB). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = -5.45 (SiCH3), -5.42 (SiCH3), 14.11 (C-18‘), 18.21 
(Cq,t-Bu), 22.69 (C-17‘), 25.00 (C-3‘), 25.79 (3 CH3,t-Bu), 29.14, 29.30, 29.36, 29.47, 29.56, 
29.63, 29.66, 29.70 (C-4‘, C-5’, C-6’, C-7’, C-8’, C-9’, C-10’, C-11’, C-12’, C-13’, C-14’, 
C-15‘), 31.92 (C-16‘), 34.48 (C-2‘), 55.26 (OCH3), 61.69 (C-1), 68.11 (C-3), 72.87 
(CH2-CPMB), 72.96 (C-2), 113.76 (2 CHPMB), 129.24 (2 CHPMB), 130.19 (CPMB-CH2), 159.21 
(CPMB-OCH3), 173.36 (C-1‘). 
ESI-MS (m/z): 593.5 [M+H]+, 610.5 [M+NH4]+, 615.5 [M+Na]+, 631.5 [M+K]+, 1223.9 
[2M+K]+. 
HR-MS (ESI): calculated for [C35H68O5SiN] ([M+NH4]+): 610.4861, found: 610.4856; 
calculated for [C35H64O5SiNa] ([M+Na]+): 615.4415, found: 615.4396; calculated for 











1-Hydroxy-3-((4-methoxybenzyl)oxy)propan-2-yl stearate (37) 
 
To a solution of 57 (100 mg, 169 µmol, 1.00 eq.) in anhydrous THF (30 mL) TBAF (1 M, 
340 µL, 88.2 mg, 337 µmol, 2.00 eq.) was added. The reaction mixture was stirred at r.t. 
over night and concentrated under reduced pressure. The product 37 (80.7 mg, 
169 µmol, quant.) was obtained as yellow solid. 
TLC (n-pentane/ethyl acetate, 3:1): Rf = 0.91. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 0.83 (s, 3H, 18’-CH3), 1.21 (s, 26H, 13 CH2), 1.39 
(s, 2H, 4’-CH2), 1.51‒1-70 (m, 2H, 3’-CH2), 2.18‒2.31 (m, 2H, 2’-CH2), 3.24‒3.37 (m, 2H, 
3-CH2), 3.40‒3.54 (m, 1H, 1-CH2,a), 3.76 (s, 3H, OCH3), 4.04‒4.18 (m, 1H, 1-CH2,b), 4.44 
(s, 2H, CH2,PMB), 6.44 (d, J = 5.8 Hz, 1H, CHPMB), 6.84 (d, J = 8.4 Hz, 1H, CHPMB), 7.21 (d, 
J = 8.1 Hz, 1H, CHPMB), 8.17 (d, J = 5.5 Hz, 1H, CHPMB). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = 14.10 (C-18’), 22.67 (C-17‘), 24.91 (C-3’), 29.13, 
29.26, 29.35, 29.46, 29.60, 29.64, 29.68, 30.31 (C-4‘, C-5’, C-6’, C-7’, C-8’, C-9’, C-10’, 
C-11’, C-12’, C-13’, C-14’, C-15‘), 31.91 (C-16‘), 34.17 (C-2‘), 55.25 (OCH3), 65.49 (C-1), 
68.72 (C-3), 70.71 (CH2-CPMB), 73.13 (C-2), 113.83 (2 CHPMB), 129.28 (CHPMB), 129.38 
(CHPMB), 129.90 (CPMB-CH2), 159.33 (CPMB-OCH3), 173.93 (C-1’). 
ESI-MS (m/z): 496.4 [M+NH4]+, 501.4 [M+Na]+, 517.4 [M+K]+, 477.4 [M-H]-. 













propan-2-yl stearate (58) 
 
The compounds 37 (30.7 mg, 64.1 µmol, 1.04 eq.) and 40 (17.8 mg, 61.7 µmol, 1.00 eq.) 
were dissolved in anhydrous DCM (800 µL) and cooled to 0 °C. The mixture was 
treated dropwise with a mixture of DCC (15.3 mg, 74.0 µmol, 1.20 eq.) and DMAP 
(9.04 mg, 74.0 µmol, 1.20 eq.) in anhydrous DCM (200 µL) and stirred at 0 °C for 16 h. 
Under reduced pressure the solvent was removed and the residue was redissolved in 
ethyl acetate (2 mL). Solid components were filtered off and the filtrate was 
concentrated in vacuo. After flash column chromatography (n-pentane/ethyl acetate, 
1:1) the pure product 58 (26.4 mg, 35.3 µmol, 57 %) was obtained as yellow solid. 
TLC (n-pentane/ethyl acetate, 1:1): Rf = 0.38. 
ESI-MS (m/z): 749.6 [M+H]+, 787.5 [M+K]+, 747.5 [M-H]-. 


















1-((tert-utyldimethylsilyl)oxy)-3-hydroxypropan-2-yl stearate (62) 
 
To a solution of 57 (1.36 g, 2.30 mmol, 1.00 eq.) in wet DCM (50 mL) DDQ (1.09 g, 
4.81 mmol, 2.09 eq.) was added. The mixture was stirred at r.t. for 24 h, diluted with 
DCM (20 mL) and washed with aqueous NaHCO3-solution (10 w/w-%, 60 mL). The 
organic extract was dried over MgSO4 and concentrated under reduced pressure. After 
purification using flash column chromatography (n-pentane/ethyl acetate, 3:1) the pure 
product 62 (1.01 g, 2.13 mmol, 92 %) was obtained as white solid. 
TLC (n-pentane/ethyl acetate, 3:1): Rf = 0.90. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 0.05 (s, 6H, 2 SiCH3), 0.85‒0.89 (m, 12H, 
3 CH3,t-Bu, 18’-CH3), 1.22‒1.27 (m, 28H, 14 CH2), 1.56‒1.65 (m, 2H, 3’-CH2), 2.28‒2.34 
(m, 2H, 2’-CH2), 3.72‒3.84 (m, 4H, 1-CH2, 3-CH2), 4.83‒4.89 (m, 1H, 2-CH). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = -5.52 (2 SiCH3), 14.11 (C-18’), 18.20 (Cq,t-Bu), 
22.69 (C-17’), 24.97 (C-3’), 25.77 (3 CH3,t-Bu), 29.13, 29.46, 29.61, 29.66, 29.70 (C-4‘, C-5’, 
C-6’, C-7’, C-8’, C-9’, C-10’, C-11’, C-12’, C-13’, C-14’, C-15‘), 31.93 (C-16’), 34.41 (C-2’), 
62.54 (C-3), 62.85 (C-1), 74.28 (C-2), 173.71 (C-1’). 
ESI-MS (m/z): 473.4 [M+H]+, 495.4 [M+Na]+, 511.4 [M+K]+, 967.8 [2M+Na]+. 
HR-MS (ESI): calculated for [C27H57O4Si] ([M+H]+): 473.4021, found: 473.4001; 
calculated for [C27H56O4SiNa] ([M+Na]+): 495.3840, found: 495.3820; calculated for 













oxy)propan-2-yl stearate (63) 
 
Compounds 62 (330 mg, 701 µmol, 1.04 eq.) and 40 (194 mg, 674 µmol, 1.00 eq.) were 
dissolved in anhydrous DCM (9 mL). The mixture was cooled to 0 °C and treated 
dropwise with a mixture of DCC (167 mg, 809 µmol, 1.20 eq.) and DMAP (99.0 mg, 
809 µmol, 1.20 eq.) in anhydrous DCM (3 mL). The reaction mixture was stirred for 
24 h at 0 °C and concentrated under reduced pressure. The residue was dissolved in 
ethyl acetate (50 mL), the precipitate was filtered off and the filtrate was concentrated 
in vacuo. After flash column chromatography (n-pentane/ethyl acetate, 3:1) the pure 
product 63 (311 mg, 418 µmol, 60 %) was obtained as yellow solid. 
TLC (n-pentane/ethyl acetate, 3:1): Rf = 0.26. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 0.03 (s, 6H, 2 SiCH3), 0.83‒0.87 (m, 12H, 
3 CH3,t-Bu, 18’-CH3), 1.19‒1.27 (m, 38H, 19 CH2), 1.49‒1.62 (m, 2H, 9‘‘-CH2), 1.66‒1.74 
(m, 4H, 3‘-CH2, 3‘‘-CH2), 1.84‒1.92 (m, 4H, 2‘-CH2, 2‘‘-CH2), 2.26‒2.32 (m, 2H, 10‘‘-CH2), 
3.73‒3.80 (m, 3H, 1-CH2,a, 3-CH2), 4.04‒4.13 (m, 1H, 1-CH2,b), 4.84‒4.90 (m, 1H, 2-CH), 
6.46‒6.51 (m, 1H, 2‘‘‘-CH), 7.03‒7.07 (m, 1H, 5‘‘‘-CH), 8.18 (dd, J = 5.2, 1.5 Hz, 6‘‘‘-CH), 
8.23‒8.29 (m, 1H, 4‘‘‘-CH). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = -5.47 (2 SiCH3), 14.11 (C-18‘), 18.20 (Cq,t-Bu), 
22.68 (C-17‘), 24.69 (C-3‘‘), 24.97 (C-3‘), 25.45 (C-9‘‘), 25.77 (3 CH3,t-Bu), 29.12, 29.26, 
29.35, 29.45, 29.65, 29.69 (C-4‘, C-5’, C-6’, C-7’, C-8’, C-9’, C-10’, C-11’, C-12’, C-13’, 
C-14’, C-15‘, C-4‘‘, C-5‘‘, C-6‘‘, C-7‘‘, C-8‘‘), 31.92 (C-16‘), 34.42 (C-2’‘), 34.92 (C-2‘), 39.19 
(C-10‘‘), 55.75 (C-1), 62.45 (C-3), 74.50 (C-2), 100.81 (C-3‘‘‘), 106.57 (C-9‘‘‘), 115.89 
(C-5’’‘), 124.99 (C-2‘‘‘), 128.89 (C-4‘‘‘), 142.79 (C-6‘‘‘), 147.93 (C-8‘‘‘), 173.73 (C-1‘, C-1‘‘). 
ESI-MS (m/z): 743.6 [M+H]+. 
HR-MS (ESI): calculated for [C44H79N2O5Si] ([M+H]+): 743.5753, found: 743.5755; 













To a solution of 63 (1.00 g, 1.35 mmol, 1.00 eq.) in anhydrous THF (220 mL) TBAF (1 M, 
2.70 mL, 2.69 mmol, 2.00 eq.) was added. The reaction mixture was stirred at r.t. over 
night and concentrated under reduced pressure. Flash column chromatography 
(DCM/ethyl acetate, 1:1) provided the pure product 59 (817 mg, 1.30 mmol, 97 %) as 
yellow solid. 
TLC (DCM/ethyl acetate, 1:1): Rf = 0.36. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 0.85 (t, J = 7.1 Hz, 3H, 18’-CH3), 1.15‒1.38 (m, 
38H, 19 CH2), 1.53‒1.70 (m, 6H, 3’-CH2, 3’’-CH2, 9’’-CH2), 2.23‒2.34 (m, 4H, 2’-CH2, 
2’’-CH2), 2.71 (t, J = 7.1 Hz, 2H, 10’’-CH2), 3.63‒3.65 (m, 1H, 1-CH2,a), 4.06‒4.20 (m, 3H, 
1-CH2,b, 3-CH2), 6.51 (d, J = 3.5 Hz, 1H, 2’’’-CH), 7.07‒7.14 (m, 1H, 5’’’-CH), 7.99 (ddd, 
J = 7.8, 2.2, 1.3 Hz, 1H, 6’’’-CH), 8.26 (dd, J = 18.7, 4.4 Hz, 1H, 4’’’-CH). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = 14.11 (C-18‘), 22.69 (C-17’), 24.78 (C-3’’), 25.00 
(C-3’), 28.92, 29.11, 29.13, 29.25, 29.36, 29.45, 29.60, 29.65, 29.69, 29.82 (C-4‘, C-5’, C-6’, 
C-7’, C-8’, C-9’, C-10’, C-11’, C-12’, C-13’, C-14’, C-15‘, C-4‘‘, C-5’’, C-6’’, C-7’’, C-8’’, 
C-9‘‘), 31.92 (C-16’), 34.01 (C-2’’), 34.13 (C-2’), 39.47 (C-10’’), 51.44 (C-1), 63.35 (C-3), 
70.28 (C-2), 101.08 (C-3’’’), 115.87 (C-5’’’), 122.61 (C-9’’’), 125.43 (C-2’’’), 129.07 (C-4’’’), 
140.03 (C-6’’’), 141.62 (C-8’’’), 173.88, 173.94 (C-1’, C-1’’). 
ESI-MS (m/z): 629.5 [M+H]+, 651.5 [M+Na]+, 627.5 [M-H]-. 
HR-MS (ESI): calculated for [C38H65N2O5] ([M+H]+): 629.4888, found: 629.4882; 











phosphoryl)oxy)propan-2-yl stearate (64) 
 
Compound 59 (31.0 mg, 49.3 µmol, 1.00 eq.) was dissolved in anhydrous THF (300 µL) 
together with triethylamine (20.0 µL, 15.2 mg, 150 µmol, 3.05 eq.). The mixture was 
added dropwise to a solution of phosphoryl chloride (14.0 µL, 23.4 mg, 153 µmol, 
3.09 eq.) in anhydrous THF (200 µL) at 0 °C. The mixture was stirred at 0 °C for 10 min 
followed by stirring at r.t. for 45 min. The reaction mixture was again cooled to 0 °C 
and treated dropwise over 15 min with ethanolamine (9.00 µL, 9.28 mg, 152 µmol, 
3.06 eq.) and triethylamine (42.0 µL, 30.4 mg, 301 µmol, 6.10 eq.) and anhydrous THF 
(500 µL). After stirring at 0 °C for 10 min the reaction mixture was stirred at r.t. over 
night. Formed precipitate was filtered off and the filtrate concentrated under reduced 
pressure. The residue was redissolved in acetic acid/water (2.4:1, 20 mL) and heated to 
70 °C for 1 h. After cooling down the mixture was extracted using chloroform 
(3   15 mL). The combined organic extracts were washed with water (2  20 mL) and 
concentrated under reduced pressure. Mass spectrometry showed formation of 
product 64 as well as phosphorylated intermediate product carrying no ethanolamine 
(65). Attempts to isolate the substances was not successful. 
ESI-MS (m/z): 752.5 [M+H]+. 














1-((tert-Butyldimethylsilyl)oxy)-3-(phosphonooxy)propan-2-yl stearate (69) 
 
Triethylamine (180 µL, 130 mg, 1.29 mmol, 3.05 eq.) and 62 (200 mg, 423 µmol, 1.00 eq.) 
were dissolved in anhydrous THF (4 mL). The mixture was cooled to 0 °C and treated 
dropwise over 15 min with a prepared solution of phosphoryl chloride (120 µL, 
200 mg, 1.31 mmol, 3.09 eq.) in THF (2.9 mL). The reaction mixture was stirred at r.t. 
for 45 min. After addition of water (10 mL) the mixture was extracted with chloroform 
(3   10 mL). The combined organic extracts were washed with water (30 mL) and 
concentrated in vacuo. The product 69 was confirmed by ESI-MS. Attempts to isolate 
the formed product were not successful. 
ESI-MS (m/z): 551.4 [M-H]-. 


















(9H-Fluoren-9-yl)methyl (2-hydroxyethyl)carbamate (66) 
 
Ethanolamine (990 µL, 1.00 g, 16.4 mmol, 1.00 eq.) was dissolved in aqueous sodium 
carbonate (10 w/w-%, 150 mL) and treated with 9-fluorenylmethoxy-carbonyl chloride 
(4.71 g, 18.2 mmol, 1.11 eq.). The reaction mixture was stirred at r.t. for 2 h and 
extracted with ethyl acetate (2  100 mL). The combined organic extracts were washed 
with hydrochloric acid (1 M, 2  150 mL) and saturated aqueous sodium chloride 
solution (1  200 mL). The organic layer was dried over MgSO4 and concentrated 
under reduced pressure. Without further purification the pure product 66 (4.64 g, 
16.4 mmol, quant.) was obtained as white solid. 
1H-NMR (400 MHz, CHCl3): δ [ppm] = 3.28‒3.36 (m, 2H, 1-CH2), 3.64‒3.74 (m, 2H, 
2-CH2), 4.20 (t, J = 6.7 Hz, 1H, CHFmoc), 4.42 (d, J = 6.7 Hz, 2H, CH2,Fmoc), 5.17 (s, 1H, NH), 
7.31 (dtd, J = 8.6, 7.5, 1.2 Hz, 2H, 2 CHFmoc), 7.36‒7.45 (m, 2H, 2 CHFmoc), 7.55‒7.60 (m, 
2H, 2 CHFmoc), 7.76 (t, J = 7.9 Hz, 2H, 2 CHFmoc). 
13C-NMR (126 MHz, CDCl3): δ [ppm] = 43.50 (C-1), 46.20 (CHFmoc), 62.30 (C-2), 66.78 
(CH2,Fmoc), 120.27 (2 CHFmoc), 125.01 (2 CHFmoc), 127.39 (2 CHFmoc), 128.26 (2 CHFmoc), 
142.43 (2 Cq,Fmoc), 143.89 (2 Cq,Fmoc), 157.17 (NCOO). 
ESI-MS (m/z): 306.1 [M+Na]+, 589.3 [2M+Na]+. 














1-((tert-Butyldimethylsilyl)oxy)-3-((4-methoxybenzyl)oxy)propan-2-yl oleate (114) 
 
Oleic acid (1.74 mL, 1.56 g, 5.53 mmol, 1.21 eq.) and 56 (1.50 g, 4.57 mmol, 1.00 eq.) 
were dissolved in anhydrous DCM (7.5 mL) and treated with DCC (1.22 g, 5.89 mmol, 
1.29 eq.) and DMAP (720 mg, 5.89 mmol, 1.29 eq.) in anhydrous DCM (28 mL). The 
reaction mixture was stirred at r.t. for 24 h, the precipitate was filtered off and the 
filtrate was concentrated under reduced pressure. Flash column chromatography 
(n-pentane/ethyl acetate, 20:1) yielded the pure product 114 (2.40 g, 4.06 mmol, 89 %) 
as white solid. 
TLC (n-pentane/ethyl acetate, 20:1): Rf = 0.49. 
1H-NMR (300 MHz, CHCl3): δ [ppm] = 0.03 (s, J = 3.1 Hz, 6H, 2 SiCH3), 0.82‒0.90 (m, 
12H, 3 CH3,t-Bu, 18’-CH3), 1.23‒1.35 (m, 20H, 10 CH2), 1.54‒1.65 (m, 2H, 3’-CH2), 1.99 
(dd, J = 12.2, 6.5 Hz, 8’-CH2, 11’-CH2), 2.26‒2.34 (m, 2H, 2’-CH2), 3.57 (dd, J = 5.0, 2.6 Hz, 
2H, 3-CH2), 3.72 (dd, J = 5.3, 0.9 Hz, 2H, 1-CH2), 3.78 (s, 3H, OCH3), 4.45 (d, J = 2.6 Hz, 
2H, CH2,PMB), 4.98‒5.07 (m, 1H, 2-CH), 5.33 (ddd, J = 5.6, 3.6, 1.9 Hz, 2H, HC=CH), 
6.82‒6.87 (m, 2H, 2 CHPMB), 7.22 (dd, J = 8.1, 1.4 Hz, 2H, CHPMB). 
13C-NMR (126 MHz, CDCl3): δ [ppm] = -5.48 (SiCH3), -5.45 (SiCH3), 14.08 (C-18‘), 18.18 
(Cq,t-Bu), 22.65 (C-17‘), 24.95 (C-3‘), 25.76 (3 CH3,t-Bu), 27.15, 27.19 (C-8‘, C-11‘), 29.07, 
29.08, 29.17, 29.28, 29.29, 29.49, 29.69, 29.74 (8 CH2), 31.87 (C-16‘), 34.42 (C-2‘), 55.19 
(OCH3), 61.65 (C-1), 68.06 (C-3), 72.84 (CH2-CPMB), 72.93 (C-2), 113.72 (2 CHPMB), 129.17, 
129.19 (C-9’, C-10’), 129.71, 129.93 (2 CHPMB), 130.14 (CPMB-CH2), 159.17 (CPMB-OCH2), 
173.24 (C-1’). 
ESI-MS (m/z): 591.5 [M+H]+, 608.5 [M+NH4]+, 613.4 [M+Na]+, 629.4 [M+K]+. 
HR-MS (ESI): calculated for [C35H66NO5Si] ([M+NH4]+): 608.4705, found: 608.4676; 
calculated for [C35H62O5SiNa] ([M+Na]+): 613.4259, found: 613.4229; calculated for 









1-((tert-Butyldimethylsilyl)oxy)-3-hydroxypropan-2-yl oleate (115) 
 
To a solution of 114 (500 mg, 846 µmol, 1.00 eq.) in wet DCM (26 mL) DDQ (400 mg, 
1.77 mmol, 2.09 eq.) was added and the mixture stirred at r.t. for 24 h. The reaction 
mixture was diluted with DCM (10 mL) and washed with aqueous NaHCO3 solution 
(10 w/w-%, 30 mL). The organic extract was dried over MgSO4 and concentrated under 
reduced pressure. After purification via flash column chromatography 
(n-pentane/ethyl acetate, 3:1) the pure product 115 (400 mg, 844 µmol, quant.) was 
obtained as brown oil. 
TLC (n-pentane/ethyl acetate, 3:1): Rf = 0.77. 
1H-NMR (300 MHz, CHCl3): δ [ppm] = 0.04 (s, J = 2.1 Hz, 6H, 2 SiCH3), 0.83‒0.89 (m, 
12H, 3 CH3,t-Bu, 18’-CH3), 1.18‒1.34 (m, 20H, 10 CH2), 1.53‒1.65 (m, 2H, 3’-CH2), 1.98 
(dd, J = 12.2, 6.5 Hz, 4H, 8’-CH2, 11’-CH2), 2.23‒2.34 (m, 2H, 2’-CH2), 3.77 (ddd, J = 8.5, 
4.8, 3.1 Hz, 4H, 1-CH2, 3-CH2), 4.86 (dt, J = 9.6, 4.8 Hz, 1H, 2-CH), 5.31 (ddd, J = 5.7, 3.5, 
22 Hz, 2H, HC=CH). 
13C-NMR (126 MHz, CDCl3): δ [ppm] = -5.53 (2 SiCH3), 14.05 (C-18‘), 18.14 (Cq,t-Bu), 
22.62 (C-17‘), 24.90 (C-3‘), 25.71 (3 CH3,t-Bu), 27.11, 27.16 (C-8‘, C-11‘), 29.04, 29.12, 29.26, 
29.27, 29.46, 29.64, 29.71, 29.74 (8 CH2), 31.85 (C-16‘), 34.33 (C-2‘), 62.42 (C-1), 62.66 
(C-3), 74.30 (C-2), 129.66, 129.94 (C-9’, C-10’), 173.24 (C-1’). 
ESI-MS (m/z): 471.4 [M+H]+, 493.4 [M+Na]+, 509.4 [M+K]+, 469.4 [M-H]-. 
HR-MS (ESI): calculated for [C27H55O4Si] ([M+H]+): 471.3864, found: 471.3858; 
calculated for [C27H54O4Si] ([M+Na]+): 493.3684, found: 493.3685; calculated for 
[C27H54O4SiK] ([M+K]+): 509.3423, found: 509.3428; calculated for [C27H53O4Si] ([M-H]-): 










oxy)propan-2-yl oleate (116) 
 
The compounds 115 (160 mg, 330 µmol, 1.04 eq.) and 49 (91.6 mg, 318 µmol, 1.00 eq.) 
were dissolved in anhydrous DCM (4 mL), cooled to 0 °C and treated dropwise with a 
mixture of DCC (78.6 mg, 381 µmol, 1.20 eq.) and DMAP (46.6 mg, 381 µmol, 1.20 eq.) 
in anhydrous DCM (1.3 mL). The reaction mixture was stirred at 0 °C for 24 h and then 
concentrated under reduced pressure. The residue was redissolved in ethyl acetate 
(2.5 mL) and filtered. The filtrate was concentrated under reduced pressure. The 
product 116 (45.1 mg, 60.8 µmol, 19 %) was isolated via flash column chromatography 
(n-pentane/ethyl acetate 3:1) and obtained as yellow solid. 
TLC (n-pentane/ethyl acetate, 3:1): Rf = 0.36. 
ESI-MS (m/z): 741.6 [M+H]+, 739.6 [M-H]-. 
HR-MS (ESI): calculated for [C44H77N2O5Si] ([M+H]+): 741.5596, found: 741.5606. 















Compound 116 (130 mg, 175 µmol, 1.00 eq.) was dissolved in anhydrous THF (38 mL) 
and treated with TBAF (1 M, 350 µL, 351 µmol, 2.00 eq.). The reaction mixture was 
stirred at r.t. over night followed by removal of solvent under reduced pressure. After 
flash column chromatography (DCM/ethyl acetate, 1:1) the pure product 117 (15.9 mg, 
25.3 µmol, 14 %) was obtained as yellow solid. 
TLC (DCM/ethyl acetate, 1:1): Rf = 0.34. 
ESI-MS (m/z): 627.5 [M+H]+, 625.5 [M-H]-. 
HR-MS (ESI): calculated for [C38H63N2O5] ([M+H]+): 627.4731, found: 627.4731; 
calculated for [C38H62N2O5Na] ([M+Na]+): 649.4551, found: 649.4544; calculated for 















3-Hydroxy-2-(stearoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate (82) 
 
MSPC (20.0 mg, 27.3 µmol, 1.00 eq.) was dissolved in chloroform (1 mL) in a reaction 
vessel with lever lid. Enzyme solution (phospholipase A1 from Thermomyces 
lanuginosus, 10 KLU/G, 80 µL) in bis-tris buffer (0.7 mL) was added and the mixture 
was vortexed for 15 min. The mixture was extracted with chloroform (3  1.5 mL) and 
the combined organic layers were concentrated under reduced pressure. After 
extraction the pure product 82 (14.2 mg, 27.1 µmol, quant.) was obtained as white solid 
without further purification. 
1H-NMR (301 MHz, CHCl3): δ [ppm] = 0.86 (t, J = 6.7 Hz, 3H, 18’-CH3), 1.23 (s, 28 H, 
14 CH2), 1.57 (dd, J = 13.4, 6.3 Hz, 2H, 3’-CH2), 2.27 (dd, J = 15.0, 7.4 Hz, 2H, 2’-CH2), 
3.27 (s, 9H, 3 CH3,PC), 3.59‒3.81 (m, 4H, 1-CH2, 2’’-CH2), 3.88‒4.14 (m, 3H, OH, 3-CH2), 
4.24‒4.37 (m, 2H, 1’’-CH2), 4.86‒4.95 (m, 1H, 2-CH). 
13C-NMR (76 MHz, CDCl3): δ [ppm] = 14.09 (C-18’), 22.67 (C-17’), 24.84 (C-3’), 29.15, 
29.30, 29.34, 29.48, 29.62, 29.65, 29.67, 29.69, 29.73 (C-4’, C-5’, C-6’, C-7’, C-8’, C-9’, C-
10’, C-11’, C-12’, C-13’, C-14’, C-15’), 31.91 (C-16’), 34.19 (C-2’), 54.40 (3 CH3,PC), 59.38 
(C-1’’), 59.75 (C-1), 60.14 (C-3), 66.33 (C-2’’), 72.96 (C-2), 173.36 (C-1’). 
ESI-MS (m/z): 524.4 [M+H]+, 546.4 [M+Na]+. 
HR-MS (ESI): calculated for [C26H55NO7P] ([M+H]+): 524.3711, found: 524.3706; 













6.5.4 Synthesis of Ca2+-sensitive Labelled Membrane Compartments 
3-((Hydroxy(2-(pent-4-ynamido)ethoxy)phosphoryl)oxy)propane-1,2-diyl dioleate (3) 
 
Pent-4-ynoic acid (PA, 10.8 mg, 110 µmol, 2.05 eq.) and DCC (16.1 mg, 78.0 µmol, 
1.45 eq.) were dissolved in anhydrous chloroform (600 µL) and stirred at r.t. for 4 h. 
DOPE (40.0 mg, 53.8 µmol, 1.00 eq.) and pyridine (2.6 mL) were added and the 
reaction mixture was allowed to stirr at 50 °C for 12 h. Solid compounds were filtered 
off and the filtrate was concentrated under reduced pressure. Flash column 
chromatography (RP silica gel, MeOH/H2O, 9:1) provided the pure product (3, 
39.5 mg, 48.0 µmol, 89 %) as white solid. 
TLC (Alugram RP-18, MeOH/H2O, 9:1): Rf = 0.53. 
1H-NMR (400 MHz, CDCl3): δ [ppm] = 0.83 (t, J = 6.5 Hz, 6H, 18’-CH3, 18’’-CH3), 1.24 
(d, J = 11.0 Hz, 40H, 20 CH2), 1.55 (s, 4H, 3’-CH2, 3’’-CH2), 1.91‒2.03 (m, 8H, 8’-CH2, 
8’’-CH2, 11’-CH2, 11’’-CH2), 2.39‒2.54 (m, 8H, 2’-CH2, 2’’-CH2, 5’’’-CH2, 6’’’-CH2), 3.36 (t, 
J = 10.4 Hz, 1H,  8’’’-CH), 3.48 (d, J = 4.1 Hz, 2H, 2’’’-CH2), 4.02 (dt, J = 9.2, 6.3 Hz, 4H, 1-
CH2, 1’’’-CH2), 4.12 (dd, J = 12.2, 6.3 Hz, 1H, 3-CH2,a), 4.33 (dd, J = 12.2, 3.3 Hz, 1H, 
CH2,b), 5.21 (dt, J = 9.5, 5.2 Hz, 1H, 2-CH), 5.30 (s, 4H, 9’-CH, 10’-CH, 9’’-CH, 10’’-CH), 
8.83 (sbr, 1H, NH). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = 14.09 (C-18’, C-18’’), 22.66, 24.85, 27.17, 27.21, 
29.07, 29.10, 29.13, 29.20, 29.29, 29.50, 29.72, 29.75, 31.88, 33.33, 33.61, 34.03 (26 CH2), 
34.19, 35.04 (C-2’, C-2’’), 40.13 (C-2’’’), 62.30 (C-1), 64.20 (C-3), 65.32 (C-1’’’), 68.83 
(C-8’’’), 69.12 (C-2), 83.13 (C-7’’’), 130.00 (C-9’, C-10’, C-9’’, C-10’’), 171.66 (C-4’’’), 
173.11 (C-1’, C-1’’). 
31P-NMR (203 MHz, CDCl3): δ [ppm] = 0.16 (s, 1P, PO4). 






HR-MS (ESI): calculated for [C46H83NO9P] ([M+H]+): 824.5800, found: 824.5809; 
calculated for [C46H82NO9PNa] ([M+Na]+): 846.5619, found: 846.5626; calculated for 





























3-(((2-(But-3-ynamido)ethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dioleate (2) 
 
But-3-ynoic acid (BA, 6.95 mg, 82.7 µmol, 2.05 eq.) and DCC (12.1 mg, 58.5 µmol, 
1.45 eq.) were dissolved in anhydrous chloroform (500 µL) and stirred at r.t. for 4 h. 
DOPE (30.0 mg, 40.3 µmol, 1.00 eq.) and pyridine (2 mL) were added and the reaction 
mixture was allowed to stirr at 50 °C for 12 h. Solid compounds were filtered off and 
the filtrate was concentrated under reduced pressure. Flash column chromatography 
(RP silica gel, MeOH/H2O, 9:1) provided the pure product (2, 26.8 mg, 33.1 µmol, 82 %) 
as white solid. 
TLC (Alugram RP-18, MeOH/H2O, 9:1): Rf = 0.46. 
ESI-MS m/z: 932.6 [M+Na]+, 848.5 [M+K]+, 854.5 [M+2Na]+, 808.6 [M-H]-. 















3β-Hydroxy-1-(1-amino-PEG4-4-alkyne)-5-cholestene 3-hemisuccinate (1) 
 
APG4A (12.5 mg, 54.1 µmol, 1.00 eq.) and ChHS (26.3 mg, 54.1 µmol, 1.00 eq.) were 
dissolved in anhydrous DCM (4 mL). EDC·HCl (15.5 mg, 81.1 µmol, 1.50 eq.) was 
added and the reaction mixture was stirred at r.t. for 2 d. The organic solvent was 
removed under reduced pressure and the crude was purified via flash column 
chromatography (DCM/MeOH, 20:1). The isolated product 1 (37.8 mg, 54.0 µmol, 
quant.) was obtained as white solid. 
TLC (DCM/MeOH, 20:1): Rf = 0.39. 
1H-NMR (400 MHz, CDCl3): δ [ppm] = 0.65 (s, 3H, CH3), 0.84 (dd, J = 6.6, 1.8 Hz, 6H, 
2 CH3), 0.89 (d, J = 6.5 Hz, 3H, CH3), 0.99 (s, 4H, CH3, CH), 1.02‒1.62 (m, 22H, 6 CH, 
8 CH2), 1.75‒1.86 (m, 3H, CH2, C≡CH), 1.88‒2.02 (m, 2H, CH2), 2.29 (d, J = 8.0 Hz, 2H, 
CH2), 2.41 (t, J = 2.4 Hz, 1H, CH), 2.46 (t, J = 6.9 Hz, 2H, CH2), 2.61 (t, J = 6.8 Hz, 2H, 
CH2), 3.39‒3.46 (m, 2H, CH2,PEG-NH), 3.53 (t, J = 5.0 Hz, 2H, CH2,PEG), 3.57‒3.70 (m, 12H, 
6 CH2,PEG), 4.18 (d, J = 2.4 Hz, 1H, O-CH2-C≡C), 4.52‒4.63 (m, 1H, O-CH), 5.34 (d, 
J = 4.3 Hz, 1H, C=CH), 6.28 (sbr, 1H, NH). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = 11.86 (CH3), 18.72 (CH3), 19.31 (CH3), 21.03 
(CH2), 22.56, 22.82, 23.83, 24.28, 27.75, 28.01, 28.23, 29.90, 30.99, 31.86, 31.91, 35.79, 36.19, 
36.60, 36.98, 38.09, 39.36, 39.52, 39.74, 42.32 (CH2-NH), 50.03 (CH), 56.14, 56.70 (2 CH), 
58.41 (CH2-C≡C), 69.12, 69.84 (2 CH2,PEG), 70.28, 70.41, 70.54, 70.62 (5 CH2,PEG), 74.26 
(O-CH), 74.59 (C≡CH), 79.60 (C≡CH), 122.63 (Cq=CH), 139.67 (Cq=CH), 171.52 (C(O)O), 
172.31 (C(O)N). 





HR-MS (ESI): calculated for [C42H70NO7] ([M+H]+): 700.5147, found: 700.5156; 
calculated for [C42H73N2O7] ([M+NH4]+): 717.5412, found: 717.5392; calculated for 






























Alkyne peptides synthesised by applying SPPS: 
Peptides shorter than ten amino acids were synthesised using the protocol GP1.1. 
 
HPLC (MN Nucleodur 100 column, RP-C18, 250 10.0 mm, 5 µm, gradient: 10‒80 % V2 
in 30 min): tR = 24.3 min. 
ESI-MS m/z: 946.5 [M+H]+, 968.5 [M+Na]+, 484.8 [M+H+Na]2+ 
HR-MS (ESI): calculated for [C52H68N9O8] ([M+H]+): 946.5185, found: 946.5174. 
 
 
HPLC (MN Nucleodur 100 column, RP-C18, 250 10.0 mm, 5 µm, gradient: 10‒80 % V2 
in 30 min): tR = 22.4 min. 
ESI-MS m/z: 897.4 [M+Na]+, 460.2 [M+2Na]2+. 
HR-MS (ESI): calculated for [C48H58N8O8Na] ([M+H]+): 897.4270, found: 897.4256. 
 
 
HPLC (ACE Excel 100A column, RP-C18, 10 2.1 mm, 2 µm, gradient: 10‒80 % V3 in 





ESI-MS m/z: 307.5 [M+H+K]2+, 576.3 [M+H]+, 598.1 [M+Na]+, 614.2 [M+K]+, 1173.4 
[2M+Na]+. 
HR-MS (ESI): calculated for [C31H38N5O6] ([M+H]+): 576.2817, found: 576.2815; 
calculated for [C31H37N5O6Na] ([M+Na]+): 598.2636, found: 598.2637; calculated for 
[C31H37N5O6K] ([M+K]+): 614.2375, found: 614.2366. 
 
 
Synthesis of the transmembrane peptide WALP25 4 was performed using the protocol 
GP1.2 for the first 24 amino acids and the protocol GP1.1 for the N-terminal unnatural 
amino acid propargyl glycine. 
 
HPLC (MN Nucleodur 100 column, RP-C18, 250 10.0 mm, 5 µm, gradient: 80‒100 % V1 
in 30 min): tR = 24.4 min. 
ESI-MS m/z: 905.2 [M+3H]3+, 912.9 [M+2H+Na]3+, 1357.8 [M+2H]2+, 1368.3 [M+H+Na]2+, 
5426.1 [2M+H]+ 
HR-MS (ESI): calculated for [C139H211N31O25Na] ([M+2H+Na]3+): 912.5358, found: 














General procedure for attachment of sensors: 
The respective sensor azide (1.00 eq.) and lipid alkyne (1.00 eq.) were added into a 
micro test tube. Then, the organic solvent (MeOH) in the stored stock solutions was 
removed under a gentle stream of nitrogen before usage. Afterwards, copper wire 
(700 mg per 100 nmol sensor) formed to a spiral was placed in the reaction vessel and 
DMF (500 µL per 100 nmol sensor) was added. The tube was agitated for 17‒24 h 
under light exclusion at 50 °C. The reaction mixture was allowed to cool down to r.t., 
the copper spiral was removed, the mixture was diluted with water and MeCN (1:1) 
and the product isolated via HPLC. 
 
HPLC (ACE Excel 100A column, RP-C18, 10 2.1 mm, 2 µm, gradient: 10‒80 % V3 in 
15 min): tR = 7.4 min. 
 
 
HPLC (ACE Excel 100A column, RP-C18, 10 2.1 mm, 2 µm, gradient: 10‒80 % V3 in 







HPLC (ACE Excel 100A column, RP-C18, 10 2.1 mm, 2 µm, gradient: 50‒80 % V3 in 







δ chemical shift 
ε extinction coefficient 
°C degree Celsius 
AcOH acetic acid 
aq. aqueous 
BA but-3-ynoic acid 
BD Becton Dickinson 
Boc tert-butoxycarbonyl 
BuLi butyl lithium 
CaM calmodulin 
Cbz carboxybenzyl 
CD circular dichroism 
ChHS cholesteryl hemisuccinate 









DOSY diffusion-ordered spectroscopy 
DSPC 1,2-distearoyl-sn-glycero-3-phosphocholine 
e.g. exempli gratia; for example 
EDC·HCl 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
eq. equivalent 
ER endoplasmic reticulum 
ESI electron spray ionisation  
EtOAc ethyl acetate 
EtOH ethanol 
Et2O diethyl ether 











HEPES 4-(2-hydroxyethyl)-1-piperazineethansulfonic acid 
HMBC heteronuclear multiple bond correlation 
HOBt 1-hydroxybenzotriazole 
HPLC high performance liquid chromatography 
HR-MS high resolution mass spectrometry 
HSQC heteronuclear single quantum coherence 
Hz hertz 
i.a. inter alia; amongst other things 
m multiplett 
M molar 
M molar mass 







MOPS 3-morpholinopropane-1-sulfonic acid 
MS mass spectrometry 
MTBE methyl tert-butyl ether 





NMR nuclear magnetic resonance 
PA pent-3-ynoic acid 
PEG polyethylene glycol 
pH pondus hydrogenii; decimal logarithm of the reciprocal of hydrogen ion 
activity 
PLC preparative thin layer chromatography 
PM plasma membrane 
PMB para-methoxybenzyl 






r.t. room temperature 
rf retention factor 
Rhod-
DOPE 
N-(lyssamine rhodamine B sulfonyl)-1,2-dioleoyl-sn-3-
phosphatidylehanolamine 
RP reverse phase 
RPC reverse phase column chromatography 
rpm rounds per minute 
RyR ryanodine receptor 
s singlett 
SNARE soluble N-ethylmaleimide-sensitive-factor attachement protein receptor 
SPPS solid phase peptide synthesis 




TBAF tert-butylammonium fluoride 
TBSCl tert-butyldimethylsilyl chloride 
TES triethylsilane 
TESCl triethylsilyl chloride 
TFA trifluoroacetic acid 
TFE trifluorethanol 
THF tetrahydrofurane 
TIPSCl triisopropylsilyl chloride 
TIS triisopropylsilane 
TLC thin layer chromatography 
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9.1 Ceramide 118 
A protocol for the synthesis of ceramides starting from D-galactose was developed by 
ASAI et al.[245] showing the examples of the total synthesis of ceramides proposed as sex 
pheromones of the hair crab Erimacrus isenbeckii. With the commercial available 
compounds of 2-hydroxydocosanoic acid (121) and phytosphinganine (119) the entire 
total synthesis can be reduced to a two-step procedure (Scheme 9.1). This short 
synthetic route consists of a protection step followed by a coupling reaction of 
sphinganine and fatty acid. 
 
Scheme 9.1 Retrosynthesis of ceramide 118. 
The first step included the protection of the secondary alcohol moiety of 
2-hydroxydocosanoic acid (121) via acetylation (Scheme 9.2). To achieve this, the fatty 
acid (121) was dissolved in pyridine and treated with acetic anhydride. The reaction 
mixture was stirred at room temperature for 13 h which yielded the protected fatty 
acid 120. It is crucial for this reaction to use fresh acetic anhydride. Utilisation of 
anhydride from bottles open for longer than approximately one month led to no 
product formation. 
 
Scheme 9.2 Protection of the secondary hydroxy group by acetic anhydride-treatment.     
Following the procedure of ASAI et al., in the second step the sphinganine 119 and the 
acetylated fatty acid 120 were diluted in benzene along with the coupling reagent 





reduced pressure and lyophilised to remove any traces of present water. Afterwards, 
the mixture was dissolved in anhydrous dichloromethane (DCM), 1-ethyl-3-(3-
dimethyl-aminopropyl)carbodiimide (EDC) as a second coupling reagent was added 
and the reaction mixture stirred for 20 h. However, following this procedure with the 
compounds shown in Scheme 9.3 product formation could not be observed. Therefore, 
the strategy was altered. Instead of diluting the starting materials together with HOBt 
in benzene and then removing solvent and water traces, phytosphinganine and 120 as 
well as HOBt and EDC were directly dissolved in anhydrous DCM and stirred at room 
temperature for 20 h under argon atmosphere. After standard workup procedure the 
coupling product was dissolved in methanol/tetrahydrofuran (MeOH/THF, 3:1) 
without preceding purification. After stirring for 2.5 h at room temperature in the 
presence of potassium carbonate (K2CO3) the acetyl group was cleaved off to yield the 
product 118. 
 
Scheme 9.3 Coupling step using HOBt and EDC followed by deprotection under basic conditions. 
Isolation of 118 was not possible since the released urea derivative after EDC activation 
appeared to be inseparable from 118. The crude product was handed over to Prof. Dr. 
I. FEUßNER for further purification with subsequent analysis of the mode of action of 














9.1.1 Synthesis of Ceramide 118 
(S)-2-Acetoxydocosanoic acid (120) 
 
To a solution of (S)-2-hydroxydocosanoic acid (121, 8.60 mg, 28.0 µmol, 1.00 eq.) in 
pyridine (550 µL) acetic anhydride (550 µL) was added. The mixture was stirred for 
13 h at r.t. and then diluted with ice water. The solvent was evaporated under reduced 
pressure and the pure product 120 (9.31 mg, 23.4 µmol, 83 %) was obtained as white 
solid. 
ESI-MS m/z: 399.3 [M+H]+, 421.3 [M+Na]+, 819.7 [2M+Na]+. 
HR-MS (ESI): calculated for [C24H47O4] ([M+H]+): 399.3469, found: 399.3464;      





(S)-2-Acetoxydocosanoic acid (120, 2.72 mg, 6.82 µmol, 1.00 eq.) and 4-hydroxy 
sphinganine (119, 2.36 mg, 7.43 µmol, 1.09 eq.) were dissolved in dry DCM (240 µL) 
under argon atmosphere together with HOBt (1.47 mg, 10.9 µmol, 1.60 eq.). To the 
mixture EDC (2.16 mg, 11.3 µmol, 1.65 eq.) was added. The mixture was allowed to stir 
for 24 h at r.t. and diluted with CHCl3. The solution was washed with water, dried 
over MgSO4 and concentrated. The residue was redissolved in THF (120 µL) and 
methanol (350 µL), K2CO3 (33.0 mg) was added and the mixture was stirred for 2.5 h. 
Removal of the solvents yielded the crude product 118 as white solid. 
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